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Studying The Clinical And Research Applications Of The Pennpet Explorer, A Long 
Axial Field-Of-View Pet Scanner 
Abstract 
This thesis characterizes the long axial field-of-view (AFOV) PennPET Explorer scanner and studies the 
benefits for clinical and research applications using both measurements and Monte-Carlo simulations. 
The significant increase in photon sensitivity from extending the standard AFOV of a PET scanner by 3-6 
times to 70-140 cm may allow for fast, low-dose imaging and more accurate quantification using a wide 
variety of radiotracers. Results of performance characterization, including sensitivity, count rate, spatial 
resolution, and lesion contrast, showed good correspondence across simulated and measured data, 
indicating an accurate model of the PennPET Explorer. A key clinical application, lesion detection, was 
studied with small lesions in both uniform and complex background distributions. Results showed that 
good lesion detectability and localization was achieved in the human subject for 30-60 s scan durations 
for the PennPET Explorer, compared to a 1.5-3 min scan on standard AFOV scanners. Dynamic imaging, 
often required for research applications, was studied using both simulated and measured datasets to 
quantify the accuracy and precision of key biologic parameters as a function of injected radioactive dose. 
Results showed that the dose can be lowered from 5-15 mCi, typical with a standard AFOV PET scanner, 
to 1-2 mCi with our long AFOV scanner while still maintaining accuracy and precision of key biologic 
parameters. These results were then used to design a dual tracer imaging study to sequentially image two 
radiotracers, labeled with the same radioisotope, to study complementary mechanisms of metabolism. 
Preliminary results indicate that a low, 3 mCi dose with the first tracer, imaged for an abbreviated 30 min, 
and followed by a 15 mCi injection of a second tracer resulted in time-activity curves (TACs) with low 
noise, and can be used to further optimize this new protocol. Combined, these results offer a quantitative 
framework for both static and dynamic imaging on the PennPET Explorer and can be applied to develop 












Positron Emission Tomography, Quantitative Image Analysis 
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4152 
STUDYING THE CLINICAL AND RESEARCH APPLICATIONS OF THE PENNPET EXPLORER, 





Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 





Supervisor of Dissertation  
 
________________________ 
Joel Karp  
Professor of Radiologic Physics in Radiology 
 
Graduate Group Chairperson 
________________________ 
Andrew Tsourkas, Professor of Bioengineering 
 
Dissertation Committee  
David Mankoff, Gerd Muehllehner Professor of Radiology  






I would like to thank everyone who made this research possible. There are definitely too many 
people to name from all my close friends who supported me to all the lab members to friends in 
both the graduate program and friends in both Philly and California.  
Specifically, I’d like to thank Dr. Margaret Daube-Witherspoon for spending hours on the phone 
with me late in the evenings and on weekends, guiding my research and helping me feel validated 
when I was thoroughly lost and confused. I’d also like to thank my advisor, Dr. Joel Karp, who took 
me into his lab and guided my research and spent more time with me on lab experiments than I 
would have expected for a professor of his stature. The work in this thesis would not be possible 
without the assistance of Dr. Suleman Surti and Dr. Austin Pantel. I am extremely appreciative of 
Dr. Jim Gee and everyone in the HHMI program at the University of Pennsylvania for this incredibly 
unique graduate school experience. 
I would also like to thank Dr. Joseph Panetta, my fellow graduate student in early years who gave 
me advice on being a grad student in the lab, really made me feel like I was a part of the lab, and 
has been my good friend and sounding board in the years since he left the group. I’d also like to 
thank Dr. Lindsay Johnson who sat next to me in the later years, was my roommate at 
conferences, and has been an invaluable friend and ally during the hardest parts of my research. 
I would also like to thank all my friends from medical school – Rachel Shulman, Jessica Zuo, 
Michael Furdyna, Gia Yannekis, Julia D’Souza, and Ruth Choa to name a few –  and my best friend 
since childhood, Desiree Ho. They have all been extremely supportive throughout grad school and 
would take the time to ask about and show interest in my research, even if they had no idea what 
I was talking about. I’d especially like to thank Rachel Shulman, Jessica Zuo, and Desiree Ho for 
being my traveling companions over the years. 
 
 
iii   
This work would not have been possible without the other members of the PennPET Explorer 
team. Specifically, Tim McDermott and Michael Geagan, who built and designed the scanner, and 
Matt Werner and Mike Parma, who dealt with data acquisition and reconstruction. I’m only sorry 
that Tim didn’t get to see the scanner in use in the clinic. I’d especially like to thank Matt Werner 
for all of his (begrudging?) conversations about coding and data processing issues. 
Finally, I’d like to thank my parents, who have supported me throughout the years and 
encouraged me to follow my dreams and enjoy what I do, my little brother, who has always been 
sweet and supportive, and my grandparents, who have wished me well from across the seas and 
have always wanted a doctor in the family, even if this wasn’t what they had in mind. 
This work was supported in part by NIH Grants R01-CA225874, R01-CA206187, R33-CA225310, 
R01-CA113941, R01-CA211337, KL2-TR001879, R01-CA196528, and a Philips Healthcare Research 
Agreement. The clinical and research studies were made possible by contributions from Erin 
Schubert, Michael Parma, Eric Blankemeyer, and Janet Reddin, Ph.D. We thank our collaborators 
at the University of Washington for sharing FLT data that made this work possible. We thank 
Calithera for generously providing CB-839.  
 
 
iv   
TABLE OF CONTENTS 
Acknowledgments .................................................................................................................................. ii 
Table of Contents .................................................................................................................................. iv 
List of Tables ......................................................................................................................................... ix 
List of Figures ......................................................................................................................................... x 
List of Equations .................................................................................................................................. xxii 
Abstract ................................................................................................................................................. 1 
Chapter 1: Introduction to thesis ............................................................................................................ 3 
Challenges and Development of New Methodologies ............................................................................... 8 
Key Takeaways ......................................................................................................................................... 17 
Chapter 2: Background ......................................................................................................................... 23 
Clinical Imaging with PET ......................................................................................................................... 23 
The Physics of PET .................................................................................................................................... 26 
Dynamic Imaging with PET ...................................................................................................................... 35 
Overview of commercial PET scanners ..................................................................................................... 38 
Advancements in PET Technology ....................................................................................................... 38 
Total-Body PET Imaging ....................................................................................................................... 42 
Chapter 3: Design and Performance of a Long AFOV Scanner ................................................................ 50 
Scanner Geometry .................................................................................................................................... 50 
GATE Simulations ................................................................................................................................ 52 
 
 
v   
70-cm PennPET Explorer Prototype .................................................................................................... 55 
NEMA Performance Testing ..................................................................................................................... 57 
Methods .............................................................................................................................................. 58 
Results: GATE Simulations ................................................................................................................... 63 
Sensitivity ........................................................................................................................................ 63 
Spatial Resolution ............................................................................................................................ 65 
Count Rate ...................................................................................................................................... 67 
Image quality ................................................................................................................................... 69 
Summary of Results ........................................................................................................................ 71 
Simulated Dose Lowering Studies ....................................................................................................... 71 
Image quality phantom ................................................................................................................... 71 
Anthropomorphic phantom ............................................................................................................ 72 
Summary of Results ........................................................................................................................ 76 
Results: Measurement on the PennPET Explorer Prototype ............................................................... 77 
Sensitivity ........................................................................................................................................ 77 
Spatial Resolution ............................................................................................................................ 78 
Count Rate ...................................................................................................................................... 80 
Image Quality .................................................................................................................................. 85 
Image Uniformity ............................................................................................................................ 86 
Summary of Results ........................................................................................................................ 87 
Human subject data measured on the PennPET Explorer ........................................................................ 88 
Summary of Results ............................................................................................................................. 95 
Chapter 4: Lesion Detectability ............................................................................................................. 97 
Abstract .................................................................................................................................................... 97 
 
 
vi   
Introduction ............................................................................................................................................. 98 
Methods ................................................................................................................................................. 100 
Scanner Geometry ............................................................................................................................. 100 
Simulation ..................................................................................................................................... 100 
Measurement ................................................................................................................................ 101 
Axial sensitivity profile .................................................................................................................. 101 
Data Acquisition and Generation. ..................................................................................................... 103 
Simulations .................................................................................................................................... 103 
Preliminary simulations ............................................................................................................ 103 
Cylindrical phantom .................................................................................................................. 105 
Measurements .............................................................................................................................. 106 
Lesion Embedding ..................................................................................................................... 107 
Spheres in air ............................................................................................................................ 108 
Cylindrical phantom .................................................................................................................. 108 
CTN torso phantom .................................................................................................................. 109 
Human subject .......................................................................................................................... 111 
Image Reconstruction and Analysis .............................................................................................. 112 
Reconstruction .......................................................................................................................... 112 
Numerical lesion detection ....................................................................................................... 112 
Results .................................................................................................................................................... 113 
Preliminary Simulations ..................................................................................................................... 113 
Summary of Results ...................................................................................................................... 118 
Axial Sensitivity Profiles ..................................................................................................................... 118 
Cylindrical Phantom ........................................................................................................................... 118 
CTN Phantom ..................................................................................................................................... 122 
 
 
vii   
Human Subject .................................................................................................................................. 124 
Discussion .............................................................................................................................................. 125 
Conclusion .............................................................................................................................................. 130 
Chapter 5: Dynamic Imaging: Quantifying bias and precision of kinetic parameter estimation ............ 131 
Abstract .................................................................................................................................................. 131 
Introduction ........................................................................................................................................... 132 
Methods ................................................................................................................................................. 134 
Dynamic FLT phantom Monte Carlo simulation ................................................................................ 134 
Scanner geometry and GATE simulations ..................................................................................... 134 
Generation and reconstruction of dynamic FLT phantom data .................................................... 135 
Data analysis for simulated dynamic FLT phantom images .......................................................... 137 
Dynamic FDG lesion embedding study .............................................................................................. 139 
Scanner geometry ......................................................................................................................... 139 
Human subject data acquisition .................................................................................................... 139 
Sphere-in-air data acquisition ....................................................................................................... 139 
Generation and reconstruction of dynamic FDG data with embedded lesions ............................ 140 
Data analysis for dynamic FDG data with embedded lesions ....................................................... 143 
Results .................................................................................................................................................... 143 
Dynamic FLT phantom Monte Carlo simulation ................................................................................ 143 
Dynamic FDG lesion embedding study .............................................................................................. 147 
Discussion .............................................................................................................................................. 152 
Conclusion .............................................................................................................................................. 156 
Chapter 6. Dynamic Modeling of Fluoroglutamine and Dual-Tracer Modeling ..................................... 157 
 
 
viii   
Abstract .................................................................................................................................................. 157 
Introduction ........................................................................................................................................... 158 
Methods ................................................................................................................................................. 162 
Mouse Models ................................................................................................................................... 162 
FGln PET Studies ............................................................................................................................ 162 
FGln Imaging Analysis .................................................................................................................... 163 
Quantitative Analysis .................................................................................................................... 163 
Adding Poisson noise to simulations ............................................................................................. 164 
Dual-Tracer Lesion Embedding Study ................................................................................................ 164 
Results .................................................................................................................................................... 168 
Mouse Models ................................................................................................................................... 168 
Blood and Tissue Time Activity Curves .......................................................................................... 168 
Compartmental Kinetic Analysis ................................................................................................... 169 
Graphical Analysis ......................................................................................................................... 171 
Mathematical Simulations ............................................................................................................ 172 
Comparison of Volume of Distribution Obtained by Kinetic Modeling Approaches and Tumor-to-
Blood Ratios from Static Images ................................................................................................... 173 
Dynamic Lesion Embedding Study ..................................................................................................... 174 
Discussion .............................................................................................................................................. 176 
Chapter 7: Conclusions and Future Directions ..................................................................................... 180 
Extension of work to other research ...................................................................................................... 185 
Future directions .................................................................................................................................... 188 
References ......................................................................................................................................... 193 
 
 
ix   
 LIST OF TABLES 
Table I. Performance characteristics for PMT-based TOF PET scanners ....................................................... 41 
Table II. Performance characteristics for SiPM-based TOF PET scanners ..................................................... 42 
Table III. Spatial Resolution for the three simulated scanners ..................................................................... 65 
Table IV. Contrast recovery values for the three simulated scanners .......................................................... 70 
Table V. Activity concentrations used for each organ in the anthropomorphic adult and child phantoms 
based on the XCAT simulation ...................................................................................................................... 73 
Table VI. Spatial resolution of PennPET Explorer whole-body imager .......................................................... 79 
Table VII. Timing resolutions as measured at 4.25 kBq/cc ........................................................................... 84 
Table VIII. Metrics for human subjects who were imaged on the PennPET Explorer [102] .......................... 89 
Table IX. List of phantom distributions used for studies in this chapter ..................................................... 103 
Table X. Measured contrast of the 7-mm spheres at the 180 s per bed position scan duration for the three 
simulated activity distributions .................................................................................................................. 114 
Table XI. Average measured contrast over all axial positions .................................................................... 120 
Table XII. Minimum scan duration* with ALROC ≥ 0.80 ............................................................................. 127 
Table XIII. Kinetic Parameters for the dynamic Fluorothymidine simulation .............................................. 136 
Table XIV. Kinetic parameters for the dynamic fluorodeoxyglucose study ................................................. 141 





x   
LIST OF FIGURES 
Figure 1. Various clinical applications of PET scans from patients scanned at the University of Pennsylvania. 
(A) FDG PET scan of a patient with lung cancer. (B) DOTATATE PET scan of a patient with metastases from 
a neuroendocrine tumor (B). (C) FDG PET scan of a patient with epilepsy showing hypometabolism in the left 
temporal lobe (top). An amyloid PET scan of a patient with florid Alzheimer’s Disease (bottom). (D) A 
rubidium perfusion test that shows myocardial blood flow at stress and rest. A defect can be seen in the 
inferior region of myocardium on the stress scan but not the rest scan indicating reversible perfusion. .... 25 
Figure 2. Schematic showing true (blue), scattered (red), and randoms (green) events in both and axial (left) 
and transverse (right) view of a PET scanner, where annihilation events are shown in yellow. The dotted lines 
represent the LORs that would be drawn for that event and the resulting mispositioning of the event. 
Positron range and acolinearity are not depicted in this schematic. The scattered event shown in the axial 
view arises from an event outside the AFOV of the scanner. The random event in the transverse view is 
erroneously placed outside the contour of the patient’s body reflecting that randoms are mostly uniform 
throughout the FOV and the randoms event in the axial view shows that randoms can arise from activity in 
the patient’s body outside the imaging AFOV. ............................................................................................. 30 
Figure 3. A schematic of Radon projection showing the object 𝑓(𝑥, 𝑦) projected along angle 𝜑 to create the 
projection 𝑝(𝑠, 𝜑). ........................................................................................................................................ 32 
Figure 4. Generic time-Activity curves shown for blood and tissue (A). A generic two-compartment with 
kinetic parameters shown that can be used to fit TACs and individually estimate all kinetic parameters shown 
(B). Plot of data fit using Patlak graphical analysis where the slope equals the flux of the tracer (C). Plot of 
data fit using the Logan graphical analysis where the slope equals the volume of distribution of the tracer 
(D). Note that one dataset will rarely fit both graphical analysis methods well. ......................................... 37 
Figure 5. Images reconstructed without (left) and with (right) TOF. ............................................................ 40 
 
 
xi   
Figure 6. Sensitivity as a function of scanner AFOV for a (A) 27-cm distributed water-filled cylinder, (B) point 
source in air and (C) a point source in a 27 cm non-radioactive water-filled cylinder. The point source is 
centered in the transverse and axial FOVs. (A-C) Data courtesy of Dr. Suleman Surti. (D) The axial sensitivity 
profiles of a line source in a 20-cm water-filled cylinder. ............................................................................. 44 
Figure 7. Patient dynamically imaged with FTT. Data courtesy of Drs. Austin Pantel and Robert Mach, 
University of Pennsylvania. Static surview (left) shows both a liver lesion and a pelvic lesion (blue arrows) in 
this patient. Dynamic imaging (right) was only acquired for the pelvic lesion due to the limited AFOV of 
commercial scanners. Early time points show uptake in the external and internal iliac arteries, and later time 
points show uptake in the pelvic lesion. ....................................................................................................... 47 
Figure 8. Geometry of a single module, tile, die, and crystal (left to right). The first two rows of the module 
are gray to reflect the data inactive regions in the PennPET Explorer prototype, but which are filled in on the 
simulated 70-cm PennPET Explorer. ............................................................................................................. 51 
Figure 9. Scanner geometries shown for both simulated scanners: (A) Philips Vereos (AFOV = 16.4 cm), (B) 
23-cm AFOV ring-segment, and (C) the 70-cm PennPET Explorer, as well as (D) the prototype PennPET 
Explorer where the light blue regions reflect the data inactive regions of the scanner (effective AFOV = 64 
cm). .............................................................................................................................................................. 53 
Figure 10. The various components used to build up the PennPET Explorer including the PDPC tile (A) made 
of an 8x8 array of LYSO crystals; the detector module (B) made of a 4x7 array of tiles; the single ring segment 
(C) made of 18 detector modules; and the PennPET Explorer (D) made of 3 ring segments in the configuration 
used for initial phantom and human studies. ............................................................................................... 56 
Figure 11. NEMA performance metric tests for (A) sensitivity, (B) count rate, (C) spatial resolution, and (D) 
image quality where red represents regions filled with activity and grey represents phantom .................. 60 
 
 
xii   
Figure 12. (A) SNMMI CTN phantom [93]. (B) CT image of the inside of the phantom showing lung regions, 
background regions, and the outlines of water-filled spheres in both the lung and background regions. (C) 
PET image of a coronal slice of the SNMMI CTN phantom and (D) the corresponding maximum intensity 
projection image to show all spheres. .......................................................................................................... 62 
Figure 13. NEMA axial sensitivity profiles for the Philips Vereos (gray), 23-cm ring-segment (red), and the 
70-cm PennPET Explorer (blue). Axial sensitivity profiles are calculated based on data from the 70-cm line 
source with one attenuating sleeve. The dashed line shows an ideal triangular axial sensitivity profile. .... 64 
Figure 14. Pictorial depictions of transverse (left) and axial (right) parallax error. Transverse parallax error 
is seen in all PET scanners and the error further degrades radial spatial resolution as the point moves radially 
towards the edge of the scanner. Axial parallax error is only evident in long AFOV scanners and the error is 
most pronounced at the axial and transverse centers of the FOV. .............................................................. 67 
Figure 15. NEMA count rate curves for the Philips Vereos (left), 23-cm ring-segment (middle), and 70-cm 
PennPET Explorer (right) depicting the trues, scatter, randoms, and noise equivalent count rates for all three 
simulations. Results for the Philips Vereos also include measured count rate results by Philips. The clinical 
FDG range is shaded in red to reflect 2-6 kBq/cc. ........................................................................................ 68 
Figure 16. Single 2-mm slices of the simulated image quality phantom with four hot spheres at a 4:1 uptake 
and two cold spheres shown for the Philips Vereos (left), the 23-cm ring-segment (middle), and the 70-cm 
PennPET Explorer (right). ............................................................................................................................. 70 
Figure 17. Background variability across ten replicates for the 23-cm ring-segment (left) and the 70-cm 
PennPET Explorer (right) .............................................................................................................................. 70 
Figure 18. (A) CRC and (B) % SD measured for emulated doses of 1 to 1/16th the original dose. ................ 72 
 
 
xiii   
Figure 19. (A) Images showing a single slice through the liver of the XCAT phantom imaged on both the 23-
cm ring segment and the 70-cm PennPET Explorer. The VOI on the liver was used to measure background 
noise which is lower for the 70-cm PennPET Explorer, despite the 5x difference in scan duration. (B) Axial 
sensitivity profiles for the 70-cm PennPET Explorer, along with both the individual five bed positions and the 
summed profile of the five bed positions on the 23-cm ring-segment. ........................................................ 74 
Figure 20. (A) CRC and (B) %SD plots as a function of emulated dose for lesions in three organs: the lung 
(left), liver (middle), and breast (right), and two lesion sizes: 10 mm (top) and 13 mm (bottom). .............. 75 
Figure 21. Axial sensitivity profiles for a 70-cm line source in air and in a 20x70-cm water-filled cylinder. 78 
Figure 22. Comparison of count rate data as a function of activity concentration for the GATE simulation 
(solid line), individual rings of the PennPET Explorer (´ markers), and as measured by Philips on the 
commercial Philips Vereos (dashed line) for both (A) singles and (B) coincidence rates including trues, 
randoms, scatter, and NECR. ........................................................................................................................ 81 
Figure 23. Trues, randoms, scatter, and noise equivalent count rates (NECR) as a function of activity 
concentration for data collected on the PennPET Explorer at 18˚C. ............................................................. 83 
Figure 24. Timing resolution as a function of activity concentration for data collected at (A) 18˚C and (B) 5˚C 
for both individual rings from the PennPET Explorer (blue) and the three-ring system (red). Y-axes are scaled 
differently for (A) and (B). ............................................................................................................................ 85 
Figure 25. Images of the central axial slice of both the half-sized sphere phantom (left) and the full-sized 
sphere phantom (right). ............................................................................................................................... 86 
Figure 26. (A) Contrast recovery for both full-sized (blue) and half-sized (red) spheres as a function of sphere 
size and (B) background variability as a function of sphere size. ................................................................. 86 
 
 
xiv   
Figure 27. (A) Coronal 2-mm slice of the reconstructed uniform cylinder. (B) Mean and standard deviation of 
counts in a 15 cm ROI as a function of axial position. (C) % SD of counts in a 15 cm ROI as a function of axial 
position shows image roughness. ................................................................................................................ 87 
Figure 28. Coronal 2-mm slice images of subject # 1 scan # 1 at various scan durations: 20 min, 10 min, 5 
min, 2.5 min 75 sec, and 38 sec (left to right). Image roughness in the liver is reported for each scan duration 
[102]. ............................................................................................................................................................ 90 
Figure 29. (A) Select 2-mm coronal slices of subjects #1 (top), #3 (middle), #7 (bottom) at various time points 
(right to left). Insets show uptake in the brain and myocardium over time at an adjusted color scale. (B) Plots 
showing the 24-hr time course of uptake in various organs for subjects #1 (left), #3 (middle), #7 (right). 
Uptake in the images and plots are both in kBq/cc and are directly comparable [104]. ............................. 92 
Figure 30. Axial (top) and coronal (bottom) 2-mm slices of a clinical patient with colorectal cancer imaged 
at an initial time point (subject #5) and a follow-up time point (subject #10) a few months later. Images are 
shown for the clinical PET/CT at the initial timepoint along with two subsequent scans on the PennPET 
Explorer, and for the clinical PET at the follow-up time point along with the PennPET Explorer scan [102].93 
Figure 31. 68Ga-DOTATATE images of a clinical patient with neuroendocrine tumors imaged on the PennPET 
Explorer at two time points after an SoC clinical scan [102]. ....................................................................... 94 
Figure 32. (A) MIP coronal images of the early time course showing blood flow through the lungs and 
vasculature. (B) Time-activity curves of the full 60-min time course for all organs in the FOV (left) and for 
various blood vessels during the first 50-s after injection [102]. .................................................................. 95 
Figure 33. (A) Schematic of the most likely positioning algorithm used to calculate the axial sensitivity for 
each axial location. Events are deposited into their corresponding axial position, based on the TOF difference 
of arrival of the two annihilation photons. (B) Schematic illustrating the axial placement of spheres in 
cylinder measurements (Table IX, Study C) with respect to the inactive regions in the PennPET Explorer. 102 
 
 
xv   
Figure 34. Images of phantoms used for preliminary data GATE simulations including (A) a uniform cylinder 
with lesions placed in a cylinder in slices at ±  6.0 cm, (B) an anthropomorphic child phantom of a 7-year-old 
female with lesion embedded in the liver, and (C) an anthropomorphic adult phantom of a 5’ 5” female with 
lesions embedded in the liver. .................................................................................................................... 104 
Figure 35. (A) Plot of the axial sensitivity profiles for both simulated and measured scanners along with the 
axial locations at which spheres were placed (diamonds). Shaded boxes below the plot indicate axial 
coverage of data active (blue) and inactive (gray) regions of the PennPET Explorer, while the red outlines 
indicate the axial coverage of the 70-cm simulated scanner. (B) Schematic of the simulated scanner and 
PennPET Explorer where shaded regions reflect axial LORs that pass through that region. The number of 
LORs that pass through any given axial location reflects the axial sensitivity at that location. ................. 108 
Figure 36. The generalized scans statistics model measures (A) local contrast of spheres in an image and (B) 
scans the background image to measure local at every voxel within the dashed circle to (C) generate the 
corresponding PDFs of contrast for the background (g(c )) and the sphere (g(c )). ALROC can then be 
calculated using the formula shown, where G(c) is the cumulative distribution function of g(c ). ........... 113 
Figure 37. Coronal 2-mm slices of the (A) 20 x 70 cm uniform cylinder and (B) anthropomorphic child 
phantom. Lesions were embedded at 2:1-, 3:1-, and 4:1-uptake and for simulations on the 23-cm ring-
segment in a single bed position (top), three bed positions with 50% overlap (middle), and simulated on the 
70-cm PennPET Explorer in one bed position (bottom). ............................................................................. 114 
Figure 38. ALROC results for GATE simulations of phantoms used for preliminary data including (A) The 20 x 
70 cm uniform cylinder (B) an anthropomorphic child phantom, and (C) the anthropomorphic phantom 
representing a 5’ 5” female adult. ALROC results are shown as a function of scan time per bed position for 
three lesion uptakes: 4:1 (red), 3:1 (blue), and 2:1 (gray). The solid line reflects the 70-cm simulation of the 
PennPET Explorer, the dashed line reflects the 23-cm ring-segment simulation for three overlapping bed 
positions, and the dash-dot line reflects the 23-cm ring-segment simulation for a single bed position. (D) 
 
 
xvi   
ALROC for the 20 x 70 cm uniform cylinder as a function of counts for simulations on the 23-cm ring-segment 
in a single bed position (triangle) and the 70-cm PennPET Explorer (circle). ............................................. 116 
Figure 39. Contrast vs. axial position for (A) 6-mm and (B) 10-mm spheres embedded in a 20-cm cylindrical 
phantom. (Top) Higher uptake and (bottom) lower uptake spheres are shown for both the simulation in red 
and measurement in blue. Scanner detector geometries for the 3 ring segments are shown in shaded boxes: 
simulation (red) and measurement (blue). The measurements cover 64 cm AFOV due to inter-ring data gaps 
indicated with lighter shading in the schematics. ...................................................................................... 119 
Figure 40. ALROC vs. axial position for 6-mm spheres embedded at 6:1 uptake in the cylindrical phantom at 
scan times ranging from 5-180 s. Scanner detector geometries for (A) simulation and (B) measurement are 
shown by shaded boxes. ............................................................................................................................. 120 
Figure 41. ALROC for (A) 6-mm and (B) 10-mm spheres in the cylindrical phantom as a function of counts. 
Note that each data point corresponds to a different axial location and counts were determined by the most 
likely positioning algorithm. Data from the simulation (red) and measurement (blue) are included for both 
the higher uptake (square) and lower uptake (star) spheres. .................................................................... 121 
Figure 42. (A) Representative images from the CTN phantom with (top) 6-mm and (bottom) 10-mm 
embedded spheres for a scan times ranging from 360 s (left) to 5 s (right) and (B) the corresponding ALROC 
plot as a function of scan duration including 6-mm (dashed) and 10-mm (solid) lesions in both the liver 
(green) and lung (blue). There were 22 spheres embedded in the lung (6 visible in the 2-mm thick coronal 
image shown) and 17 spheres in the liver (3 visible) distributed volumetrically throughout each organ region. 
The embedded lesions are circled to identify them from the physical CTN spheres. .................................. 122 
Figure 43. (A) Representative images from the human subject with (top) 6-mm and (bottom) 10-mm 
embedded spheres for a scan times ranging from 180 s (left) to 5 s (right) and (B) the corresponding ALROC 
plot as a function of scan duration including 6-mm (dashed) and 10-mm (solid) lesions in both the liver 
 
 
xvii   
(green) and lung (blue). There were 27 spheres embedded in the lung (5 visible in the 2-mm thick coronal 
image shown) and 16 spheres in the liver (3 visible) distributed volumetrically throughout each organ. The 
embedded lesions are highlighted. ............................................................................................................. 123 
Figure 44. ALROC for the (a) 4:1-uptake 6-mm spheres and (b) 3:1-uptake 10-mm spheres as a function of 
measured axial counts for the cylindrical phantom (red and blue squares), CTN phantom (yellow diamonds), 
and human subject (green diamonds) with corresponding trend curves. .................................................. 124 
Figure 45. Ideal simulated FLT time-activity curves for the low, medium, and high uptake lesions (blue) in the 
modified NEMA image quality phantom along with the blood input function (red). Images (2-mm slice) of 
the modified IQ phantom for the full-dose dataset are shown at the top. An early frame clearly (at 22 s, 5 s 
duration) shows blood pool uptake and a later frame (at 32 min, 5 min duration) shows uptake in the low 
(top), medium (middle), and high (bottom) flux lesions and the difference between the 13 mm (left) and 10 
mm (right) lesions. Example data points from a single dynamic phantom simulation, are shown in gray for 
the 10-mm spheres at full dose (4 mCi, 148 MBq). .................................................................................... 137 
Figure 46. Ideal TACs for FDG lesion embedding for the lung (left) and liver (right). ................................. 141 
Figure 47. (A) Representative images of the modified image quality phantom at full-dose on both the 23-cm 
(top) and 70-cm scanners (bottom) at various time points: 22 sec (5 s duration), 32 min (5 min), 60 min (5 
min) and summed 19-60 min (left to right). (B) TACs with measured data at full-dose for all sphere sizes and 
fluxes for both the 23-cm scanner (left) and the 70-cm scanner (right). .................................................... 144 
Figure 48. Bias (A) and % SD (B) results quantifying flux (KFLT) fit using a two-tissue-compartment model. 
Data are from the FLT simulation for the 23-cm ring-segment (red) and the 70-cm PennPET Explorer 
simulation (blue). Results are shown for the low, medium, and high (left to right) flux spheres and for the 10 
mm (top) and 13 mm (bottom) spheres. .................................................................................................... 145 
 
 
xviii   
Figure 49. Bias (A) and % SD (B) results quantifying delivery (K1) fit using a two-tissue-compartment model. 
Data were measured from the FLT simulation for both the 23-cm ring-segment (red) and the 70-cm PennPET 
Explorer simulation (blue). Results are shown for the low, medium, and high (left to right) flux spheres and 
for the 10 mm (top) and 13 mm (bottom) spheres. ................................................................................... 146 
Figure 50. Maximum intensity projection images showing early, middle, and late (left to right) frames for 
the medium flux lesion datasets. 10 lesions are visible in the liver, 7 lesions are visible in the right lung, and 
6 lesions are visible in the left lung. ............................................................................................................ 147 
Figure 51. Plots depicting the correspondence between measured sphere data (colored x’s) and ideal curves 
(black lines) for embedded spheres in the lung (A) and liver (B). Data shown are for the 10-mm spheres from 
the 15 mCi dose dataset. Also shown are the measured blood curve (red), background lung curve (sky blue), 
and background liver curve (olive green). .................................................................................................. 148 
Figure 52. Bias (A) and % SD (B) results quantifying flux (KFDG) using Patlak graphical analysis as measured 
from the FDG PennPET Explorer emulation for the 6-mm sphere (medium blue) and the 10-mm sphere (dark 
blue). Results are shown for the low, medium, and high (left to right) flux spheres for the lung (top) and liver 
(bottom). Note the y-axis for the liver plots of % SD has a maximum of 80% as opposed to 40% for all other 
% SD plots. .................................................................................................................................................. 149 
Figure 53. Bias (A) and % SD (B) results quantifying flux (KFDG) using a two-compartment fit as measured 
from the FDG PennPET Explorer emulation for the 6-mm sphere (lighter blue) and the 10-mm sphere (dark 
blue). Results are shown for the low, medium, and high (left to right) flux spheres and for the lung (top) and 
liver (bottom). ............................................................................................................................................ 150 
Figure 54. Bias (A) and % SD (B) results quantifying delivery (K1) using a two-compartment fit as measured 
from the FDG PennPET Explorer emulation for the 6-mm sphere (medium blue) and the 10-mm sphere (dark 
 
 
xix   
blue). Results are shown for the low, medium, and high (left to right) flux spheres and for the lung (top) and 
liver (bottom) spheres. ............................................................................................................................... 151 
Figure 55. Metabolic pathways of glucose and glutamine along with their corresponding PET radiotracers 
FDG and FGln. FGln enters the cell through a transporter and a small portion may be metabolized into 
proteins and macromolecules. Glutamine enters the cell and can be metabolized into proteins and 
macromolecules or enter the mitochondria. Glutamine in the mitochondria can then be metabolized to 
glutamate via glutaminase (GLS). Glutaminolysis can be inhibited via the drug CB-839. Glutamate then 
enters the tricarboxylic cycle (TCA). Glucose enters the cell through a transporter and is then converted to 
pyruvate through a series of steps. In cancerous cells, conversion of pyruvate to lactate is preferred as an 
energy source. In healthy cells pyruvate is converted into acetyl CoA in the mitochondria and enters the TCA 
cycle. FDG enters the cell through a non-specific transporter and is converted to FDG6P via hexokinase (HK). 
Further metabolism of FDG does not occur due to increased specificity of enzymes. GLS refers to 
glutaminase, HK refers to hexokinase, G6P refers to glucose-6-phosphate, FDG6P refers to FDG-6-
phosphate, a-KG is alpha-ketoglutarate, OAA is oxaloacetic acid. CB-839 is a glutaminase inhibitor. ..... 161 
Figure 56. TACs for the dual tracer study with 3 mCi injections of FGln for medium flux lesions. TACs are 
shown for both a 30 min interval between injections and a 45 min interval between injections. ............. 166 
Figure 57. Coronal and axial slices of a patient with ER+ breast cancer imaged with FGln (left) and FDG 
(right). Courtesy of Dr. Austin Pantel. ........................................................................................................ 167 
Figure 58.  Static images of TNBC (A, B) and ER+ (C, D) tumor xenografts and the response to glutaminase 
inhibition (post-CB-839 images in the right-hand column).  Tumor and blood time activity curves 
demonstrate adequate temporal sampling of radiotracer uptake over time [153]. .................................. 169 
 
 
xx   
Figure 59. Single-compartment model fit (A, C) and two-compartment model fit (B, D) of the same 
representative time-activity curves for the ER+ and TNBC mice prior to treatment. The two-compartment fit 
separately shows the time course of the individual compartments [153]. ................................................. 170 
Figure 60. (A) Logan graphical analysis and (B) Patlak graphical analysis of the same representative time-
activity curves for the ER+ and TNBC mice prior to treatment [153]. ......................................................... 171 
Figure 61. Comparison of true vs estimated VD values for a one-compartment (left) and a two-compartment 
model with trapping (right) [153]. ............................................................................................................. 173 
Figure 62. Comparison of volume of distribution of FGln by compartmental and graphical analysis, as well 
as tumor-to-blood ratios [153]. .................................................................................................................. 174 
Figure 63. Coronal 2-mm slices showing the last frames for the FGln injection with 30 min, 45 min, and 60 
min (top, left to right) between injections and for an early and late FDG frame (bottom, left to right). The 
early frame (shown in maximum intensity projection, MIP) shows residual activity from the FGln injection. 
Data are shown for medium flux embedded spheres and a 3 mCi injection of FGln. ................................. 175 
Figure 64. TACs with measured sphere contrasts for the dataset with (A) 30 min and (B) 45 min interval 
between injections of FGln and FDG. Blue diamonds show measured TACs for the 16 lung lesions embedded 
in the data. ................................................................................................................................................. 175 
Figure 65. (A) Development of a segmentation algorithm using dynamic FLT simulation data from Chapter 
5 showing representative center slice images (top) and average per-region TACs (bottom) of true 
segmentation labels (left) and segmentation results using Rad-FIT clustering (right). (B) Application of the 
Rad-FIT clustering algorithm to segmenting primary breast cancer tumors of FDG patients dynamically 
imaged showing axial slice images of a late frame (left), subregions identified using the Rad-FIT algorithm 
(middle) and corresponding TACs for each identified region (right) [156]. ................................................ 185 
 
 
xxi   
Figure 66. (A) Axial and coronal 2-mm slices of the XCAT phantom reconstructed using standard PET 
reconstruction with known attenuation correction (left) and reconstructed using CT-less PET reconstruction 
(right). (B) Axial and coronal 2-mm slices of the dynamic FDG human subject data reconstructed with 
analytic DIRECT, iterative DIRECT and 4D-DIRECT (left to right). Courtesy of Drs. Yusheng Li and Samuel Matej
 ................................................................................................................................................................... 186 
Figure 67. (A) Axial spatial resolution of point sources and (B) CRC of a 6-mm sphere as a function of axial 
location for a  GATE simulation of a 140-cm 6-ring scanner [158]. ............................................................ 187 
Figure 68. (A) Image of the 5-ring PennPET Explorer and attached CT scanner. (B) MIP coronal image of nine 
point-sources imaged on the 5-ring PennPET Explorer. Point sources are 12 cm apart and the full axial length 





xxii   
LIST OF EQUATIONS 
Equation I. MLEM reconstruction algorithm formulation [28] ..................................................................... 35 
Equation II. Calculation of the number of sphere list-mode events to embed with desired uptake ........... 108 
 
 
1   
ABSTRACT 
This thesis characterizes the long axial field-of-view (AFOV) PennPET Explorer scanner and studies 
the benefits for clinical and research applications using both measurements and Monte-Carlo 
simulations. The significant increase in photon sensitivity from extending the standard AFOV of a 
PET scanner by 3-6 times to 70-140 cm may allow for fast, low-dose imaging and more accurate 
quantification using a wide variety of radiotracers. Results of performance characterization, 
including sensitivity, count rate, spatial resolution, and lesion contrast, showed good 
correspondence across simulated and measured data, indicating an accurate model of the 
PennPET Explorer. A key clinical application,  lesion detection, was studied with small lesions in 
both uniform and complex background distributions. Results showed that good lesion 
detectability and localization was achieved in the human subject for 30-60 s scan durations for 
the PennPET Explorer, compared to a 1.5-3 min scan on standard AFOV scanners. Dynamic 
imaging, often required for research applications, was studied using both simulated and 
measured datasets to quantify the accuracy and precision of key biologic parameters as a function 
of injected radioactive dose. Results showed that the dose can be lowered from 5-15 mCi, typical 
with a standard AFOV PET scanner, to 1-2 mCi with our long AFOV scanner while still maintaining 
accuracy and precision of key biologic parameters. These results were then used to design a dual 
tracer imaging study to sequentially image two radiotracers, labeled with the same radioisotope, 
to study complementary mechanisms of metabolism. Preliminary results indicate that a low, 3 
mCi dose with the first tracer, imaged for an abbreviated 30 min, and followed by a 15 mCi 
injection of a second tracer resulted in time-activity curves (TACs) with low noise, and can be used 
to further optimize this new protocol. Combined, these results offer a quantitative framework for 
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both static and dynamic imaging on the PennPET Explorer and can be applied to develop new 
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CHAPTER 1: INTRODUCTION TO THESIS  
Positron emission tomography (PET) imaging is a widely used clinical and research functional 
imaging modality for measuring the physical behavior of injected radiotracers in the body. PET is 
uniquely positioned for these studies because it has epic photon sensitivity compared to other 
imaging modalities that allows for imaging of radiotracers at very low concentrations, on the order 
of pico-molar. In general, the low concentration of injected radiotracers allows PET to probe 
biologic systems without disrupting them, which minimizes toxicities and adverse effects of 
injecting a radiotracer into a patient compared to contrast agents for other imaging modalities. 
The primary clinical tracer used in PET imaging is fluorodeoxyglucose (FDG), which measures 
glycolysis, although other tracers are also employed to image biologic processes other than 
glycolysis, including 82Rb for cardiac perfusion imaging or 68Ga-DOTATATE for somatostatin 
receptor imaging of neuroendocrine tumors. PET’s major clinical uses include detecting and 
following response to treatment of cancer in oncology, quantifying myocardial blood flow and 
viability in cardiology, and localizing seizure foci and assessing amyloid burden in neurology.  
While current PET/CT instruments provide excellent image quality, there are many situations 
where higher sensitivity would be desirable for clinical PET studies. Some examples include 
imaging of large patients where many of the emitted photons are attenuated or scattered in the 
body or cases where injecting a lower radioactive dose would be desirable such as imaging 
pediatric patients or imaging patients who get numerous PET scans over the course of their 
treatment. 
Additionally, many newer PET tracers show valuable research applications such as imaging tau 
neurofibrillary tangles, studying how cancer cells use different energy sources, and tracking the 
efficacy of immunotherapy treatments over time (e.g. CAR-T cells). Dynamic imaging of 
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radiotracers, where a patient is injected with the tracer and the time course of uptake in each cell 
is measured, is a PET imaging method used to study newly developed radiotracers and their 
potential clinical uses. Dynamic data can be used to not only look at whether uptake is increasing 
within a cluster of cells but can also be fit to compartmental models to quantify parameters such 
as flux through the tissue, volume of distribution of a compartment, or binding potential to a 
receptor. These parameters are typically correlated with key clinical metrics or physiologic 
parameters of interest. Dynamic imaging is also often used to determine the optimal time point 
at which a new tracer be used for a static clinical acquisition protocol. However, to get temporally 
continuous dynamic information, data can only be taken in a single bed position, which typically 
limits the coverage to a single organ, since commercial PET scanners have a < 30 cm standard axial 
length. 
Recent advances in commercial PET technology have led to improved image quality and shorter 
patient scan times in the clinic. This is mainly due to the transition from using analog detectors – 
conventional photomultiplier tubes (PMTs) – to digital detectors – silicon photomultipliers – 
which has enabled improvements in timing resolution from 500 ps to 200 ps, spatial resolution 
from 5 mm to < 4 mm, and count rate linearity at very high activity concentrations. However, 
while PET is a very sensitive clinical imaging modality, current commercial instruments still only 
detect only 1-2 percent of emitted photons. In addition, static imaging of the whole patient 
requires multiple bed positions due to its limited axial extent for a total imaging scan time on the 
order of 10-20 min in order to cover an axial extent from the patient’s eyes to their thighs, a 
typical whole-body survey. 
A very significant gain in total sensitivity (20-40x) can be achieved by extending the axial length of 
a PET scanner to cover a major fraction of the patient. In addition, the long axial length enables 
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the possibility to perform multi organ dynamic imaging. The sensitivity gain is achieved by (1) 
increasing the solid angle at which coincident photons can be detected and (2) detecting photons 
emitted over a greater portion of the patient’s body. Until recently there have been few resources 
available to increase the axial length of clinical PET scanners, mainly due to increased cost of 
materials, engineering complexity, and difficulty handling the size of data collected. However, in 
2015 the EXPLORER (Extreme performance long research scanner) consortium was formed and 
tasked by the NIH (R01-CA206187) to build a long axial field of view PET scanner and investigate 
the benefits and potential applications of such a system. 
The major motivations and potential benefits of a long axial field of view (AFOV) PET scanner are 
outlined in detail below. The benefits of the long AFOV PET scanner depend on its higher 
sensitivity for static imaging and on dynamic imaging of the whole body simultaneously. One 
exploratory application for long AFOV scanners is dual-tracer imaging where dynamic imaging of 
multiple tracers that offer complementary information about the function of an organ or lesion is 
acquired in a single imaging session while the subject is in a fixed physiologic state. Dual-tracer 
imaging leverages both the increased sensitivity of a long AFOV scanner and whole-body dynamic 
imaging to collect accurate kinetic information from both tracers imaged. 
A. Static Imaging 
o PET images can be acquired in the same amount of time as current clinical PET scans with 
much better image quality due to higher statistics.  
o The improved count statistics can also be leveraged to either inject lower radioactive dose 
into patients, which is especially valuable for populations that get numerous PET scans 
throughout their treatment. 
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o The increased sensitivity of a long AFOV scanner can also be used to acquire short scans 
at a standard dose, which could be valuable for (1) imaging pediatric patients who are 
currently anesthetized or for (2) breath hold imaging of respiratory disease to reduce 
motion blurring. 
o Finally, the improved count statistics will facilitate improved quantitative accuracy of 
lesion uptake and detectability, important clinical metrics. 
B. Dynamic Imaging 
o Total body dynamic PET can be used to image multiple organs simultaneously over a 
larger axial range where current dynamic imaging on standard AFOV scanners is forced to 
image a single organ. This would enable studies of lesions in different organs and the 
relationships between different organs in certain disease states (e.g. brain-gut 
relationships in Parkinson’s’ disease). 
o The increased sensitivity of a total body scanner will allow for accurate estimation of 
kinetic parameters of interest at lower injected doses and more accurate estimation of 
the blood input function with finer temporal sampling, a key input for kinetic modeling. 
o Additionally, since many vessels will be within the FOV, blood input functions can be 
accurately measured locally for various lesions in distant locations depending on the 
blood supply for that lesion. 
C. Dual (Multi) Tracer Dynamic Imaging 
o The increased sensitivity of a total body scanner will permit injection of the first 
radiotracer at a lower dose with dynamic imaging for an abbreviated time course followed 
by a standard injection of a second radiotracer (e.g. FDG) that is imaged dynamically for 
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the standard time course (e.g. 60 min for FDG). The overall time course and patient dose 
will be decreased compared to multiple dynamic imaging sessions. 
At the onset of this work, plans were in place to begin construction of two long AFOV systems, 
which have since been completed: the 194-cm uExplorer developed by United Imaging and sited 
at UC Davis, and the PennPET Explorer, which was originally tested in a 70-cm prototype 
configuration and is currently being extended to an axial length of 140 cm at new imaging facility 
within Penn’s School of Medicine. This thesis was designed to quantitatively evaluate long AFOV 
systems using the 70-cm prototype PennPET Explorer, which is 3-4x the length of standard AFOV 
PET systems. We began with simulation studies of a 16.4-cm long scanner and a 23-cm long 
scanner, meant to represent a standard AFOV system, followed by simulations of a 70-cm long 
AFOV scanner and measurements on the 70-cm long PennPET Explorer. 
The goal of this work is to understand and quantify the benefits of the increased sensitivity of a 
70-cm long AFOV PET scanner in comparison to scanners with a standard axial length while 
considering how a long AFOV scanner will perform when extended to 140 cm and beyond. 
Importantly, this information is needed to design and optimize imaging protocols to best leverage 
the benefits of the PennPET Explorer once it becomes operational for clinical research. We 
designed simulations and measurements of the 70-cm long PennPET Explorer for four major 
studies and compared results to a standard AFOV scanner. The first two studies described here 
are focused on clinical applications for the scanner, that is static imaging of lesions with a focus 
on accurate quantitation and detectability, while the final two studies focus on potential research 
applications for long AFOV imaging with dynamic protocols that allow characterization of cancer 
lesions using tracer kinetic models. 
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1. Quantify the instrument performance using the standard National Electrical 
Manufacturers Association (NEMA) performance tests – sensitivity, spatial resolution, 
count rate, and image quality – and assess how they depend on the axial length of the 
scanner to establish baseline information to test the hardware and software of the 
instrument. (Chapter 3) 
2. Quantify the improvement in lesion detectability for a long AFOV scanner, the 70-cm 
three-ring PennPET Explorer, compared to a standard AFOV scanner, the 23-cm ring-
segment, and its relationship with sensitivity and axial location with the AFOV. We use 
lesion detectability as a metric for the clinical task performed by radiologists. This study 
will inform how adjusting scan parameters, such as scan time and injected dose, will affect 
detectability and therefore clinical performance of a long AFOV scanner. (Chapter 4) 
3. Understand how the increased sensitivity of total-body PET imaging, compared to 
standard length scanners, affects quantification of kinetic parameters when dynamically 
imaging a single tracer. This study will also focus on how kinetic parameter estimation 
behaves at lower injected doses so that we can understand the quantitative accuracy of 
results are when imaging with novel tracers at lower doses. (Chapter 5) 
4. Design a dual tracer dynamic imaging protocol that maintains accurate kinetic parameter 
estimation of both radiotracers while minimizing total scan time and injected dose of the 
first tracer. This protocol will use fluoroglutamine (FGln) as the first tracer and FDG as the 
second tracer. It will be implemented on the PennPET Explorer to image two tracers that 
will offer complementary insights into the biology of cancers imaged. (Chapter 6) 
CHALLENGES AND DEVELOPMENT OF NEW METHODOLOGIES 
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To complete this work, a number of new technologies had to be implemented in the lab, and a 
few new methodologies were developed. Additionally, during the course of this work, the 
PennPET Explorer was built and tested. The following section describes my role in the 
development and implementation of the work done, along with well-established standards and 
methodologies that I learned and expanded for this work. 
All simulations in this work were run using Geant4 Application for Tomographic Emission (GATE). 
GATE is a well-established open source software used for simulations of PET scanners; however, 
when we first decided to run GATE simulations in January of 2017, no one currently working in 
the lab had any experience implementing or running GATE. The most common simulation tool 
used in the lab at that point was EGS4, which offered a simple simulation of a cylindrical PET 
system but did not model the details of scanner geometries. GATE, although slower and more 
cumbersome than EGS4, models every detail of the scanner geometry, simulates complex objects 
based on activity values, and includes all aspects of photon interactions with media. Facilitated by 
Dr. Amy Perkins, our Philips Healthcare liaison, Philips provided files defining the scanner 
geometry of the Philips Vereos, files defining common phantoms imaged, and scripts to convert 
the output files from GATE into list-mode files that would result from data acquisition on a Philips 
scanner. At this point in time, with the assistance of Dr. Margaret Daube-Witherspoon, a research 
scientist in the lab who has spent countless hours mentoring and advising me throughout the 
thesis, I had spent a full year in the lab learning to process, reconstruct, and analyze both dynamic 
human research data and static phantom data using tools specific to the Philips format, which is 
common to both Philips and our work at UPenn. The tools provided by Philips for GATE 
simulations to convert the GATE output into the data format shared by Philips and Penn 
significantly decreased the time required to implement these simulations. Throughout this first 
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year of simulation work, Amy was instrumental in helping us compare my results with data 
measured on the Philips Vereos. 
To implement running GATE on our lab cluster efficiently, I had assistance from Dr. Yannick Berker, 
a former visiting post-doctoral fellow from Germany who primarily worked on image 
reconstruction algorithms, and Dr. Dale Stentz, a post-doctoral fellow who works on building and 
characterizing a cardiac SPECT system. Yannick was key in helping me understand the more 
technical components of running GATE and understanding the structure of the ROOT output 
format, while Dale helped me troubleshoot errors, offered advice on visualization tools, and 
assisted in deciphering and updating the Philips scripts that converted the ROOT data into a Philips 
list-mode format. These scripts were not only written in C code, which I did not have familiarity 
with, they also directly wrote out data into list-mode by shifting bits. The goal of this work was to 
extend Philip’s GATE simulations of the Philips Vereos to a long AFOV system by placing multiple 
Philips Vereos systems back-to-back. While implementing this extension of the AFOV in the GATE 
geometry files was simple, adjusting the conversion from ROOT format to list-mode files was not. 
With Dale’s assistance, we were able to decipher how the conversion scripts calculated crystal 
positions and we updated the files to accurately calculate these values for the long AFOV systems 
we were designing. We also updated the files to write list-mode data into generic text files that 
could then be converted into the Philips list-mode format instead of shifting bits to write directly 
into the Philips list-mode format.  
GATE simulations of three geometries were then run to quantify the NEMA standards: the original 
16.4-cm Philips Vereos, a 23-cm ring-segment, and the 70-cm PennPET Explorer. The NEMA 
standards were relatively simple to implement since Philips had provided the phantom geometry 
files; however, while running count rate analyses, we discovered that at higher activity 
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concentrations, the GATE coincidence processor had computational deadtime that resulted in 
fewer events than were expected based on physics. This resulted a month or so of study before I 
learned that the developers of GATE were aware of this issue and that the newest version of GATE 
had fixed these issues. GATE V8.0 came out in late April of 2017, at which point we re-ran all of 
our NEMA simulations for the three scanners we were interested in, and the new version of GATE 
successfully corrected this error. 
After simulating simple geometries in GATE, we decided to move towards anthropomorphic 
phantoms and purchased the 4D Extended Cardiac-Torso Phantom (XCAT). The XCAT simulation 
is based on a composite of MRIs of patients to create a non-uniform rational basis spline (NURBS) 
definition of organs within a patient. The XCAT simulates every organ imaginable so we first had 
to make some executive decisions on which organs to include and which could be ignored. We 
chose to simulate the female XCAT phantom with 17 organs defined. The next hurdle was finding 
data to fill these organs with a standard FDG-like distribution. There was surprisingly little 
literature available despite the widespread use of FDG; however, we used a composite of data 
acquired in the clinic, along with two atlas papers, to fill the anthropomorphic phantom with an 
FDG-like distribution. Finally, there were two major issues in implementing GATE simulations of 
the XCAT phantom. First, the XCAT simulation outputs a phantom with given attenuation values; 
however, GATE requires definitions of the object based on materials like water, air, liver, or lung 
which are listed in a database as composite of elements or other materials. I had to segment the 
output attenuation image and assign constant values for each of the 17 organs, so that each 
organ’s attenuation could be assigned based on a GATE material. The second issue was 
computational in nature. One of the goals of the XCAT simulation was to include 10-13 mm 
diameter spheres to assess quantitation on our simulated scanners; however, the GATE memory 
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requirements for the XCAT simulation were much greater than anticipated. To ensure sufficient 
parallelization of GATE runs, the XCAT image had 3 mm voxels, which would have resulted in very 
coarsely sampled spheres. For reference, a 3 min scan of the XCAT phantom imaged one hour 
after a 10 mCi injection of FDG takes five days to simulate using much of the computational power 
of our lab cluster (168 cores). Therefore, we made the decision to simulate spheres separately, 
define them based on geometry, and combine the sphere and XCAT list-mode data after the fact. 
At this point, most of the difficult legwork for implementing the simulations was complete and all 
future simulations were based on these efforts. Some of these simulation results, along with 
preliminary details of building the PennPET Explorer, were also published in a conference 
proceeding that I wrote for a talk given by my advisor (Prof. Joel Karp) at the Jagellonian PET 
conference in June of 2017. I presented the simulated NEMA and XCAT work on the 23-cm ring-
segment and 70-cm PennPET Explorer at the 2017 IEEE Molecular Imaging conference (MIC) in 
Atlanta, GA that was subsequently published in the conference record. These results are included 
in Chapter 3 of this thesis.  
Over the summer of 2017, I also began to participate in building components of the PennPET 
Explorer and in the latter half of 2017, I began helping with data acquisition and processing, and 
writing scripts to efficiently reconstruct and analyze multi-ring data. The first multi-ring dataset 
acquired was of a small cylindrical phantom in late November of 2017 on two ring-segments of 
the PennPET Explorer prototype. By May of 2018 we had built and collected data on a three-ring 
system and by August of 2018 we imaged our first human subject on the three-ring PennPET 
Explorer prototype. One of the key difficulties with acquiring data from multiple rings is that all 
the rings were designed to operate independently and the time clocks between the rings had to 
be synchronized to properly reconstruct and analyze data. We tested several methods but found 
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that acquiring a point source at the center of reach ring at the beginning of every acquisition was 
the best option going forward; however, the PennPET Explorer Team is still working on 
streamlining this process to minimize the number of points acquired before a scan and to 
maximize reliability of the methodology. From early 2018 through mid 2019, I organized the 
collection of phantom datasets for NEMA standards, assisted in collecting human subject and 
patient data on the scanner, created scripts and processed reconstructions of all data collected 
on the scanner, and performed NEMA analyses of data collected. Building the scanner and 
evaluating its performance gave me a greater appreciation of the complexity of the system and 
the potential sources of error that could be present in reconstructed images. While instrumental 
in helping me to achieve the goals of my research, this work also contributed significantly to the 
broader goals of NIH funded projects supporting development of the scanner (R01 CA-113941, 
R01-CA225874). Additionally, I ran GATE simulations of a six-ring system to help software 
developers on the PennPET Explorer team to expand data formats and update tools to efficiently 
handle data from the system, when it is complete. Currently, five of the six rings have been built 
in our imaging facility and we have collected and reconstructed five ring point source data. 
In late 2017/early 2018 in collaboration with the group of investigators from the NIH Cancer 
Moonshot project (R33-CA225310), I designed a framework to dynamically simulate spheres in 
the image quality phantom. This simulation was based on FLT, a dynamic tracer associated with 
cellular proliferation, and early on, this work was going to be based on dynamic breast FLT data 
acquired at the University of Washington in Seattle and analyzed by Mark Muzi, one of our 
collaborators with a long history working with dynamic data and who helped with subsequent 
dynamic imaging studies. Unfortunately, due to the instability of the data and disagreement 
between analysis at the two centers, we chose to use blood data provided by the breast FLT 
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patients and kinetic parameters from lung cancer patients imaged with FLT to design our studies. 
For this work, we had to use both PMOD and STELLA, two kinetic modeling software packages. 
PMOD takes the blood and tissue TACs as input and outputs the best fit kinetic parameters for a 
given model, while STELLA uses the kinetic parameters and blood input function as inputs and 
outputs the tissue TAC for a given model. I had previously learned how to use PMOD in early 2016 
when I was analyzing dynamic patient data from a research study. I learned to use STELLA for this 
work with the assistance of Dr. Austin Pantel, who was an instrumental collaborator in all the 
clinical and dynamic work done in this thesis. I presented results this work in June 2018 in an oral 
presentation at the Total-Body PET conference in Ghent, Belgium and are included in Chapter 5. 
During this time period, I also began working on lesion detectability studies using simulations of 
a uniform cylinder, the adult female XCAT phantom, and a female child XCAT phantom. Although 
lesion detectability using the generalized scan statistics methodology, a numerical approach, was 
well established and had been thoroughly characterized by Dr. Suleman Surti, an associate 
research faculty member within the group, both Suleman and I had difficulty interpreting results 
from the study. The generalized scan statistics methodology effectively compares the probability 
distribution functions (PDF) of the background to the PDF of the lesions to calculate detectability 
of those lesions. We discovered that when simulated on the 70-cm PennPET Explorer, the signal-
to-noise of the background of the cylinder varied with axial position. So, if one used the whole 
axial length of the cylinder to generate the background PDF, the results did not agree with 
Suleman’s past simulations done using EGS4. This result was further studied by embedding lesions 
in slices throughout the axial extent of the scanner and showed that there was a direct 
relationship between the number of counts collected in each axial location, the signal-to-noise of 
the background at that axial location, and the detectability of the spheres in that axial location. 
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This work was then extended to embedding lesions in more complex activity distributions 
including the lung and liver of a human subject. The generalized scan statistics methodology had 
only been applied in uniform cylinders until then, so applying it to a non-cylinder and embedding 
lesions in the lung of the human subject, a non-uniform background, was not guaranteed to 
produce reasonable results. I presented the preliminary results on the simulated cylinder in an 
oral presentation at the Total-Body PET conference in Ghent, Belgium. I presented the final results 
of this work in an oral presentation at the June 2019 Society of Nuclear Medicine and Molecular 
Imaging (SNMMI) meeting in Anaheim, CA. It won the 2019 Physics, Instrumentation and Data 
Sciences Council Young Investigator award. This work has recently been published in Physics in 
Medicine and Biology and is fully described in Chapter 4. 
Over the summer of 2018, I began working on dynamically embedding lesions into dynamic FDG 
data acquired on the PennPET Explorer. Early work focused on a thorough literature search in an 
effort to select kinetic parameters that would best characterize dynamic lung and liver cancer. 
Eventually, we selected parameters from a range of lung cancers and from metastatic liver lesions 
from colorectal cancer, since primary liver cancers behave somewhat differently. After using 
STELLA to generate lesion TACs, we saw that early frames had lower lesion uptake compared to 
background, especially in the liver. This posed an issue since list-mode lesion embedding had only 
been used to add lesion data to the background. With the assistance of Matt Werner, our software 
programmer, we attempted to implement an additional data correction that would have resulted 
in less uptake in the lesion location compared to the background; although this should have 
theoretically worked, the resulting images had odd artifacts. When conversing with Suleman on 
possible avenues to implement this methodology, it was mentioned that lesion embedding was 
originally done with sinograms, and it would have been easy to remove counts locally with such a 
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method. Therefore, I attempted a few tests using histo-images, a sinogram-like data format that 
includes TOF information, which traditional sinograms did not (note: newer sinogram formats 
from Siemens and GE do include TOF information). Dynamic lesion embedding using histo-images 
was quickly successful and we were able to move ahead with the rest of the study. I presented 
this work in an oral presentation at the 2019 IEEE MIC meeting in Manchester, UK and is currently 
under revision at IEEE Transactions on Radiation and Plasma Medical Sciences. It is fully described 
in Chapter 5 of this thesis. 
From August of 2018 until now, I have been working with Dr. Austin Pantel to analyze dynamic 
PET data from mice with breast cancer tumors injected with FGln, a tracer that measures 
glutamine pool size. The mice were separated into four groups: estrogen receptor positive (ER+) 
breast cancers treated with a glutaminase inhibitor, ER+ mice with placebo, triple negative breast 
cancer (TNBC) mice with treatment, and TNBC mice with placebo. Mice were imaged before and 
after treatment. The goal of this work was to understand whether to model FGln using a one-
compartment model or a two-compartment model with trapping. Throughout the course of this 
work, we worked with software developers at MIM Software Inc. to develop a tool that would 
detect the peak VOI (the mean VOI with maximum uptake) within a search volume, which was 
then used on the mice tumors to measure TACs. We also developed a method to determine the 
noise on the measured kinetic parameters by un-correcting measured TACs so that values would 
reflect collected counts from that region, adding Poisson noise, re-correcting measured TACs, and 
fitting them in PMOD. The mean and standard deviation of resulting metrics would reflect the 
bias and precision of measured data. A summary of this work is presented in Chapter 6 and we 
are currently in the process of submitting it to the Journal of Nuclear Medicine. 
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Finally, we chose to extend our dynamic lesion embedding to a dual tracer study where a lower 
dose of the first tracer, FGln, would be injected followed by a standard 15 mCi injection of FDG. 
The dynamic FDG human subject was used as background for both injections, albeit scaled to the 
injected dose, since dynamic FGln data on the PennPET Explorer had not been acquired. Since we 
could only scale all of the data uniformly, we debated how to define how the data from the first 
injection would behave during the second scan. The choice was either to follow the slow washout 
of the blood curve or to assume that the concentration of activity remained constant. We chose 
to extrapolate the blood curve out to two hours and use the ratios from the washout of the blood 
to define how the data from the first injection would behave after the first scan. Data from the 
lesion embedding are shown in Chapter 6. However, current tools like PMOD are not designed to 
fit dual tracer data and account for the contamination from the first study, so we are still 
considering other tools and methods to fit this data. 
This was a brief description of some of the major challenges encountered in this work and the 
solutions we found to overcome them. 
KEY TAKEAWAYS 
Described below is a brief summary of key results from this thesis and the associated impact of 
these results for imaging on a long AFOV system. A more thorough summary will follow in Chapter 
7. 
Simulations based on a model of Vereos were modified and extended to the 3-ring PennPET 
Explorer and used to predict higher sensitivity, 90 kcps/MBq, a factor of 16x higher. Transverse 
spatial resolution was similar, 4.0 mm (FWHM), and axial spatial resolution was only degraded by 
0.5 mm at the center despite the significant increase in axial acceptance angle. These GATE 
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simulations, which were later extended further to 6 rings, formed the basis of the more complex 
XCAT studies and also helped guide the development of the scanner and evaluation of its 
performance. 
The PennPET Explorer was constructed and measurements were performed following the NEMA 
standards, when appropriate, resulting in a transverse spatial resolution of 4.0 mm, in agreement 
with the predictions, and a sensitivity of 55 kcps/MBq, a value lower than simulation due the 
presence of data readout gaps (5 of 7 tile rows per rings). Additionally, we measured 12% energy 
resolution and 256 ps timing resolution, improved compared to Vereos due to operation at a 
lower temperature. Importantly these values are very stable even at high count-rates, and a very 
high noise-equivalent count rate above 1000 kcps beyond 30 kBq/mL is achieved due to the 
parallel acquisition and processing of the multiple rings, far outperforming PET scanners with a 
standard AFOV. 
These excellent results led to the measurements of multiple phantoms, including the NEMA image 
quality (IQ) and SNM CTN torso phantoms, to characterize the imaging performance and validate 
the modified data correction and image generation tools. Success in generating high quality 
images of these complex and realistic lesion phantoms gave us confidence to initiate a small 
human pilot study in our laboratory to test the performance of the scanner beyond that of 
physical phantoms. These first human studies validated the successful implementation of many 
of the key design components related to data acquisition and reconstruction of large datasets. 
We demonstrated the ability to scan for a shorter duration or, alternatively, with less activity, 
without a compromise in image quality. Delayed images, up to 10 half-lives with FDG, revealed 
biologic insight and supported the ability to track biologic processes over time. In a clinical subject, 
the PennPET Explorer better delineated the extent of FDG–avid disease. In a second clinical study 
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with DOTATATE, we demonstrated comparable diagnostic image quality between the PennPET 
scan and the clinical scan, but with one-fifth the activity. Dynamic imaging studies captured 
relatively noise-free input functions for kinetic modeling approaches. Additional studies with 
experimental research radiotracers illustrated the benefits from the combination of large axial 
coverage and high sensitivity. 
At the completion of this pilot study we prepared to move the PennPET Explorer to the new 
imaging facility, which entailed disassembly of the 3 rings in the prototype scanner and building 
an additional 3 rings. I ensured that I had completed my measurements before disassembly began 
in order to complete my studies of lesion detectability using the scan statistics numerical observer 
methodology. Detectability was studied as a function of background activity distribution, scan 
duration for a single bed position, and axial location of the lesions. The area under the localization 
receiver operating curve (ALROCs) of small (10 mm diameter) lesions placed in the 
anthropomorphic phantom and human subject resulted in ALROCs of 0.8 or greater (a value 
considered to be clinically acceptable) for scan times longer than 30 s in the lung region and 60 s 
in the liver region for standard-of-care (SoC) doses. These results are consistent with expected 
improvements due to the higher sensitivity of the PennPET Explorer compared to PET instruments 
with a standard AFOV and will be used to guide decisions on imaging parameters, such as scan 
time and patient dose, when imaging patients in a single bed position with this instrument.  
I also completed studies quantifying bias and precision of kinetic parameter estimation from 
dynamic studies using the PennPET Explorer. This work consists of two studies, the first a 
simulation study of a modified NEMA IQ phantom with a kinetic model based on FLT, and the 
second a lesion embedding study of spheres in the lung and liver of a human subject dynamically 
imaged with FDG on the PennPET Explorer. Quantification of flux (KFDG or KFLT) and delivery (K1) 
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showed significantly lower bias and better precision for both radiotracers when imaging on the 
long AFOV scanner, compared to a standard AFOV, even at doses as low as 0.5-2 mCi. These 
results depend on the flux and size of the sphere; and flux was also calculated using a graphical 
analysis method, which can only be applied to certain tracers such as FDG because it assumes 
irreversible trapping of the radiotracer. In contrast, when data were fit using a 2-compartment 
model that fully models flow through multiple tissue compartments, quantification of both flux 
and delivery showed a larger bias but still with relatively good precision. These results will be used 
to guide future dynamic studies on long AFOV systems and assist in interpreting the results of 
kinetic modeling analyses. 
These studies with a single tracer were a crucial step to formulate the design of a dual tracer study 
with FDG and FGln that has been planned for several years and constitutes one of the major aims 
of a very prestigious NIH Cancer Moonshot grant awarded to our institution in 2017. Our goal is 
to demonstrate in vivo interrogation of two distinct biologic processes in the same imaging session 
by taking advantage of the very high sensitivity of long AFOV scanners, where a similar study on 
a standard AFOV scanner would require imaging on two separate days to allow sufficient tracer 
decay between injections. Based on dynamic imaging data from a mouse model of breast cancer 
I was able to construct a simulation of a protocol whereby FGln is injected first into a human at a 
relatively low dose, followed by FDG at 15-60 minutes later and at higher dose. My analyses will 
determine the optimal time point at which to inject FDG after FGln such that both tracers can be 
accurately modeled, thereby providing complementary information of metabolism. The volume 
of distribution of FGln will be calculated from kinetic analysis of 15-60 minutes of dynamic data 
and both delivery and flux will be estimated from 60 min of FDG data, with the analysis accounting 
for residual FGln. Ultimately, these studies will be used to guide the estimation of kinetic 
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parameters of tumor glutamine and glucose metabolism in humans. We plan to demonstrate this 
study with human subjects on the PennPET Explorer once the scanner upgrade is complete and 
the facility is open. Other tracer pairs are also possible—e.g., FDG and DOTATATE—enhancing the 
ability of PET to characterize tumor biology to inform treatment.  
Overall, this body of work offers quantitative results that can be used to determine imaging 
parameters for both static and dynamic studies on long AFOV systems based the increased 
sensitivity of long AFOV systems. They also offer a steppingstone to design future studies on long 
AFOV systems using cohorts of patients with specific diseases to assess improvements in lesion 
detectability or kinetic parameter estimation. For example, results from the detectability study 
show that an ALROC of 0.8 is achieved at a scan duration of 30 s for a 10-mm lesion in the lung 
with 6:1-uptake. Based on this, we can assume that 30-s breath-hold studies of a cohort of lung 
cancer patients undergoing staging on PET studies can also be imaged on the PennPET Explorer, 
to further explore the quantitative benefits of imaging on a long AFOV system. Similarly, our 
results show that low dose dynamic studies of new tracers and dual tracer studies can leverage 
the increased sensitivity of long AFOV systems to image at much lower doses without 
compromising kinetic parameter estimation. Additionally, FDG simulations of the XCAT phantom 
are currently being used to test a reconstruction algorithm that will output quantitatively accurate 
PET images without an external transmission source for attenuation correction, in lieu of acquiring 
a CT, resulting in further dose reduction for sensitive populations. Both the simulated and 
measurement dynamic datasets are currently also in use to (1) test a reconstruction algorithm 
that will directly output images of tracer flux and (2) design a machine learning algorithm that 
uses time course information to characterize PET tumor heterogeneity. Both of these studies are 
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part of the R33 project, and they will make use of the dual-tracer dataset for further testing in the 
future. 
We believe that while current commercial scanners of standard AFOV are well equipped to handle 
standard oncologic imaging with FDG, the future of long AFOV systems lies in conducting research 
studies. These research studies would include early biodistribution studies of new tracers, 
dynamic studies of new tracers to evaluate and understand their mechanism of action, and 
imaging to assess the efficacy of treatments associated with newly developed radiotracers. To this 
end, it is most likely that long AFOV systems of various lengths will exist in all research centers, 
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CHAPTER 2: BACKGROUND 
CLINICAL IMAGING WITH PET 
Positron emission tomography (PET)/ computed tomography (CT) is a regularly used clinical 
imaging modality for oncologic, cardiac, and neurologic purposes. PET imaging detects the 
distribution and utilization of a molecule within the human body coupled to a positron-emitting 
radioisotope (e.g. 18F or 68Ga), collectively referred to as a radiotracer. The most commonly used 
radiotracer is a form of glucose called 18F-fluorodeoxyglucose, which when injected into a patient 
and imaged with PET offers information on glycolysis (i.e. the process where cells use glucose as 
a source of energy). Additionally, PET imaging is quantitative, and images reflect the rate of 
radiotracer uptake and trapping locally within tissues of the body. In static imaging, this is 
reflected in the standardized uptake value (SUV) which normalizes the estimated amount of 
radiotracer per volume by the injected radioactive dose per patient weight.  
Because PET is an inherently quantitative imaging modality, it is used in oncology to characterize 
primary tumors, detect the extent of metastases, track a tumor’s response to treatment over 
time, and monitor tumor recurrence in a patient (Figure 1A). FDG is especially useful for imaging 
cancers due to the Warburg effect. In the 1930s, Warburg observed that cancer tissues use large 
amounts of glucose to generate energy via anerobic glycolysis while normal surround tissues use 
the more efficient method of oxidative metabolism [1]. When FDG was developed [2] in the 1970s, 
it was first applied to brain imaging [3, 4] to characterize regional performance in diseases such 
as Alzheimer’s and Parkinson’s diseases, as well as epilepsy. In the 1990s, FDG was more routinely 
applied to whole-body imaging of cancer [5, 6], and lesions on PET scans were more easily 
detectable at an early stage compared to other imaging modalities due to the high uptake of FDG 
in tumors and low uptake in the background. FDG is most commonly used for lymphomas and 
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lung cancers but is also used for a variety of other cancers as well. However, while FDG is highly 
sensitive to cancerous lesions, other cell types can also use large amounts of FDG. The main source 
of false positives is acute or chronic inflammation or infection, where neutrophils and activated 
macrophages use large amounts of glucose [7].  In addition, while most cancers do use large 
quantities of FDG (i.e. they are FDG avid), some cancers are not FDG avid. For example, 
neuroendocrine tumors (NETs) that are well differentiated are not FDG avid; therefore, they are 
better imaged instead using  68Ga-DOTATATE, a somatostatin analogue that binds to somatostatin 
receptors present on NETs (Figure 1B) [8]. DOTATATE is a newly approved tracer for clinical use in 
oncology and hopefully other tracers will also prove useful for additional characterization of 
different non-FDG avid tumors in the future.  
In neurology, FDG PET is used to determine foci of seizures in the brain by looking for areas of 
hypometabolism compared to the contralateral side. There are also three radiotracers, 18F-
Florbetapir, 18F-Florbetaben, and 18F-Flutemetamol, approved for clinical use to image beta-
amyloid in the brain to track and follow patients with Alzheimer’s disease or other 
neurodegenerative conditions (Figure 1C) [9]. Radiotracers to image tau neurofibril tangles and 
synaptic density are also in development [10]. 
PET is most frequently used in cardiology to assess perfusion of the coronary arteries. The 
radiotracers used are either 82Rb or 13NH3 and the patient is imaged before and after 
pharmacologic stress or an exercise test. Both 82Rb and 13NH3 are potassium analogues that are 
taken up by healthy myocardial, cells via the Na/K adenosine triphosphatase pump and uptake in 
myocardial cells is associated with well perfused tissue [11, 12]. Figure 1D shows an 82Rb cardiac 
study where the inferior myocardium is perfused under rest conditions but not under stress 
conditions, implying that the defect is reversible [13, 14]. FDG PET scans of the heart can also be 
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used to assess myocardial viability and the comparison between perfusion and viability can be 
used to determine whether heart muscle is hibernating (i.e. recoverable after a duration of rest) 




Figure 1. Various clinical applications of PET scans from patients scanned at the University of Pennsylvania. (A) FDG 
PET scan of a patient with lung cancer. (B) DOTATATE PET scan of a patient with metastases from a neuroendocrine 
tumor (B). (C) FDG PET scan of a patient with epilepsy showing hypometabolism in the left temporal lobe (top). An 
amyloid PET scan of a patient with florid Alzheimer’s Disease (bottom). (D) A rubidium perfusion test that shows 
myocardial blood flow at stress and rest. A defect can be seen in the inferior region of myocardium on the stress scan 
but not the rest scan indicating reversible perfusion. 
 
Because standard AFOV PET scanners have a limited axial range < 30 cm, most clinical PET scans 
are acquired in multiple bed positions over a 10-20 min period, usually one hour after the patient 
has been injected with the radiotracer, generally used because metabolism in the tissues is 
assumed to have reached steady state. This is referred to as static imaging and, of the imaging 
tracers described above, static imaging is used for FDG, DOTATATE, and amyloid imaging; 
however, cardiac perfusion studies like 82Rb are acquired dynamically and processed with multiple 
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are not necessarily fully at steady state one-hour post injection. FDG is still being taken up in 
lesions and washing out of normal tissue at this time point, so the one-hour post-injection scan is 
only a snapshot of uptake in time.  The one-hour time point is short enough to minimize the 
patient wait time, but long enough for the tracer to reach steady state without losing too much 
signal due to decay of the injected radiotracer. 18F and 68Ga have a 110- and 68-min half-lives, 
respectively, so after an hour 70% of 18F and 55% of 68Ga dose, relative to time of injection, remain. 
Patients are typically imaged in multiple step-and-shoot bed positions, each 1.5-3 min long 
depending on BMI, with 50% overlap (using Philips PET/CT scanner) to cover the axial extent of 
the patient from skull base to thighs for up to a total 20 min imaging duration. Newer scanners 
from Siemens use continuous bed motion to image a patient where the bed moves at 0.7-3.0 
mm/s, depending on BMI, to image the whole body. Continuous bed motion can be tuned to 
spend more time imaging larger areas of the body, such as the torso where counts tend to be 
attenuated, and image regions like the brain or legs, which have less attenuation, for shorter time 
periods. 
THE PHYSICS OF PET  
PET imaging detects the distribution of a positron emitting isotope, such as 18F, in a patient’s body. 
The positron emitting isotope is joined to a small biologic molecule, most commonly glucose, 
allowing for imaging of the distribution and metabolism of that small molecule. The emitted 
positron will travel a short distance, where this distance is referred to as the positron range and 
is dependent on the energy with which the positron is emitted. Once the positron loses most of 
its kinetic energy it will combine with a nearby electron and form positronium. Positronium is a 
short-lived hydrogen-like “atom” that will annihilate (i.e. mass is converted into photons with a 
defined energy 𝐸	 = 	𝑚 ∗ 𝑐!) emitting two 511 keV gamma rays. These gamma rays are emitted 
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nearly 180˚ apart from each other and are not directly colinear due to conservation of the angular 
momentum of the positron-electron pair. This is referred to as non-collinearity of the gamma rays, 
which results in spatial resolution limitations for human PET scanners. A PET scanner then detects 
the two gamma rays using scintillator crystals and if they arrive within a set coincidence timing 
window, usually set equal to the time required for light to travel across the scanner, then it is 
assumed that they were (1) emitted from the same annihilation event and (2) that the annihilation 
occurred somewhere along the imaginary line of response (LOR) drawn between the two crystals. 
There are two predominant types of timing windows: the single window and the multiple window. 
The single window method opens a window upon the arrival of the first gamma rays and considers 
any other single events in that window to be in coincidence with the first event. The multiple 
window method opens a coincidence window for each even that arrives and uses a logical OR to 
determine coincidences. The single window method is known to miss coincidence events that are 
written when using the multiple window method, but the multiple window method can be 
computationally expensive. Most hardware coincidence sorters are a combination of the two 
methods and can be difficult to model in simulation [16]. Additionally, the difference in the precise 
arrival time of each gamma ray at the detectors can be used to further localize the annihilation 
event along the LOR. This is referred to as time-of-flight (TOF) imaging.  
PET is a quantitative imaging modality which means that the value of voxels in reconstructed 
images reflect the number of annihilations that occurred in that voxel. It is assumed that the 
location of the annihilation is at the same location as the radio-tracer from which the positron 
was emitted; however, the positron range is 0.6 mm on average for 18F and 3.5 mm on average 
for 68Ga [17], so this is not exactly true and can result in some spatial resolution degradation of 
PET images. The quantitative information in a PET image is typically correlated with a biological 
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process of clinical significance. For an 18F attached to a glucose molecule, the uptake in a voxel is 
related to glycolysis. To reconstruct quantitatively accurate images, a number of corrections must 
be applied. These corrections are scatter correction, randoms correction, attenuation correction, 
and normalization, and they are further described below. 
The measured detector ‘hits’ define the line-of-response (LOR) for the two gamma rays. However, 
events collected within the coincidence timing window, referred to as prompt events, can (1) arise 
from a single annihilation and gamma rays travel in a straight line before hitting a detector (true 
events), (2) arise from a single annihilation and one or both of the gamma rays are scattered in 
the attenuating medium (scattered events), or (3) arise from two separate annihilations and 
randomly arrive within the same timing window (random events).  True events are the events we 
aim to reconstruct in the final PET image. The maximum oblique angle at which true events can 
arrive determines the solid angle. However, scattered and random events require corrections to 
exclude them from the final reconstructed image (Figure 2). Scattered events occur when one or 
both of the gamma rays undergoes Compton scatter while passing through an attenuating 
medium (e.g. the human body) and experiences a loss of energy and a change in direction. When 
it arrives at the scintillation crystals, the LOR drawn will lead to mispositioning of the annihilation 
event. Scatter within the FOV is reduced by imposing an energy window, where events are 
rejected if they arrive with an energy less than about 450 keV, set depending on the energy 
resolution of the system. Scatter from outside the AFOV can be reduced by placing lead septa at 
the ends of the scanner so that any photons arriving from outside the AFOV are attenuated in the 
lead and never arrive at the scanner detectors. Scatter collected within the energy window is 
estimated by first calculating the distribution of single scattering and then scaling to regions 
outside the known attenuation distribution. Single scatter is when one of the two gamma photons 
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is scattered once, while multiple scatter means that either one of the gamma rays is scattered 
more than once or that both gamma rays experience scattered. Single scatter estimation is done 
using an analytic simulation based on the Klein-Nishina formula [18]. Inputs include the 
attenuation distribution, typically derived from a registered CT image, and the estimated activity 
distribution. Scatter estimation is done through an iterative process where the estimated scatter 
is applied to the reconstructed activity image, and then the new activity image is used to generate 
an improved scatter estimate. This process typically converges after four iterations [19]. The 
scatter estimation process that scales multiple scatter by fitting the sinogram tails to the single 
scatter distribution assumes the shape of the distributions of multiple and single scatter are the 
same, which is an approximation. 
The next correction applied is randoms correction. The number of randoms detected increases 
based on the size of the coincidence window and the square of the number of single gamma rays 
detected (referred to as “singles”) which is linearly related to the amount of radioactivity within 
the field of view. There are two methods by which randoms are corrected for: (1) use the singles 
event distribution and coincidence window (𝜏) to calculate the randoms distribution (2𝜏 ∗ 𝑆" ∗
𝑆!), where 	2𝜏 reflects a singles event that can arrive either 𝜏 ns before or after a given singles 
event, or (2) measure coincidences between single events in the prompt timing window and in a 
delayed window of the same size, where the time delay between windows is much larger than 
the time required to travel the longest LOR in the scanner. The delay window method accurately 
reflects the number of randoms collected but requires smoothing to avoid propagating noise in 
the reconstruction and is limited at lower doses due to statistical uncertainty. The singles method 
is more statistically precise but can be computationally expensive to calculate in hardware.  
Randoms are distributed throughout the FOV depending to a degree on the activity distribution 
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in the FOV since the two singles events are uncorrelated. Both randoms and scattered events are 
modeled in the reconstruction as additive corrections. 
 
Figure 2. Schematic showing true (blue), scattered (red), and randoms (green) events in both and axial (left) and 
transverse (right) view of a PET scanner, where annihilation events are shown in yellow. The dotted lines represent 
the LORs that would be drawn for that event and the resulting mispositioning of the event. Positron range and 
acolinearity are not depicted in this schematic. The scattered event shown in the axial view arises from an event 
outside the AFOV of the scanner. The random event in the transverse view is erroneously placed outside the contour 
of the patient’s body reflecting that randoms are mostly uniform throughout the FOV and the randoms event in the 
axial view shows that randoms can arise from activity in the patient’s body outside the imaging AFOV.  
 
In addition to correcting for randoms and scatter in the reconstruction, attenuation of gamma 
rays through the patient’s body must also be corrected for. Because a PET scanner detects two 
gamma rays that are assumed to travel along the same LOR, the total attenuation of both gamma 
rays is equivalent to the attenuation of an external transmission source passing through that LOR. 
For this reason, external transmission sources have been used for attenuation correction. In the 
1980s and 1990s, attenuation correction was done using a rotating 68Ge line source or using a 
137Cs transmission source [20, 21]. The 68Ge line source emitted gamma rays from positron 
annihilations so attenuation information was collected at the same energy as the PET photons 
(511 keV), while the 137Cs rotating point source emitted 662-keV gamma rays, which were mapped 
to 511 keV to calculate the attenuation correction. In the late 1990s, CT replaced the rotating 
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is acquired in seconds, albeit at a higher dose, does not add noise to the resulting images as 
previous methods had done, and is a valuable anatomic correlate for clinicians when reading PET 
scans [22]. The CT offers attenuation information for photons at 120-140 keV, and the values are 
mapped to the attenuation of a 511 keV photon using a bilinear function [23]. The corresponding 
attenuation is then modeled for each LOR during reconstructing to create quantitatively correct 
PET images. Unlike scatter and randoms, attenuation is a multiplicative correction. 
The final correction is normalization, an additional multiplicative correction, which corrects for 
differences in performance of every LOR. These differences can be related to variations in crystal 
properties or detector properties, the angle of incidence of the LOR onto the crystal, or the overall 
geometry of the scanner. A number of activity distributions can be used to calculate normalization 
including a uniform cylinder, a plane source rotated to various angles, or a rotating line source 
meant to emulate an annulus source. The goal of all of these distributions is to measure events in 
all LORs within the FOV of the scanner. The collected data are then typically binned into a 
sinogram which reflects the number of events collected from each LOR. The sinogram is then 
divided by an ideal sinogram of the activity distribution imaged to calculate the normalization 
factors [24]. Smoothing is sometimes applied to avoid noise in the normalization sinogram from 
propagating to the reconstructed image [25]. 
To reconstruct PET images where the voxel reflects the amount of activity in that location, a 
scanner calibration factor is calculated by first imaging a uniform cylinder with known activity. A 
large volume of interest is then drawn over the reconstructed cylinder image and the ratio 
between the average number of counts in the VOI and the corresponding activity in that volume 
is the scanner calibration factor. It is then applied to all images acquired on that scanner to convert 
raw reconstructed image counts to radioactivity within a voxel. 
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All PET reconstruction is based the Radon transform and its inverse, shown graphically in Figure 3 
[26]. Figure 3A shows how PET projection data (LORs collected at a given angle) are the Radon 
transform (i.e. the forward projection) of an object; a PET dataset consists of projections at many 
angles. The inverse Radon transform (i.e. back projection) can be used to create an image from 
data collected as projections. Collected projection data are often stored as a sinogram (𝑝(𝑠, 𝜑)), 
named since a point source appears as a sine wave. As the number of angles increases, the signal-
to-noise of the image improves. Reconstruction was originally done analytically with an algorithm 
called filtered back projection (FBP), which back projects collected data and applies a filter in 
Fourier space to remove higher frequency noise. FBP has high noise and is prone to artifacts while 
an iterative algorithm like maximum likelihood expectation maximization (MLEM) can be used to 
reconstruct images with better image quality because it models the Poisson noise in the data to 
estimate the object that gave rise to the collected data [27]. The reconstruction algorithm for 
MLEM is described below, although a more commonly used reconstruction method is ordered 
subset expectation maximization (OSEM). OSEM has the same underlying algorithms and follows 
 
Figure 3. A schematic of Radon projection showing the object 𝑓(𝑥, 𝑦) projected along angle 𝜑 to create the projection 
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the same paradigm as MLEM but separates data into subsets when iterating for faster 
reconstruction.  
MLEM attempts to estimate the PET activity distribution that gave rise to the measured data. In 
essence, MLEM iteratively compares the forward projection of the estimated PET image (𝜆) to the 
measured PET data (𝑦) (Equation I) [28]. For this formulation 𝑖 refers to the LOR index, 𝑗 refers to 
the voxel index, 𝑡 refers to the TOF bin, and 𝑘 refers to the iteration number. The Radon transform 
is applied by summing over 𝑗 and the inverse Radon transform is performed by summing over 𝑖. 
The system matrix 𝑐 includes the effects of geometry (𝑃#$%&$'()), including the contribution of 
each LOR to a particular voxel, along with detector sensitivity (𝑃*%(&+,-.+'-%*), attenuation factors 
(𝑃+''$*/+'-%*). The system matrix can also include the effects of detector blurring (𝑃0$'.2,/() and 
positron range (𝑃3%4-'(%*), although neither is included in the standard reconstruction algorithm 
we use. The MLEM formulation compares the estimated image to the measured data by (1) 
multiplying by the system matrix (𝑐) and forward projecting the image into data space (∑ 𝑥55 ), (2) 
adding the scatter (𝑠) and randoms (𝑟) estimates, and (3) comparing with the measured PET data 
(𝑦). The correction ratio is then scaled by the system matrix and back projected into image space 
(∑ 𝑥-- ). The result is normalized by the system matrix in image space and then multiplied by the 
current PET image estimate (𝜆6) to calculate the updated PET image estimate (𝜆67"). 
The implementation of OSEM uses this formulation for subsets of the data and will iterate until 
the result roughly converges. The more iterations and subsets used in the reconstruction, the 
noisier the resulting image will be. Therefore, clinical protocols usually stop at a fixed number of 
iterations where the image may not be fully converged. In an effort to improve image quality, 
point spread function (PSF) modeling can be included in the reconstruction or applied to the 
reconstructed image to sharpen the image and improve contrast of small objects and post-
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smoothing is often applied to the image to reduce image noise. Neither PSF modeling nor 
smoothing are employed directly in this thesis because the reconstruction used implements blob 
basis functions that effectively improves contrast of the image while maintaining low noise [29]. 
The MLEM reconstruction algorithm shown here is for reconstruction from sinogram data; 
however, data can also be collected in list-mode, a format where each pair of photons within a 
coincidence window are stored in a tabulated list. The MLEM formula described in Equation I is 
still used, but the acquired PET data (𝑦-') is replaced with 1 to represent a single event. For the 
purposes of this thesis, most reconstructions were done using blob-based list-mode time-of-flight 
OSEM (LM-TOF-OSEM) [30]. LM-TOF-OSEM uses chronological subsets of the list-mode events 
and blob basis functions instead of cubic voxels with a 5.7-mm full-width at half-maximum 
(FWHM) and 6-mm spacing on a body-centered cubic grid [29]. The blob basis functions have been 
shown to diminish image noise without sacrificing image resolution and are used by Philips as 
their factory reconstruction algorithm. We use 25 subsets and 4 iterations for analysis of data 
included in this thesis since we want to be consistent with methods and parameters used for 
clinical data. 
Recently, our lab as developed a reconstruction framework based on histo-images, a binned 
representation of the data (as with sinograms) that uses TOF information to decrease the number 
of angular projections necessary [31]. For comparison, we use 288 angles in a sinogram but only 
need 40 views in a histo-image to completely sample the data. Histo-images are a representation 
of the data in the same voxel format as the final image to be reconstructed, so the forward and 
back projection operations can be efficiently performed using Fourier methods. Histo-image data 
can then be reconstructed using direct image reconstruction for time-of-flight PET (DIRECT). 
Iterative DIRECT uses a row-action maximum likelihood algorithm (RAMLA) which is based on the 
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MLEM update and uses a relaxation parameter to control updates to the image and ensure fast 
convergence [31, 32]. DIRECT also includes LOR modeling, which models the width of the LOR, 
and image filtering such that the reconstruction can be tuned to match the noise and contrast 
properties of standard reconstructions. For reconstructions using DIRECT in this thesis, we use 4 
mm3 histo-images with 40 views and 9 tilts (144 x 144 x 160 slices x 40 views x 9 tilts), 50 RAMLA 
iterations, 2.0 mm LOR resolution modeling, 5.5 mm image resolution modeling to match the size 
of the blob basis function used for LM-TOF-OSEM, and 5.5 mm image filtering to match the noise 
of LM-TOF-OSEM reconstructions. Resulting 4 mm3 images were resampled in the spectral domain 
into 2mm3 images for the computational speed of reconstruction 4 mm3 histo-images compared 
with 2 mm3 histo-images. 
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DYNAMIC IMAGING WITH PET 
While static clinical PET imaging is a valuable diagnostic tool, additional information about 
biological processes can be determined by imaging the time course of tracer uptake. This is 
referred to as dynamic imaging and is typically done in a single bed position to continuously 
capture the time course of tracer uptake in the area of interest. The patient is injected with the 
radiotracer while lying on the scanner bed and imaged continuously for one to two hours. The 
time course of tracer uptake (i.e. time-activity curve; TAC; Figure 4A) in different tissues offers 
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additional information since, as noted above, many tracers do not actually reach steady state by 
60-min post-injection. To dynamically image more than a single bed position, continuous bed 
motion or rapid cycling through multiple bed positions has been employed. The first few minutes 
are imaged over the heart to capture the peak of the blood input function followed by repeated 
scans of the whole body. While this allows for whole body dynamic imaging, each whole-body 
pass takes 5-10 min resulting in very coarse time samples and poor data quantitation [33]. 
The tracer flow over time can be estimated using a compartmental model (Figure 4B), which can 
have a varying number of compartments and flow parameters that reflect the underlying 
biochemical behavior of the radiotracer. The model shown has two compartments and four flow 
parameters implying reversible flow through all the compartments. Typically, flow parameters 
(a.k.a. kinetic parameters) are associated with either flow of a molecule into the cell or an 
enzymatic step. FDG is typically modeled using a two-compartment model with three parameters, 
K1, k2, and k3, where k4 is assumed to be zero; therefore, there is no flow out of the second 
compartment and the radiotracer is trapped. In the case of FDG and other tracers with similar 
behavior, the first compartment is referred to as the free or reversible compartment, while the 
second compartment is referred to as the trapped compartment. K1 and k2 for FDG reflect flow 
into and out of the cell via a glutamine transporter and k3 reflects hexokinase activity in cells which 
phosphorylates FDG molecules to produce FDG-6-phosphate (FDG6P). Two factors result in 
trapping of FDG in the cells in its phosphorylated form. First, the enzyme that would further 
metabolize phosphorylated glucose (Glucose-6-phospate; G6P), phosphoglucoisomerase, is 
specific to G6P and does not recognize FDG6P as a substrate. Second, the enzyme that 
dephosphorylates G6P, glucose-6-phosphatase, is not present in most organs (which would be 
reflected in a non-zero k4 value). Therefore, FDG gets trapped as FDG6P in most cells. The kinetic 
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parameter of interest in such a model is flux (𝐾- = (𝐾" ∗ 𝑘8)/(𝑘! + 𝑘8)) through hexokinase (i.e. 
the rate of turnover of a substrate through a given enzyme). Flux of a tracer that can be 
represented using a two-compartment model with trapping can also be estimated using Patlak 
graphical analysis, which transforms the data to a linear model that can then be fit using a linear 
regression (Figure 4C).  Patlak graphical analysis plots ∫ 𝐶9𝑑𝑡	
'
: /	𝐶9	vs 𝐶;/𝐶9 (𝐶;  is the tissue TAC 
and 𝐶9 is the blood TAC) where the slope of the linear regression is the flux of the tracer through 
a key enzymatic step (e.g., the conversion of FDG to FDG6P). 
 
 
Figure 4. Generic time-Activity curves shown for blood and tissue (A). A generic two-compartment with kinetic 
parameters shown that can be used to fit TACs and individually estimate all kinetic parameters shown (B). Plot of 
data fit using Patlak graphical analysis where the slope equals the flux of the tracer (C). Plot of data fit using the 
Logan graphical analysis where the slope equals the volume of distribution of the tracer (D). Note that one dataset 
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Another kinetic parameter of interest is the volume of distribution (𝑉< = (𝐾" + 𝑘=)/(𝑘! + 𝑘8)	 
for the first compartment in the two-compartment model shown). VD can also be used to quantify 
radiotracer uptake, with specific use depending on tracer biology.  Pool size is commonly used for 
tracers that bind to receptors, where a measure of specific binding to a receptor is the parameter 
of interest. Pool size can also be used for tracers that do not have irreversible trapping; therefore, 
if the pool size is large, tracer uptake is large and the ratio of uptake in the tissue to the blood is 
large. VD can also be estimated for a model with any number of compartments with reversible 
flow of tracers using the Logan graphical analysis, which similar to Patlak, transforms the data 
such that a linear fit can be performed. Logan plots show ∫ 𝐶9𝑑𝑡	
'
: /	𝐶; 	vs ∫ 𝐶;𝑑𝑡	
'
: /	𝐶; 	and the 
slope of the line is the tissue volume of distribution (Figure 4D).  
While dynamic analysis is performed on the aforementioned cardiac perfusion studies to estimate 
flow, it is not largely used in the clinic. However, dynamic analyses are performed on all tracers 
that are under development to fully understand the kinetics and biology of the new tracer and to 
discern what key parameters can be used to correlate to clinical metrics. 
OVERVIEW OF COMMERCIAL PET SCANNERS 
ADVANCEMENTS IN PET TECHNOLOGY  
In the past twenty years, there have been many advancements in PET including fully 3D imaging, 
quantitative iterative reconstruction, CT attenuation correction, improved scintillators, time-of-
flight (TOF), and silicon photodetectors that were important when building our long AFOV scanner 
with a scalable design to make it possible to build scanners with varying AFOVs. A brief history of 
each of these advancements follows. 
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Prior to the early 1990s, with a few exceptions such as the 3D imaging NaI PET scanner developed 
at UPenn [34], PET scanners were separated into multiple 2D rings by lead septa, and coincidences 
were only accepted within rings or between neighboring rings. Removing these septa allowed for 
oblique coincidences and a 5-10x increase in photon sensitivity, allowing for shorter scan times 
[35] albeit with a marked increase in accepted scatter and randoms. Additionally, the 
implementation of iterative reconstruction algorithms led to improved image quality, since they 
model the Poisson nature of the data in the reconstruction [27]. The use of CT for attenuation 
correction made it possible to measure attenuation in seconds that clinicians could also use to 
localize lesions and make decisions about treatment using both lesion size and FDG avidity as 
biomarkers [36].  
Time-of-flight (TOF) was a major advancement that greatly improved image quality, patient 
throughput, and lesion detectability of PET imaging. Good timing resolution uses the precise 
arrival time of each gamma ray to restrict the back projection of the event along an LOR (e.g. for 
300 ps timing resolution, Δ𝑥 = 0.5 ∗ 300	𝑝𝑠 ∗ 3 ∗ 10":𝑐𝑚/𝑠	 = 4.5	𝑐𝑚 ). Using TOF is more 
accurate than assuming a uniform probability distribution along the LOR of where the annihilation 
occurred. TOF is effectively a sensitivity amplifier and maintains low image noise while improving 
lesion contrast (Figure 5) and is especially valuable when scanning obese patients where increased 
attenuation leads to fewer detected events [37]. Today’s standard AFOV PET scanners with 
conventional PMTs have a timing resolution of about 500 ps. Historically, BGO was the scintillator 
crystal of choice for non-TOF imaging, because it was cheap to produce and had a high stopping 
power. However, due to its poor intrinsic timing properties (decay constant 300 ns), it could not 
be used for TOF imaging and prompted the move to using cerium-doped LSO/LYSO. These 
scintillators have a slightly lower stopping power than BGO and are costly to produce due to the 
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high cost of materials needed to grow the crystals at extremely high temperatures. However, 
LSO/LYSO has a timing decay constant of 40 ns, which, together with high light output allows for 
good timing resolution for TOF imaging [38]. An overview of the impact of TOF can be found in 
[38-40].  
 
Figure 5. Images reconstructed without (left) and with (right) TOF. 
 
The background radiation from naturally occurring lutetium in LSO/LYSO (Lu-176; beta decay 
followed by cascade gamma emissions at 401, 307, 202, and 88 keV) may be a contaminant in low 
dose imaging studies [41] but should be accurately accounted for in the randoms correction. 
Conversely, background radiation from Lu-176 has recently shown potential for use as a 
transmission source for novel CT-less reconstruction algorithms that generate both a PET emission 
and transmission image [42]. 
The most recent commercial PET/CT systems built using PMTs include the Siemens mCT, the 
Philips Ingenuity, and the GE Discovery 690 [43-45]. These systems are all built with LSO/LYSO, 
have a 500-600 ps timing resolution (equivalent to 6-9 cm), and use PMTs with Anger logic for 
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large number of crystals[46-48]. Anger logic uses the relative amounts of light detected in a cluster 
of PMTs to calculate the crystal at which the gamma ray arrived. For reference, the Philips 
Ingenuity has an average of 68 crystals per PMT [49]. A summary of the key scanner geometry 
metrics and the NEMA performance metrics are summarized for these three scanners below 
(Table I) [50-52].  







Crystal LYSO LSO LYSO 
Crystal Size 4 × 4 × 22 mm3 4 × 4 × 20 mm3 4.2 × 6.3 × 25 mm3 
    
Scanner Axial Length 18 cm 21.8 cm 15.7 cm 
    
Sensitivity  7.3 cps/kBq 9.7 cps/kBq 7.4 cps/kBq 
Timing Resolution 502 ps 580 ps 544 ps 
Spatial Resolution 4.8 - 5.1 mm 4.4 – 5.9 mm 4.7 – 5.5 mm 
Peak NECR (see Ch. 3) 124 kcps @ 20 kBq/cc 180 kcps @ 28 kBq/cc 139 kcps @ 29 kBq/cc 
 
Within the last five years, scanners have started to move from using conventional photomultiplier 
tubes (PMTs) to silicon photodetectors (SiPMs). Although they are currently more expensive than 
PMTs, silicon detectors are robust, compact, and can be 1:1 coupled to crystals, negating the need 
for Anger logic and therefore decreasing the system dead time of calculating the position of 
events and diminishing light lost due to light sharing across PMTs. While the Philips Vereos [53] 
uses 1:1 coupling with digital SiPMs to achieve a stellar timing resolution, the newest PET/CT 
scanners from GE and Siemens, the Discovery MI and the Vision, with silicon detectors still use a 
small amount of light sharing to reduce the number of SiPMs needed in an effort to minimize 
costs. These scanners boast highly improved timing resolution, better image quality, higher count 
rate performance, and better spatial resolution. A summary of these newer SiPM based 
commercial PET/CT scanners is included below (Table II) [54-56].  
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Crystal LYSO LSO LYSO 
Crystal Size 4 × 4 × 19 mm3 3.2 × 3.2 × 20 mm3 3.95 × 5.3 × 25 mm3 
    
Scanner Axial Length 16.4 cm 26.1 cm 25 cm 
    
Sensitivity  5.2 cps/kBq 16.4 cps/kBq 20.84 cps/kBq 
Timing Resolution 310 ps 210 ps 382 ps 
Spatial Resolution 4.2 - 5.5 mm 3.5 mm 4.3 – 7.4 mm 
Peak NECR 153.4 kcps @ 55 kBq/cc 306 kcps @ 32 kBq/cc 266 kcps @ 21 kBq/cc 
 
TOTAL-BODY PET IMAGING 
Our goal in building and testing a long AFOV system at this time is to take advantage of all recent 
PET advancements including improved timing resolution, better spatial resolution, and SiPM 
detectors, to build a state-of-the-art long AFOV scanner with boundless potential. 
While the idea of total-body PET imaging is not new, the push towards building a new system was 
stimulated by the NIH-funded EXPLORER (Extreme performance long research scanner) project 
(R01 CA-206187), which has brought the concept to the forefront of PET research [57-60]. The 
two major benefits of a long AFOV system are the increased photon sensitivity (i.e. the number 
of annihilation events detected for a given amount of activity in the FOV; hereafter referred to as 
sensitivity) and the ability to image the whole-body simultaneously. The increased sensitivity is a 
result of imaging more of the radioactive patient at once and the increased solid angle of collected 
events. The relationship between sensitivity and a scanners AFOV is shown in Figure 6 for three 
activity distributions: activity distributed in a 27-cm cylinder to represent the attenuation of an 
average-sized patient, a point source in air to reflect axial sensitivity (i.e., the sensitivity at a 
specific axial location) in an ideal situation, and a point source in a 27-cm cylinder to reflect axial 
sensitivity of a lesion in a patient with attenuation. For a 2-m-long scanner, the increase in total 
sensitivity of a line source in air, also reflected in a 27 cm cylinder, can be up to 40x that of 
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standard AFOV scanners (< 30 cm AFOV), and the sensitivity gain for a 70-cm system is closer to 
8x. However, the gain in axial sensitivity (i.e. the number of counts detected and imaged at each 
axial location) is not as dramatic. The axial sensitivity gain can be studied using a point source as 
shown in Figure 6. This point source is centered in the AFOV to reflect the maximum axial 
sensitivity possible with a scanner of a given AFOV. The increase in sensitivity for a point source 
in air at the center of the AFOV is 2.5-3.5x for a 70-200 cm AFOV system; however, that gain is 
closer to 2.1-2.5x in an attenuating medium like a water-filled cylinder or the human body. The 
sensitivity gains of a point source in a (non-radioactive) water-filled cylinder plateau at an AFOV 
of 70-80 cm. Because this scenario best reflects imaging a lesion in a patient, this means that most 
of the sensitivity gain can be achieved in a 70-cm system. However, these gains are only achieved 
at the center of the AFOV for a 70-cm system and further extending the AFOV extends the axial 
range of the scanner over which these gains are achieved.   
Many groups have used simulations to study the sensitivity gain as a function of acceptance angle 
for various total body PET scanner geometries [61-64] and its effect on lesion detectability [65]. 
Early work at UC Davis by Poon et al. studied the NECR gain for long AFOV scanners and showed 
the 25-30x increase in sensitivity possible with a 2-m-long scanner [64]. Schmall et al. studied how 
axial parallax error affected spatial resolution depending on the length of the scanner. They found 
a modest degradation in axial resolution of about 1 mm for even a 2-m long scanner [66].  Surti 
et al. studied how NECR and lesion detectability changed depending on the length and thickness 
of LSO crystals while maintaining a constant volume of crystals.[67]. Surti et al. also did further 
lesion detectability studies that showed that injected activity can be reduced by a factor of 10x 
when extending the AFOV of the scanner from 18 cm to 72 cm while maintaining detectability of 
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small lesions [68]. These simulations provided the basis for the expected performance benefits of 
long AFOV systems. 
 
Figure 6. Sensitivity as a function of scanner AFOV for a (A) 27-cm distributed water-filled cylinder, (B) point source 
in air and (C) a point source in a 27 cm non-radioactive water-filled cylinder. The point source is centered in the 
transverse and axial FOVs. (A-C) Data courtesy of Dr. Suleman Surti. (D) The axial sensitivity profiles of a line source 
in a 20-cm water-filled cylinder. 
 
The increased sensitivity of long AFOV scanners can be leveraged to either lower the radioactive 
dose injected into patients or decrease the imaging scan time. Low-dose FDG PET imaging is 
valuable for imaging both adult and pediatric patients, especially when patients are imaged many 
times throughout their course of treatment. Low-dose PET imaging is especially of interest for 
pediatric patients since they are more susceptible to radiation exposure. Low-dose imaging is also 
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valuable when testing newer radiotracers that are often injected at 3-6 mCi, as opposed to the 15 
mCi at which FDG is typically injected. This is due to either limitations in generating the 
radiopharmaceutical or limitations in the radioactive dose received by a radio-sensitive organ with 
high uptake of the radiotracer. Thus far, Zhang et al have implemented their kernel reconstruction 
algorithm for long AFOV data and shown that data from a 20 min scan of a simulated human 
injected with 675 µCi of FDG can be reconstructed into a low noise, high contrast image [69]. 
Conversely, utilizing the increased sensitivity of a long AFOV scanner to scan for as short as 30 s 
to 1 min can be valuable for both adult and pediatric imaging. Younger pediatric patients are 
typically anesthetized using general anesthesia to prevent motion during the PET study, and 
general anesthesia has recently been shown to be associated with neurodevelopmental risks later 
in life [70]. If 30 s scans with good image quality can be taken on a long AFOV system, then the 
pediatric patients could forgo such risks. In adult imaging, the decreased scan time when imaging 
on a long AFOV system could enable higher throughput static FDG imaging. Also, interestingly, it 
could be used to acquire good quality breath-hold images of patients to mitigate the blurring 
effects of respiratory motion. Breath-hold imaging would be especially interesting for lung cancer 
patients with small lesions that are typically blurred due to respiration. 
The high sensitivity of a long AFOV system can also be used to image low positron fraction isotopes 
or isotopes with short half-lives. While imaging of 90Y, with a 0.0034 % positron fraction, may still 
prove challenging even with a long AFOV system, imaging radiotracers labeled with 89Zr, with a 
22.3 % positron fraction, could result in good quality images. 90Y microspheres are used for 
radioembolization of the hepatic artery to treat patients with unresectable liver cancers [71] and 
imaging is used to track the microspheres. Conversely, 89Zr has a relatively long half-life (t1/2 = 3.27 
d) and is typically labeled to long-lived theranostic agents such as monoclonal antibodies or CAR-
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T cells [72-74], so a long AFOV system can also enable tracking of such antibodies as late as 3 half-
lives (10 d). Similarly, image quality of data acquired can be improved when imaging radioisotopes 
with shorter half-lives. These include cardiac imaging isotopes like 82Rb with a 76 s half-life, but 
more interestingly 68Ga (t1/2 = 68 min) which is currently used to label DOTATATE, a somatostatin 
analogue used to image neuroendocrine tumors, along with a PSMA tracer for prostate cancer 
imaging. The shorter half-life of 68Ga results in poorer image quality and lesion localization, since 
fewer events are collected when imaged one-hour post-injection. Imaging on a long AFOV scanner 
would improve image quality and allow for imaging at later time points for better lesion contrast. 
Additionally, current biodistribution studies acquire data in 4-5 multi-bed scans taken over the 
course of hours, where the subject may require multiple CT scans for attenuation and scatter 
correction after each break. Today, a 10 mCi injection of FDG is approximately a 7.5 mSv dose for 
the patient, considerably higher than a low dose CT which can be as low as 1 mSv dose [75]. 
Because of the increased sensitivity of the long AFOV scanner, there is potential to use a lower 
tracer dose for the PET study. Second, since the long AFOV scanner will cover all organs in the 
thorax and pelvis, multiple bed positions will no longer be required for scanning. Instead, dynamic 
data of multiple organs can be acquired in a single bed position. Therefore, a long AFOV scanner 
will be an ideal means to test the pharmacodynamics of new drugs and filter out ineffective drugs 
in early stages of testing. This will be especially useful for full body dynamic imaging of theranostic 
agents, such as monoclonal antibodies (mAb) or CAR-T cells. After imaging at low dose to confirm 
that the tracer distribution corresponds to sites with cancer, the uptake can be used to calculate 
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Figure 7. Patient dynamically imaged with FTT. Data courtesy of Drs. Austin Pantel and Robert Mach, University of 
Pennsylvania. Static surview (left) shows both a liver lesion and a pelvic lesion (blue arrows) in this patient. Dynamic 
imaging (right) was only acquired for the pelvic lesion due to the limited AFOV of commercial scanners. Early time 
points show uptake in the external and internal iliac arteries, and later time points show uptake in the pelvic lesion. 
 
In addition to static imaging, a long AFOV scanner is uniquely valuable for dynamic imaging of the 
whole body simultaneously. UC Davis helped to develop and opted to purchase a 194-cm long PET 
scanner with 505 ps timing resolution from United Imaging (Shanghai, China). The team at UC 
Davis has developed algorithms to implement direct reconstruction of flux from FDG data of 
normal humans, have shown TACs of various blood input sources, and reconstructed sub-second 
dynamic images to show the beating heart activity in various blood vessels [76-78]. Studying 
heterogeneity within and across lesions in distant axial locations (e.g. the pelvis and the lungs) is 
key for characterization of lesions within a patient and assessing treatment options that can be 
tuned to each lesion’s unique phenotype and avoid selecting for highly treatment-resistant tumor 
cells. This can be achieved by (1) dynamically imaging all lesions in the body simultaneously and 
(2) imaging with multiple dynamic tracers sequentially. Dynamic imaging of multiple lesions will 
be valuable for many ongoing research studies at the University of Pennsylvania and one example 
5 s
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of such a study is shown in Figure 7. 18F-Fluorthanatrace (FTT) is a poly (ADP-ribose) polymerase 
(PARP) inhibitor, where PARP is an overexpressed receptor in many cancers, used to image 
glioblastomas as well as metastatic ovarian, breast, prostate, and pancreatic cancers. If lesions 
are positive on an FTT scan, patients can be treated with PARP inhibitors including Olaparib, 
Rucaparib, Niraparib, or Talazoparib which will inhibit the DNA repair mechanism and lead to cell 
death [79, 80]. 18F-Fluoroglutamine (FGln) measures the utilization of glutamine as a source of 
energy in the cell and is used to image triple negative breast cancer (TNBC). For patients with 
lesions that use large amounts of glutamine as an energy source, the glutaminase inhibitor by 
Calithera can be prescribed [81, 82]. Dynamic imaging of new tracers is not limited to FTT and 
FGln; however, they are likely to be some of the early dynamic research studies performed on the 
long AFOV system at the University of Pennsylvania.  
To reduce the radioactive burden on the patient when imaging with multiple tracers sequentially 
and minimize the contamination of the first tracer into the second, the high sensitivity of a long 
AFOV system will be leveraged to inject a low dose of the first tracer, followed by subsequently 
higher doses of the following tracers. Ideally, a dose would be selected such that quantitation of 
kinetic parameters of interest, which are typically correlated with clinical metrics, will not be 
compromised. We refer to this as dual-tracer or multi-tracer imaging depending on the number 
of tracers injected which is further studied in Chapter 6. Additionally, the imaging time between 
tracer injections may be reduced in an effort to directly register data collected from the multiple 
tracers and avoid collecting multiple CT scans and ensure the patient is in a common physiologic 
state. The first dual-tracer study planned for the PennPET Explorer is FGln followed by FDG in a 
patient with TNBC. This would allow for assessment of the relative contributions of glutamine and 
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glucose as energy sources for the tumors and treatment would be designed to target both energy 
sources and effectively starve the tumor. 
As noted in Chapter 1, there are currently two long AFOV systems currently in use: (1) the 194-
cm United Imaging uExplorer at the UC Davis Medical center and (2) the 70-cm prototype PennPET 
Explorer which will soon be operational with an extended AFOV of 140 cm. Since the data, both 
simulated and measured, for this thesis are mainly based on the 70-cm PennPET Explorer, a more 
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CHAPTER 3: DESIGN AND PERFORMANCE OF A LONG AFOV SCANNER 
This chapter provides details of the three simulated scanners used in this thesis: the 16.4 cm 
Philips Vereos, the 23-cm ring-segment, and the 70-cm three-ring PennPET Explorer, followed by 
the geometry of the 70-cm PennPET Explorer prototype, the scanner on which we collected 
measured data. All measurement data in this thesis was taken on the prototype scanner including 
both phantom measurements and datasets of both human volunteers and clinical patients. A 
detailed analysis of NEMA performance metrics for all three simulated scanners and the 70-cm 
PennPET Explorer prototype is then presented, followed by a brief overview of human subject 
imaging on the scanner, and the valuable data acquired. 
SCANNER GEOMETRY 
Both the simulated scanners and the prototype PennPET Explorer are based on the same 
underlying geometry. The simulation is based on a physical model of the detector and 
experimental benchtop measurements were used to determine details of the detector 
performance. The basic building block of all of these scanners is the Philips digital photon counting 
(PDPC) tile that is currently used in the Philips Vereos PET/CT [56]. A tile is comprised of an 8 x 8 
array of 3.86 x 3.86 x 19 mm3 LYSO crystals with an average crystal pitch of 4 mm (Figure 8) This 
array of crystals is coupled to a digital SiPM developed by Philips Digital Photon Counting [83]. 
The SiPM sensor tile is fully digital, with 16 individual devices (dies), each generating an 
independent time stamp. The simulations indirectly simulate SiPMs by calculating the coincidence 
sensitivity, as described in more detail in the following section. The crystals are arranged into 2 x 
2 arrays of “dies” where a tile is made up of a 4 x 4 array of dies and spacing of crystals within the 
die is slightly smaller than spacing across dies.  Additionally, reflector is placed outside the die so 
no light is shared across dies; however, based on benchtop measurements, it has been 
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determined that about 9% of light from any of the four crystals within the die is shared across the 
other three crystals [84]. There is a 1:1 crystal–sensor coupling that leads to nearly ideal crystal 
identification, high count-rate capability, and superior timing resolution. A 4 x N array of tiles 
(transverse x axial) is used to comprise one module of the scanner and a ring of 18 modules 
completes the full scanner, where each ring segment measures 76.4 cm in diameter. N is the 
number of axial tiles and is used to vary the axial length of the various simulated scanners. The 
70-cm PennPET Explorer prototype is composed of three rings, each with 7 axial tiles, where 2 of 
the 7 tiles cannot be read out due to current electronics limitations, reducing the effective AFOV 
of the prototype scanner to 64 cm [85]. Lead shielding was added at the ends of the scanner for 
all the simulated scanners, and while the commercial Philips Vereos has lead shielding, it was not 
included in the PennPET Explorer prototype since the goal of long AFOV imaging is to include much 
of the patient’s body within the AFOV, so there will be minimal activity outside the FOV. 
 
Figure 8. Geometry of a single module, tile, die, and crystal (left to right). The first two rows of the module are gray 
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GATE SIMULATIONS 
Monte-Carlo simulations were performed in advance of building the prototype PennPET Explorer 
to quantify performance of a long AFOV scanner based on the Philips Vereos geometry and 
understand the gains of such a scanner compared to a commercial length scanner.   
Simulations were done using Geant4 Application for Emission Tomography (GATE) v8.0, a Monte-
Carlo modeling software that allows a user to input a scanner geometry, phantom geometry, and 
phantom activity distribution and will then trace the path of every radioactive event [16]. GATE is 
based on Geant4, a physics modeling toolkit that includes the ability to model a large variety of 
interactions between particles, photons, and matter. This includes effects specific to PET imaging 
such as positron range, positron-electron annihilation, and non-collinearity, as well as the physics 
effects that result in attenuation and scattering of gamma rays including the photoelectric effect, 
electron ionization, Compton scattering, Rayleigh scattering, and the Bremsstrahlung effect. 
Additionally, GATE will model the timing and energy resolutions of events and can sort singles 
events into prompt and delay coincidence events given a defined timing window and delay 
window. 
Our GATE simulations included modeling of positron range, non-collinearity, and radioactive 
decay, as well as trues, randoms, and both Compton and Rayleigh scattering. All simulations were 
either run with a timing resolution of 320 ps to match the Philips Vereos timing resolution when 
operated at room temperature (18˚C) or at 250 ps to match the timing resolution when the 
scanner is operated near 5˚C [85]. Energy resolution for all simulations was 11 % with an energy 
window of 444 keV to 613 keV, and the coincidence timing window was 4.02 ns with a delay 
window of 500 ns. A multiple window coincidence sorter was used. Additionally, coincident events 
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had to arrive at modules separated by at least four modules in the transverse direction restricting 
the transverse FOV to about 60 cm. 
 
Figure 9. Scanner geometries shown for both simulated scanners: (A) Philips Vereos (AFOV = 16.4 cm), (B) 23-cm 
AFOV ring-segment, and (C) the 70-cm PennPET Explorer, as well as (D) the prototype PennPET Explorer where the 
light blue regions reflect the data inactive regions of the scanner (effective AFOV = 64 cm). 
 
Three scanners with similar underlying geometries, described in the previous section, but varying 
axial lengths were simulated in GATE for this work: (A) the Philips Vereos with a 16.4 axial length 
made of 5 axial rows of tiles, (B) the single ring-segment of the PennPET Explorer with a 23 cm 
axial length made of 7 axial tiles, and (C) the PennPET Explorer with a 70 cm axial length made of 
21 axial tiles. We refer to the three simulated scanners in this work as the Vereos, 23-cm ring-
segment, and the 70-cm PennPET Explorer (Figure 9A-C). We will often refer to the PennPET 
Explorer geometry as the “three-ring” geometry because in practice, the scanner will be 
comprised of three separately functioning rings of the 23-cm axial length PennPET Explorer ring-
segment; however, the extra separations between ring-segments present in the PennPET Explorer 
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Output data from GATE are stored in a ROOT file with raw information about the arrival times of 
all coincident events. This is then converted into list-mode file where each coincident event is 
written in a list that records the time-of-flight bin (where each bin is 19.53 ps), the transverse 
crystal, the axial crystal and the energy of each of the two coincident photons. Prior to writing the 
list, light sharing is randomly implemented for 9% of events using a random number generator 
that shifts the crystal of arrival to one of the other three crystals in the die.  
In addition, coincidence sensitivity is incorporated before writing the list-mode events. Benchtop 
measurements of the detectors were used to estimate the coincidence sensitivity of LORs in the 
scanner to randomly reject a percent of events. The coincidence sensitivity is based on two 
effects: the 5x5 cluster grouping efficiency that reflects the number of dies over which light is 
collected due to Compton scatter of gamma rays across crystals and the PDPC live time that 
reflects the percent of time when the PDPC sensor can process a newly detected event. The 
cluster grouping efficiency is always 98%, while the PDPC live time improves as the sensor is 
cooled to lower temperatures due to lower dark noise in the sensor. The PDPC live time is 90% at 
18˚C and 97% at 10˚C; we do not have benchtop measurements for the live time at 5˚C so the 
PDPC live time at 10˚C was used. The coincidence sensitivity is calculated as 
(𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑖𝑛𝑔	𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 ∗ 𝑃𝐷𝑃𝐶	𝑙𝑖𝑣𝑒	𝑡𝑖𝑚𝑒)!. Therefore, the coincidence sensitivity at 18˚C is 
0.78 (0.90 ∗ 0.98)!	and is 0.90 at 10˚C (0.97 ∗ 0.98)! resulting in the rejection of 22% and 10% of 
counts, respectively [84]. 
Prior work by Trindade et al. has shown good correspondence between performance of the 
Vereos simulations and measurement [86]; therefore, this work should hold for extension to the 
PennPET Explorer based on the same detector and electronics model. Finally, normalization 
correction for all simulations was generated by simulating a 60-cm diameter cylinder filled with 
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18F and dividing by an ideal cylinder of the same geometry to calculate the attenuation correction 
factors [24]. The normalization primarily includes the effects of the scanner geometry and solid 
angle, but since simulated scanners do not reflect differences in crystal efficiencies present in an 
actual scanner, this is not included. 
70-CM PENNPET EXPLORER PROTOTYPE 
The PennPET Explorer is a scalable PET system built at the University of Pennsylvania with 3 rings 
(70 cm AFOV) and is now being expanded to 6 rings (144 cm AFOV). The 70-cm prototype system 
was tested and used for all work utilizing measured data in this thesis. Because the simulation of 
the PennPET Explorer was extended from a representation of the Philips Vereos, aspects of the 
prototype scanner’s design reflect the design of the simulations.  
The detector module design allows close ring spacing and operation at 5˚C with the first photon 
trigger level setting (trigger 1) [87] to optimize the timing resolution. The entire gantry and its 
associated electronics are water-cooled; a chiller is used to cool facility water to approximately 
0˚C to achieve 5˚C at the sensor with less than 1˚C variation over the full system. Condensation is 
prevented by infusion of dry purge air to the scanner. In contrast, the same devices in the Philips 
Vereos PET/CT scanner [56] operate at 18˚C and at a higher trigger level (trigger 2). The trigger 
level refers to the threshold at which the time stamp of an event is determined, where trigger 1 
is at a lower threshold than trigger 2. If this threshold is too low, then dark noise from the detector 
is mistaken for a photon event, and the time associated with processing that “event” creates dead 
time and an associated loss in sensitivity. For this reason, trigger level 1 can only be used when 
the scanner is cooled and the dark noise of the detector is lowered; otherwise it results in a 50% 
decrease in point source sensitivity [88]. The PennPET Explorer is fully sealed and maintains its 
own cool, dry environment independent of ambient conditions. The ring segments are mounted 
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on linear rails to allow for service access and system expansion. The prototype configuration used 
in this work consists of 3 ring-segments, where two of the seven axial rows of tiles in a module 
have data readout limitations and effectively create 7.6 cm axial gaps between rings of the 
scanner and reduce the effective AFOV of the scanner to 64 cm (Figure 9D). Images of the PDPC 
tile, detector module, single scanner ring, and full PennPET Explorer are shown in Figure 10. 
 
Figure 10. The various components used to build up the PennPET Explorer including the PDPC tile (A) made of an 8x8 
array of LYSO crystals; the detector module (B) made of a 4x7 array of tiles; the single ring segment (C) made of 18 
detector modules; and the PennPET Explorer (D) made of 3 ring segments in the configuration used for initial phantom 
and human studies. 
  
The data acquisition system uses the Philips Vereos electronic components and collects data as 
single events. A master clock distributed to all rings was implemented to eliminate any timing 
discrepancies between rings. Data are buffered independently on each ring segment and can be 
collected up to rates of 100 Mcps that are then merged into a single stream of time sorted singles 
data. Since each ring segment operates autonomously, the system maintains high throughput, 
independent of the number of ring segments. This results in minimal dead time, a key 
requirement for dynamic imaging in which the full tracer bolus will be in the field of view after 
injection. After transfer from the hardware, the singles data are sorted in software into 
coincidence list files of prompt and delayed events using a 2.49 ns timing window, a 500 ns delay 
window, and a multiple window coincidence sorter.  
D. PennPET ExplorerC. single ring-segmentB. ModuleA. PDPC tile
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Normalization data were acquired with a thin steel tube filled with approximately 70 MBq of 18F 
centered in a thin-walled, 2.54-cm diameter carbon fiber tube with negligible attenuation that 
provides rigidity and dampening over the 70-cm length. The rotating tube is meant to emulate an 
annulus source, which can be used to measure the crystal efficiencies and geometric efficiencies 
of every LOR up to the radius at which the annulus source is located [24]. Using an asynchronous 
motor mounted onto the back plate of the gantry, the line rotates at 2 rotations per minute at a 
radius (30 cm) just outside the transverse field of view, and data are acquired for about 1 hr to 
collect a sufficient number of counts for all LORs. Normalization correction factors are generated 
by calculating the ratio of the collected data to an analytic rotating line sinogram, followed by 
modest smoothing according to the method of Casey et al. [25] The normalization correction 
sinogram created for measured data from the PennPET Explorer includes the effects of varying 
crystal efficiencies per LOR that were not included in the simulated normalization sinogram, while 
geometric and solid angle effects were included in both the measured and simulated 
normalization corrections. 
NEMA PERFORMANCE TESTING 
NEMA performance testing is traditionally performed on newly developed commercial PET/CT 
scanners, first in the factory by the vendor to assess various performance metrics [89], and then 
again by medical physicists at the installed site to determine whether to accept the instrument. 
NEMA testing is a critical component of quantifying the performance of a newly installed scanner 
and ensure that it performs within desired specifications so that clinical data taken on the scanner 
will be reliable. The NEMA metrics are sensitivity, spatial resolution, count rate performance, 
image quality, corrections for count losses and randoms and PET/CT co-registration. The four 
major performance tests – sensitivity, spatial resolution, count rate performance, and image 
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quality – were both simulated and measured on the 70-cm PennPET Explorer prototype. 
Simulations that emulated the NEMA performance tests were run on the simulated Philips Vereos 
to corroborate performance of the simulation against measured data. Performance testing was 
also performed on the 23-cm ring-segment simulation, the building block of the PennPET Explorer, 
along with a simulation of the 70-cm PennPET Explorer consisting of 3 ring-segments. NEMA 
performance testing was then performed on the PennPET Explorer prototype for comparison with 
simulation and characterization of the system in comparison to other commercial systems. We 
selected the NEMA performance tests that best demonstrated the advantages on long AFOV 
imaging. In addition to standard NEMA testing, a few other tests were performed to assess 
uniformity and quantitation of reconstructed images at lower doses than specified by NEMA, 
which was designed for clinical scanners with a standard AFOV. 
Note that both the NEMA sensitivity and count rate phantoms are 70-cm long, which at the time 
was significantly longer than any commercial scanner and also reflect the average length of a 
patient’s torso. NEMA tests are currently only defined for scanners with an AFOV shorter than 65 
cm, but we still use 70-cm long phantoms to test the 70-cm PennPET Explorer. For scanners with 
longer AFOVs, the NEMA standards will need modification for proper testing, although these 
changes have not been defined. 
METHODS 
The first NEMA test performed assesses the sensitivity of the system. Sensitivity reflects the 
percent of counts collected by the scanner given the amount of activity within the field of view 
(FOV). Sensitivity is measured by placing a 70-cm long line source in the center of the scanner and 
acquiring with increasing attenuation around the line source (Figure 11A). This is done by taking 
sequential measurements of a thin line source with five aluminum sleeves of varying diameters 
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to successively increase attenuation (see Figure 11A). Using the five data points, sensitivity 
measures calculated for each aluminum sleeve are fit to an exponential (measured sensitivity vs 
attenuation) to estimate sensitivity when attenuation is zero. For scanners longer than 65 cm, a 
plastic tube with little attenuation can be used to avoid building a longer and more cumbersome 
phantom; however, sensitivity would be slightly underestimated. The extrapolated sensitivity at 
zero attenuation is reported as the system sensitivity in units of kcps/MBq. This measurement is 
repeated 10-cm off center to assess the stability of system sensitivity as a function of radial 
position. 
NEMA prescribes the spatial resolution measurement using five point-sources placed in an L shape 
at the following positions: (0,1), (0,10), (0,20), (10,0), and (20,0) cm (Figure 11C). Data are 
reconstructed using an analytic reconstruction algorithm to quantify the system spatial 
resolution. Profiles through the five points are drawn in the radial, tangential, and axial directions 
and are used to calculate the full width at half maximum (FWHM) and full width tenth maximum 
(FWTM) of each point. These are then reported as the spatial resolution of the system. 
Count rate performance is measured using a 20 cm diameter x 70 cm long cylindrical polyethylene 
phantom with a 70 cm long line source placed 4.5 cm off-center to simultaneously quantify both 
count rate and scatter fraction using a single phantom (Figure 11B) [90]. The line source is placed 
4.5 cm off center because it best represents the scatter fraction of a uniformly filled 20-cm water 
cylinder. The phantom was designed to represent a 20x70 cm cylinder of water filled with activity; 
however, since the associated radiation risk of spilling activity when filling such a large and heavy 
radiation source is high, and since the large volume of the source would be difficult to fill uniformly 
and store, the plastic cylinder with a line source was designed. Activity in the line source is filled 
to represent the concentration in the 20x70 cm cylinder (Volume = 22 L), and data are taken from 
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roughly 60 kBq/cc to activities as low as 0.5 kBq/cc. Because the location of the line source is 
known, thresholds can be drawn in sinogram space to estimate the number of true (𝑇), randoms 
(𝑅), and scatter events (𝑆). The noise equivalent count rate (𝑁𝐸𝐶𝑅 = 𝑇!/(𝑇 + 𝑅 + 𝑆)) is then 
calculated at each measured activity concentration. The NECR is linearly correlated with the 
square of the signal to noise of the data and a higher NECR reflects better image quality data and 
lower noise [91]. The concentration at which the maximum NECR is achieved is referred to as the 
peak NECR and the concentration and NECR at that concentration are both reported. Additionally, 
the NECR at 3.7 kBq/cc is sometimes also reported, since it is a typical concentration at which FDG 
PET scans are acquired, given a 10 mCi injection into a 70 kg patient imaged 1-hour post-injection.  
 
Figure 11. NEMA performance metric tests for (A) sensitivity, (B) count rate, (C) spatial resolution, and (D) image 
quality where red represents regions filled with activity and grey represents phantom 
 
The final NEMA test we performed is of image quality. The NEMA image quality (IQ) phantom is a 
21-cm long torso-like phantom with three regions: a water-filled background region, six spheres 
of different pre-defined diameters (10-37 mm), and a central rod filled with Styrofoam beads to 
replicate the attenuation of lung (Figure 11D). The background region is typically filled with 3.7 
kBq/cc, the spheres are filled with either 4x or 8x the background concentration, and the lung rod 
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is typically cold. The six spheres have diameters of 10, 13, 17, 22, 28, and 37 mm and the two 
largest spheres are left cold according to NEMA 2012 standards; however, NEMA 2018 standards 
now prescribe filling the two largest spheres with a 4:1 uptake. The phantom is centered such that 
the spheres are aligned with the axial center of the scanner and the phantom is abutted with the 
count rate phantom, filled with 18F, to represent out of field scatter and activity from the rest of 
the patient’s body. NEMA prescribes that the scan time be equivalent to the scan duration of a 
single bed position when imaging 100 cm axially of a patient in a total 30 min imaging session. 
This primarily depends on the axial translation of the bed between positions and is calculated as 
𝑠𝑐𝑎𝑛	𝑡𝑖𝑚𝑒 = 30	𝑚𝑖𝑛 ∗ 𝑎𝑥𝑖𝑎𝑙	𝑠𝑡𝑒𝑝	(𝑚𝑚)	/	100𝑐𝑚. The axial step size of Philips PET scanners, 
which is what we used to make this calculation, is close to half the axial length of the scanner. 
Today’s commercial PET scanners have axial lengths of 16.4 – 25 cm, so the calculated scan time 
would be 2.5 – 3.75 min. For the purposes of this work, we chose image for 3 min regardless of 
the axial length of the scanner since the purpose of a long AFOV scanner would be to image in a 
single bed position. To quantify the measurement error, we image for 30 min and separate data 
into ten 3-min datasets before reconstructing with the vendor supplied clinical algorithm. 
Volumes of interest (VOIs) with diameters equal to the sphere sizes are placed on each sphere to 
measure 𝐻 , the mean activity in the hot sphere. Spheres of similar size are placed in the 
background to measure 𝐵, the mean activity in the background. The contrast recovery coefficient 
(𝐶𝑅𝐶	 = 	 (𝐻/𝐵	 − 1	)/	(𝑎	– 	1)) is then calculated, where 𝑎  is the known uptake. The CRC is 
reported for each sphere size and the value reflects the impact of partial volume effects for 
spheres of various sizes. Image quality is the only test that includes the effects of the clinical 
default reconstruction algorithm to assess the quantitative accuracy of the scanner. The 
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reconstruction cannot be tuned by altering the number of iterations, image voxel size, or post-
reconstruction smoothing to improve CRC or image noise results for a given system. 
In addition to the NEMA performance phantoms, there are a few other phantoms that have been 
developed by third parties to augment performance testing of scanners. The harmonization 
project was developed by the Universities of Washington, Iowa, and Pennsylvania to harmonize 
the image reconstruction of data collected on different scanners so that multi-center clinical trials 
can report quantitative results that can be directly compared [92]. To that end, they have 
recommended that the image quality phantom be scanned with the NEMA spheres (10-37 mm 
diameter) and also with “half-sized” spheres that have sizes of 8.5, 11.5, 15, 19.5, 25, and 32.5 
mm diameter, and have recommended that spheres be filled with a higher sphere:background 
ratio of 9.7:1. CRCs of these half-sized spheres are calculated and results agree with the trend 
shown by data from the full-sized (NEMA) spheres when plotting CRC vs. sphere size [93]. Due to 
the small size of the 8.5 mm sphere, it is particularly important to carefully fill the spheres since 
mis-calculating the volume of activity in the sphere can result in a slight underestimation of CRC. 
 
Figure 12. (A) SNMMI CTN phantom [93]. (B) CT image of the inside of the phantom showing lung regions, background 
regions, and the outlines of water-filled spheres in both the lung and background regions. (C) PET image of a coronal 
slice of the SNMMI CTN phantom and (D) the corresponding maximum intensity projection image to show all spheres. 
 
In addition to the IQ phantom with half-sized spheres, the Society of Nuclear Medicine and 
Molecular Imaging (SNMMI) has developed the clinical trials network (CTN) torso phantom [93], 
A B C D
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which is used for studies in Chapter 4. The phantom includes spheres in a more anthropomorphic 
distribution over a larger axial range of slices. It is in the shape of a small person’s upper torso, 
starting at the neck and ending near the diaphragm, without including arms. Within this phantom 
is a background region, a lung region, and a number of spheres in both regions ranging in size 
from 7 – 37 mm. There are two 10 mm spheres placed 1 cm apart in the lung region meant to test 
resolution of the scanner if the two spheres can be fully resolved, while the 7 mm sphere further 
test partial volume effects of the scanner (Figure 12). Since newer scanners have improved spatial 
resolution, 10 mm spheres can be easily detectable, and a 7 mm sphere can prove to be more of 
a challenge. However, all quantifications of CRC are highly dependent on the reconstruction 
algorithm parameters, whether or not TOF or PSF modeling are included, and the voxel size of the 
resulting image. Typically, factory recommended reconstruction parameters for the scanner are 
used for analysis; however, values with various reconstruction options are also reported. 
RESULTS: GATE SIMULATIONS 
Sensitivity 
Sensitivity was calculated for simulations of the Philips Vereos, 23-cm ring-segment, and the 70-
cm PennPET Explorer. The total sensitivity for the Philips Vereos was 5.5 kcps/MBq when centered 
in the transverse FOV and 5.5 kcps/MBq when 10 cm off center. The reported measured 
sensitivity of the Vereos was 5.1 kcps/MBq [56], which is in agreement with the simulated value 
of 5.5 kcps/MBq. The sensitivity of the 23-cm ring-segment was 10.8 kcps/MBq when centered 
and 10.8 kcps/MBq at 10 cm off center. The doubling of sensitivity between the Philips Vereos 
and the 23-cm ring-segment roughly agrees with the increase in axial length (and corresponding 
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Explorer was 90.5 kcps/MBq centered and 90.0 kcps/MBq at 10-cm off center. Based on the 
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9.3); however, the sensitivity gain when compared to the 23-cm ring-segment is closer to 8.4x. 
This is due to the effect of the solid angle, where more oblique LORs (i.e. LORs where coincident 
photons have a large axial difference) experience a lower flux of photons, resulting in lower 
sensitivity of those LORs. This reduction can be seen in the axial sensitivity profile for the 70-cm 
scanner (Figure 13). These profiles were created using data simulated with a single attenuating 
sleeve (as per NEMA) and events were placed in their most likely position along the LOR based on 
TOF information. Note that the axial sensitivity profile is not perfectly triangular. Therefore, the 
sensitivity gain does not simply scale with the square of the axial length of the scanner.  
 
Figure 13. NEMA axial sensitivity profiles for the Philips Vereos (gray), 23-cm ring-segment (red), and the 70-cm 
PennPET Explorer (blue). Axial sensitivity profiles are calculated based on data from the 70-cm line source with one 
attenuating sleeve. The dashed line shows an ideal triangular axial sensitivity profile. 
 
Additionally, clinical PET imaging is done in multiple overlapping bed positions to minimize axial 
noise variations in the image. With 50% overlap between bed positions, a uniform axial sensitivity 
profile can be achieved over much of the axial extent (Figure 19A). The axial sensitivity profiles 
reflect that the average gain in sensitivity at each axial position, referred to as the axial sensitivity, 
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is closer to 2-3x for the 70-cm scanner. The gain in sensitivity of the 70-cm scanner at the center 
of the AFOV is 3.6x compared to the Philips Vereos and 2.5x compared to the 23-cm ring-segment. 
The axial sensitivity gain will better approximate per-organ benefits of imaging with a long AFOV 
scanner as opposed to the total sensitivity gain. 
Table III. Spatial Resolution for the three simulated scanners 




3D FRP Simulated  3D FRP Simulated  3D FRP Simulated Analytic DIRECT Simulated 3D FRP Simulated Analytic DIRECT 
FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM 
center [mm] - 1 cm 3.99 8.30 3.90 7.86 3.90 8.00 3.96 7.83 3.99 8.62 4.06 8.00 
radial 10 cm 4.65 9.05 4.44 8.51 4.47 8.71 4.63 9.06 4.06 7.52 4.77 9.45 
tangential 10 cm  4.37 8.83 4.26 8.48 4.48 8.67 4.15 7.88 4.94 12.90 4.16 7.91 
radial + tangential 10 
cm  4.51 8.94 4.35 8.50 4.35 8.53 4.39 8.47 4.50 10.21 4.47 8.68 
radial 20 cm 5.73 10.23 5.78 10.27 6.13 11.44 6.10 11.34 5.26 8.73 6.24 11.54 
tangential 20 cm  4.91 10.42 5.06 10.92 4.75 8.99 4.41 7.96 6.98 20.41 4.39 7.94 
radial + tangential 20 
cm  5.32 10.33 5.42 10.59 5.44 10.22 5.25 9.65 6.12 14.57 5.31 9.74              
Axial Spatial 
Resolution (mm) Measured 
Simulated  
3D FRP Simulated  3D FRP Simulated Analytic DIRECT Simulated 3D FRP Simulated Analytic DIRECT 
FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM 
Average at center - 
1cm 4.00 8.45 3.78 7.53 3.77 7.52 4.01 8.08 4.31 10.18 4.49 10.39 
Average at 10 cm 4.47 8.85 4.05 7.96 4.06 7.96 4.18 7.99 6.81 16.66 4.77 10.38 
Average at 20 cm 4.35 8.45 4.57 8.79 4.70 8.94 4.22 7.96 9.88 20.60 4.73 9.99 
 
Spatial Resolution 
Spatial resolution measures were calculated for the Philips Vereos, 23-cm ring-segment, and the 
70-cm PennPET Explorer simulations (Table III). Measured and simulated results on the Philips 
Vereos, both reconstructed with the analytic algorithm, 3D Fourier reprojection (3D FRP) [94], 
show good correspondence of transverse and axial spatial resolution measures for points at 
various radii. NEMA dictates that an analytic algorithm with ramp filtering be used for spatial 
resolution measurements since analytic algorithms are linear and consistent, where results from 
an iterative algorithm can vary depending on the number of iterations. 3D FRP was developed for 
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fast 3D PET reconstructions utilizing fast Fourier transform processors to (1) re-project data into 
Fourier space, (2) interpolate to fill in missing data from oblique projections, and (3) reconstruct 
the data with 3D filtered back projection. We used 3D FRP with a Colsher filter [95], a 3D filter 
analogous to the 2D ramp filter, so that reconstructions reflect the resolution of the system and 
not the image resolution, which can easily be tuned by using point spread function modeling or 
post-reconstruction smoothing. Results show that at the center of the scanner, spatial resolution 
is 3.9 mm, and the radial resolution degrades to 5.8 mm at 20 cm off-center while the tangential 
resolution only degrades to 4.9 mm. The larger degradation of the radial resolution compared to 
the tangential is expected due to transverse parallax error, which increases towards the edges of 
the scanner (Figure 14). Due to memory limitations in our implementation, 3D FRP was not 
designed to handle the large number of axial tilt angles in long AFOV data, and the coarse axial 
sampling from an insufficient number of axial samples leads to artificially degraded axial 
resolution measures for the 70-cm PennPET Explorer simulation. To that end, we tested 
reconstructions using analytic DIRECT. The 23-cm ring-segment spatial resolution data were 
reconstructed using both 3D FRP and analytic DIRECT [31, 96]. Analytic DIRECT can be 
reconstructed using a variety of LOR and image resolution modeling functions. A range of 
parameters was tested and the parameters that showed the closest agreement between analytic 
DIRECT and 3D FRP (no LOR resolution modeling and 2.0 mm image resolution modeling) for the 
23-cm ring-segment were used for spatial resolution reconstructions of the 70-cm PennPET 
Explorer. While analytic DIRECT reflects slightly improved spatial resolution for tangential 
resolution at 10 and 20 cm off-center and for axial resolution at 20 cm off-center, these 
differences are no more than 0.5 mm. Spatial resolution results for the 70-cm PennPET Explorer 
are shown when reconstructed with both 3D FRP and analytic DIRECT (Table III). Transverse spatial 
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resolution measures, when reconstructed using analytic DIRECT, show no difference between the 
70-cm PennPET Explorer and the 23-cm ring segment; however, axial resolution measures show 
a consistent 0.5 mm degradation in the FWHM and a 2.2 mm degradation in the FWTM due to 
the axial parallax error (Figure 14).  
 
Figure 14. Pictorial depictions of transverse (left) and axial (right) parallax error. Transverse parallax error is seen in 
all PET scanners and the error further degrades radial spatial resolution as the point moves radially towards the edge 
of the scanner. Axial parallax error is only evident in long AFOV scanners and the error is most pronounced at the 
axial and transverse centers of the FOV. 
 
Count Rate 
Count rate was simulated using the NEMA count rate phantom on the Philips Vereos, 23-cm ring-
segment, and the 70-cm PennPET Explorer for activity concentrations of 1-60 kBq/cc, and plots 
are shown in Figure 15. Measured results for the Philips Vereos [86] are included for comparison 
and the clinical FDG concentration range is shaded in red. Within the clinical FDG range, the 
measured and simulated Philips Vereos results agree well; however, the simulation has a higher 
trues count rate compared to the measurement. Since the system has been shown to linearly 
acquire singles up to a rate of 100 Mcps, the lower trues rate as measured by Philips is most likely 
due to dead time in the coincidence processing, since the discrepancy increases at higher activity 
concentrations. To our knowledge, the simulations accounted for the same dead time effects as 
Transverse Parallax Error Axial Parallax Error
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Trindade et al. [86], but perhaps the dead time effects of the Philips hardware are not accurately 
modeled. However, the performance of the PennPET Explorer prototype does not depend on the 
hardware modeling of the Philips Vereos since we do not utilize their hardware coincidence 
processor. Because data measured on the PennPET Explorer are collected in singles and sorted 
into coincidences in software off-line, as opposed to having hardware coincidence processors, we 
expect measured data to more closely follow the simulation. 
 
Figure 15. NEMA count rate curves for the Philips Vereos (left), 23-cm ring-segment (middle), and 70-cm PennPET 
Explorer (right) depicting the trues, scatter, randoms, and noise equivalent count rates for all three simulations. 
Results for the Philips Vereos also include measured count rate results by Philips. The clinical FDG range is shaded in 
red to reflect 2-6 kBq/cc. 
 
The maximum singles rate of the measured Philips Vereos data was 75 Mcps at 58 kBq/cc, well 
below the threshold of 100 Mcps. Trues count rates for the 23-cm ring-segment and the 70-cm 
PennPET Explorer scale according to their sensitivity gains, and plots show linearity of the trues 
rates. NECR slowly continues increasing in both simulations and measurement up to 60 kBq/cc. 
At 3.7 kBq/cc the NECR measured on the simulated Philips Vereos, 23-cm ring-segment and 70-
cm PennPET Explorer are 35, 70 and 805 kcps, respectively. The gain in NECR at this activity 
concentration for the 70-cm PennPET Explorer compared with the Philips Vereos is 23x. The 
scatter fraction is an average of 30%, 28%, 28% for the Philips Vereos, the 23-cm ring-segment, 
and the 70-cm PennPET Explorer, respectively, and changes by no more than 2 % as the activity 
concentration increases. It is also important that the scatter fraction does not increase as the 









































































69   
AFOV is extended from the Philips Vereos to the 70-cm PennPET Explorer, despite the lack of 
shielding. 
Image quality 
Images of the simulated image quality phantom with a 3-min scan duration on the Philips Vereos, 
23-cm ring-segment, and the 70-cm PennPET Explorer are shown in Figure 16, while contrast 
values for the four hot spheres are show in Table IV. The images show a marked improvement in 
background noise with increased sensitivity, which is reflected in the lower % SD of the 
background. Note that there is little difference in background noise between the Philips Vereos 
and the 23-cm ring segment, since the noise is related to gains in axial sensitivity, which is small 
between these two scanners. CRC is constant across the three scanners, with a slight decrease in 
CRC for the 10-mm sphere on the PennPET Explorer, possibly due to the axial parallax error that 
increased the axial resolution by about 0.5 mm. The 17-mm and 22-mm spheres are unaffected, 
but the 13-mm sphere also appears to experience a slight decrease in CRC due to the increased 
FWTM of the axial spatial resolution due to the increased FWTM evident in spatial resolution 
results (see previous section). Background variability measures the uniformity of the background 
of specific sizes or regions that relate to the spheres of interest, and results for the 23-cm ring-
segment and the 70-cm PennPET Explorer are shown in Figure 17. Background variability for the 
70-cm PennPET Explorer is roughly half that of the 23-cm ring-segment. 
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Figure 16. Single 2-mm slices of the simulated image quality phantom with four hot spheres at a 4:1 uptake and two 
cold spheres shown for the Philips Vereos (left), the 23-cm ring-segment (middle), and the 70-cm PennPET Explorer 
(right). 
 
Table IV. Contrast recovery values for the three simulated scanners 





10 mm 0.43 0.40 ± 0.03 0.34 ± 0.02 
13 mm 0.52 0.49 ± 0.03 0.46 ± 0.01 
17 mm 0.62 0.59 ± 0.02 0.59 ± 0.01 
22 mm 0.67 0.67 ± 0.02 0.66 ± 0.01 
28 mm 0.72 0.71 ± 0.01 0.72 ± 0.00 
37 mm 0.81 0.80 ± 0.01 0.81 ± 0.00 
Lung Rod 8.1 % 7.3 % 7.7 % 
% SD background 11.5 % 11.1 % 6.0 % 
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Summary of Results 
NEMA performance tests were run comparing three scanners: the 16.4-cm Philips Vereos, the 23-
cm ring-segment, and the 70-cm PennPET Explorer. The sensitivity of the three scanners is 5.5 
kcps/MBq, 10.8 kcps/MBq, and 70.5 kcps/MBq, respectively. The sensitivity gain of the 70-cm 
PennPET Explorer is 8.4x compared to the 23-cm ring-segment and 16.5x compared to the Philips 
Vereos. Spatial resolution simulations showed a 4.0 mm transverse spatial resolution at the center 
of the AFOV for all three scanners simulated, nothing that transverse spatial resolution does not 
degrade as the AFOV of the scanner is extended. The FWHM of the axial resolution was degraded 
by 0.5 mm due to axial parallax error when comparing the 70-cm PennPET Explorer to the 23-cm 
ring segment. The axial resolution degradation resulted in a corresponding decrease in CRC of 10 
mm and 13 mm spheres in the image quality phantom. Count rate results showed the linearity of 
the trues rate up to 60 kBq/cc for all three simulations. The NECR gain for the 70-cm PennPET 
Explorer compared to the Philips Vereos simulation was 23x at 3.7 kBq/cc. 
SIMULATED DOSE LOWERING STUDIES 
Image quality phantom 
To further probe the quantitative accuracy of long AFOV scanners compared to commercial 
scanners, data from the image quality simulations on the 23-cm ring segment and the 70-cm 
PennPET Explorer were subsampled to one-half, one-quarter, one-eighth, and one-sixteenth of 
the full-dose, 3-min scan. At each of the five emulated doses, data were bootstrapped to create 
20 replicate list files that were then reconstructed. Mean (?̅?) and SD (𝑠) of the CRC across twenty 
replicates was calculated for each of the four hot spheres at each of the five emulated doses and 
results are shown in Figure 18A. Percent standard deviation was calculated as %	𝑆𝐷 = 100 ∗ 𝑠/?̅? 
and is plotted for the four sphere sizes as a function of emulated dose in Figure 18B. CRC measures 
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are consistent for both scanners, even at very low doses; however, precision of the CRC 
measurement is markedly improved when imaging on the 70-cm PennPET Explorer simulation. 
Depending on the sphere, data can be acquired on the 70-cm scanner at ½ - ¼ the dose with the 
same measurement precision as imaging on the 23-cm ring-segment at the full dose, which agrees 
well with the 2-3x axial sensitivity gain of the 70-cm scanner. This implies that dose or scan 
duration can be reduced by a similar fraction when imaging on a 70-cm system while maintaining 
quantitative accuracy and precision of resultant PET images. 
 
Figure 18. (A) CRC and (B) % SD measured for emulated doses of 1 to 1/16th the original dose. 
 
Anthropomorphic phantom 
To extend the study done using the IQ phantom to understand how lowering the emulated dose 
effects quantitation, as measured by the CRC, an anthropomorphic adult female phantom was 
simulated on the 23-cm ring-segment and the 70-cm PennPET Explorer. The anthropomorphic 
phantom was generated using the adult female 4D extended cardiac-torso (XCAT) phantom 
simulation and the organ regions were filled to reflect activity concentrations one hour after an 
injection of 10 mCi of FDG (Table V) [97]. SUV values were determined for each of the 17 organs 
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of interest based on both literature and measurements on clinical FDG patients imaged at the 
University of Pennsylvania [98, 99]. Table V also includes the activity concentrations for organs in 
an anthropomorphic child phantom (7 year old female) to emulate imaging one-hour after a 2.77 
mCi injection (0.1 uCi/kg, 27 kg phantom) of FDG. The SUV values of organs are the same as were 
used for the anthropomorphic adult phantom and the child phantom is simulated and used in 
Chapter 4. The XCAT was simulated on the 23-cm ring-segment in five 3-min bed positions with 
50% overlap, for a total scan duration of 15 minutes, to better emulate a clinical protocol, albeit 
for a patient with a much higher BMI. In contrast, the XCAT was simulated on the 70-cm PennPET 
Explorer in a single 3-min bed position. This will result in a trapezoidal axial sensitivity profile for 
the 23-cm ring-segment and a triangular axial sensitivity profile for the 70-cm PennPET Explorer, 
with a maximal gain of 2.7 in the center of the AFOV (Figure 19B). The XCAT phantom was 
simulated with four lesions in the lung, liver, and breast each, where two of the four lesions had 
a 10 mm diameter and the other two had a 13 mm diameter. Lesions in the lung had a 10:1 local 
uptake while the liver and breast lesions had an uptake of 3:1. 
Table V. Activity concentrations used for each organ in the anthropomorphic adult and child phantoms based on the 
XCAT simulation 




Air 0.00 0.00 
Body (i.e. Fat) 0.89 1.51 
Other Bone 0.89 1.51 
Lung 1.43 2.41 
Breast (F) 1.78 3.02 
Muscle 2.67 4.52 
Pancreas 4.28 7.24 
Gut (Stomach + Intestines) 4.64 7.84 
Spleen 5.35 9.05 
Blood Pool 5.35 9.05 
Uterus (F) 5.35 9.05 
Spine Bone 5.71 9.65 
Liver 7.13 12.07 
Kidney (medulla) 7.13 12.07 
Brain (WM) 7.13 12.07 
Myocardium 14.27 24.13 
Brain (GM) 28.53 48.26 
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Figure 19. (A) Images showing a single slice through the liver of the XCAT phantom imaged on both the 23-cm ring 
segment and the 70-cm PennPET Explorer. The VOI on the liver was used to measure background noise which is lower 
for the 70-cm PennPET Explorer, despite the 5x difference in scan duration. (B) Axial sensitivity profiles for the 70-cm 
PennPET Explorer, along with both the individual five bed positions and the summed profile of the five bed positions 
on the 23-cm ring-segment. 
 
Similar to the IQ phantom, list-mode files from both scanners were subsampled to one-half, one-
quarter, one-eighth, and one-sixteenth the original dose, and data at each dose were 
bootstrapped, where events from list files were randomly selected to create ten statistically 
independent replicates [100]. Lesion CRC was calculated for each dose and each organ, and mean 
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Figure 20. (A) CRC and (B) %SD plots as a function of emulated dose for lesions in three organs: the lung (left), liver 
(middle), and breast (right), and two lesion sizes: 10 mm (top) and 13 mm (bottom). 
 
Figure 19A shows a coronal 2-mm slice of the XCAT phantom simulated on both the 23-cm ring-
segment and the 70-cm PennPET Explorer. Even scanning for 5x longer, the total number of counts 
measured on the 23-cm ring-segment in five bed positions is less than 60 % of the total counts 
measured in a single bed position on the PennPET Explorer. One liver lesion is clearly visible and 
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cm ring-segment and 8.6% on the 70-cm PennPET Explorer. In addition to the improved image 
noise, imaging 70-cm on the PennPET Explorer required 1/5th the imaging time, since data on the 
23-cm ring-segment was acquired in 5 bed positions to achieve even this image quality.  
Figure 20A plots the mean (𝜇) and standard deviation (𝜎) of CRC as a function of emulated injected 
FDG dose, while Figure 20B plots %SD (100 ∗ 𝜎/𝜇) as a function of dose. Lung lesions consistently 
underestimate the CRC measured using the IQ phantom for a given lesion size, and measured CRC 
decreases for both scanners as the emulated dose decreases. CRC estimates for lesions in the liver 
and breast agree with the IQ phantom, and are mostly consistent as dose decreases. Percent SD 
plots show consistently better measurement precision for the 70-cm PennPET Explorer when 
compared to the 23-cm scanner. Although the improvement in precision is at best a factor of 2x, 
there is an additional factor of 5x improvement included inherently in the total scan times 
required for the two scanners to image a 70-cm axial extent. 
Summary of Results 
Overall, CRC studies on the IQ phantom and the anthropomorphic phantom show little differences 
in measuring CRC as a function of emulated dose, as expected; however, CRC of the 70-cm scanner 
is consistently lower than CRC of the 23-cm scanner for 10-mm and 13-mm spheres, due to axial 
resolution degradation as discussed in the NEMA performance testing. Precision, as measured by 
% SD of the CRCs, for the IQ phantom study is consistently lower for the 70-cm PennPET Explorer 
by a factor of 2x-4x, which roughly agrees with gains in sensitivity. Additionally, precision of CRC 
measurement on the 70-cm PennPET Explorer is always improved at the same dose for the 
anthropomorphic phantom compared to the 23-cm ring-segment, even with a 5x longer scan for 
the 23-cm ring-segment. 
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RESULTS: MEASUREMENT ON THE PENNPET EXPLORER PROTOTYPE  
Sensitivity 
Sensitivity on both a single ring and the three-ring PennPET Explorer prototype were measured at 
both 18˚C and 5˚C. 18˚C is the standard operating temperature and timing pickoff for the Philips 
Vereos and results in a timing resolution of 320 ps, while cooling the system to 5˚C results in a 
timing resolution of 250 ps when implementing trigger 1 timing pickoff. The average single ring 
sensitivity at 18˚C was 4.95 ± 0.11 kcps/MBq, which agrees well with the 5.1 kcps/MBq reported 
by Rauch et. al. in their performance testing of the Philips Vereos [56]. At 5˚C, measured single 
ring sensitivity was 6.63 ± 0.28 kcps/MBq. The 30% increase in sensitivity is due to the lower dark 
noise in the PDPC detector at the lower temperature and implementing trigger 1 timing pickoff. 
The corresponding three-ring sensitivities of the scanner at 18˚C and 5˚C are 41 kcps/MBq and 54 
kcps/MBq, respectively, at a radius of 0 cm. At 10 cm off-center, the sensitivity is 44 kcps/MBq at 
18˚C and 57 kcps/MBq at 5˚C. 
The axial sensitivity profiles for a line source in air acquired at 5˚C statistically attenuated through 
a 20-cm water-filled cylinder are shown in Figure 21 to reflect the sensitivity of a lesion within an 
attenuating medium like the human body. Events were statistically removed from the list file 
based on the probability of attenuation of the corresponding LOR by the cylinder. This metric will 
be relevant to studies presented in future chapters. Although the sensitivity is much higher than 
that of commercial instruments, the data gaps in the prototype lead to a 2x reduction in total 
sensitivity compared to a 70-cm scanner without axial gaps and regions of lower sensitivity in the 
axial sensitivity profile corresponding to areas with the fewest LORs passing through them, and 
five peaks. The peaks correspond to areas with the most LORs contributing, while the dips 
correspond to areas with the least number of LORs. The first, third, and fifth peaks correspond to 
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the centers of the three individual rings, the second and fourth peaks are a result of interactions 
of LORs between rings 1&2 and rings 2&3, respectively. The third peak is the highest because it 
also includes the interaction of LORs between rings 1&3.  
 
Figure 21. Axial sensitivity profiles for a 70-cm line source in air and in a 20x70-cm water-filled cylinder. 
 
Spatial Resolution 
Spatial resolution was measured using a 0.5-mm-diameter 22Na point source encased in a 1 cm3 
plastic cube, and imaged at multiple radial (1, 5, 10, 15, and 20 cm) and axial locations (0, 4, 12, 
20, 24, and 28 cm) relative to the AFOV center. Per NEMA, single-ring data were reconstructed 
using the analytic DIRECT algorithm. Results are also reported for LM-TOF-OSEM iterative 
reconstructions for 1-ring segment and 3-ring-segment data, using parameters optimized for high-
resolution imaging (1 mm3 voxels, 4 iterations). Although this may not yield an absolute measure 
of spatial resolution for a point source in air, the results provide insight into the dependence of 
spatial resolution on the axial acceptance angle as it increases toward the mid-AFOV. 
Table VI shows the spatial resolution results for the scanner including the radial, tangential, and 
axial spatial resolutions averaged over all point sources acquired. Axial spatial resolution 
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measures are also included in Table VI at the center of the AFOV, the center of the data readout 
gap (12 cm from AFOV center), and the axial edge of the scanner (24 cm from AFOV center). 
Transverse results are averages over all axial source positions at that radial position; axial results 
are averages over all transverse source positions, and the uncertainties shown are the SD across 
the different source positions. Because of the axial data readout gaps in the scanner, an analytic 
algorithm could not be used for reconstructing data. Analytic algorithms have evolved to 
interpolate existing data to estimate missing data in oblique projections in 3D PET data; however, 
they rely on complete sampling of direct LORs (i.e. LORs within a single ring of crystals without an 
axial tilt). Since we do not have complete sampling of direct LORs in the data readout gaps, LM-
TOF-OSEM was used to reconstruct spatial resolution data. The radius of the blob basis function 
was decreased to 3.75 mm spaced on a 3 mm cubic grid to properly reflect the spatial resolution 
of the system.  
Table VI. Spatial resolution of PennPET Explorer whole-body imager 
Overall Spatial Resolutions 
R (cm) # rings Algorithm Radial (mm) Tangential (mm) Axial (mm) 
FWHM FWTM FWHM FWTM FWHM FWTM 
1 1 Analytic 4.2 ± 0.3 8.5 ± 0.8 3.9 ± 0.4 8.4 ± 0.9 4.1 ± 0.2 7.9 ± 0.2 
1 1 Iterative 3.9 ± 0.3 7.2 ± 0.4 3.8 ± 0.3 7.1 ± 0.2 3.6 ± 0.2 6.8 ± 0.2 
1 3 Iterative 3.9 ± 0.2 7.4 ± 0.6 3.9 ± 0.3 7.3 ± 0.2 3.9 ± 0.3 7.8 ± 1.2 
10 3 Iterative 4.2 ± 0.2 8.1 ± 0.2 3.9 ± 0.2 7.2 ± 0.2 3.9 ± 0.3 7.6 ± 0.8 
20 3 Iterative 5.6 ± 0.2 10.4 ± 0.3 3.9 ± 0.4 7.2 ± 0.2 3.7 ± 0.3 7.3 ± 0.7 
    
Axial Spatial Resolution as a function of axial position 
R (cm) # rings Algorithm Center (mm) Gap (mm) Edge (mm) 
FWHM FWTM FWHM FWTM FWHM FWTM 
1-20 1 Iterative --- --- --- --- 3.5 ± 0.2 6.8 ± 0.1 
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Overall, the spatial resolution at the center of the FOV is 4.0 mm with an expected 1 mm radial 
resolution degradation when moving from a radius of 1 cm to 20 cm off center due to transverse 
parallax error. There is little resolution degradation in the tangential or axial directions as a 
function of radial position. The degradation in axial spatial resolution due to axial parallax error is 
0.4 mm FWHM and 1.6 mm FWTM when moving from the edge to the center of the AFOV. This is 
roughly in agreement with the axial resolution degradation observed in simulation which was 0.5 
mm FWHM and 2.2 mm FWTM. Additionally, the axial spatial resolution in the gap is slightly worse 
than the center of the AFOV due to the lack of direct LORs collected. Overall, the axial resolution 
degradation is small compared to the radial resolution degradation and the corresponding 
transverse parallax error. 
Count Rate 
The count-rate measurement was performed with a 70-cm long line source offset inside a 20-cm 
diameter polyethylene scatter cylinder, at an initial activity concentration of approximately 40 
kBq/cc. The phantom was suspended axially from both ends with 7 cm extended out from the 
back of the scanner and with the phantom flush with the front of the scanner. The count-rate data 
were also used for measuring the timing resolution as a function of activity. Count rate data were 
measured on the PennPET Explorer at both 18˚C, corresponding to a nominal timing resolution of 
320 ps, and at 5˚C, corresponding to a timing resolution of 250 ps.  
Figure 22 compares results from the Vereos, as measured by Philips on a commercial Philips 
Vereos (dashed line), against the Vereos GATE simulation (solid line), and measured single ring 
data from the three individual rings on the PennPET Explorer (´ markers) at the warmer 
temperature (18˚C) to best reflect the GATE simulations. Figure 22A shows a comparison of singles 
rates as a function of activity concentration and Figure 22B shows trues, randoms, scatter, and 
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NEC rates as a function of activity concentration. Singles results show slightly lower singles rates 
for data measured by Philips when compared to simulated data; however, data measured on the 
PennPET Explorer shows a range of singles rates that span both the simulation and measurement 
by Philips. The ring with the highest singles rates was the central ring which experienced the most 
out of field activity, since roughly 20 cm of the phantom extended outside the AFOV of the ring 
on either side. Out of field activity is defined as single photons with annihilations that occurred 
outside the AFOV of the scanner and they can arrive in coincidence as randoms or scattered 
events (Chapter 2, Figure 2). The central ring has the highest singles rate because the phantom 
extends into the first and third rings which have lower singles rates. This is most likely why the 
singles rates measured by Philips are more closely in line with the outer rings of the PennPET 
Explorer. Overall, the singles rates are linear up to very high activity concentrations, implying 
minimal dead time, which will allow for imaging at very high count rates. We will later see in our 
human subject studies that a bolus injection of 15 mCi of FDG has a maximum per-ring singles 
rate of 60 Mcps, well below the number of singles measured at the highest activity 
concentrations, which corresponds to 30-40 kBq/cc as seen in Figure 22. 
 
Figure 22. Comparison of count rate data as a function of activity concentration for the GATE simulation (solid line), 
individual rings of the PennPET Explorer (´ markers), and as measured by Philips on the commercial Philips Vereos 
(dashed line) for both (A) singles and (B) coincidence rates including trues, randoms, scatter, and NECR. 
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Coincidence results show that results measured by Philips are lower than the GATE simulation at 
higher count rates while results from the PennPET Explorer either agree with or are slightly higher 
than the GATE simulation (Figure 22B). The difference in the trues rates, given that the singles 
rates are roughly in agreement, implies that the commercial Philips Vereos experiences some 
dead time due to hardware coincidence sorting. As expected, data from the PennPET Explorer do 
not reflect the lower count rates of the data measured by Philips because data are collected in 
singles mode and sorted into coincidence lists using an offline software processor.  
The randoms measured on the PennPET Explorer are consistently higher compared to the GATE 
simulation, due to the slightly larger timing window of 2.49 ns compared to 2.01 ns, which was 
increased to achieve a transverse FOV of 576 mm for the most oblique LORs in the three-ring 
PennPET Explorer. The window was not increased for GATE simulations since objects imaged were 
small (20-30 cm) and this is only a consideration for larger objects. Scatter fraction for both the 
GATE simulations and the measured PennPET data change no more than 2% as the activity 
concentration increases. Scatter fraction, as measured by Philips, increases by 3% as the activity 
concentration increases. The average scatter fraction for the GATE simulations, the three PennPET 
rings, and as measured by Philips are 30%, 32%, and 32%, respectively. The peak NECR is never 
achieved for any of the datasets; however, the NECR does plateau near 30 kBq/cc. The NECR at 
30 kBq/cc for the GATE simulations, the three PennPET rings, and as measured by Philips are 176 
kcps, 167 kcps, and 141 kcps, respectively. 
Count rate results for three-ring data from the 70-cm PennPET Explorer prototype will now follow. 
Due to the data readout gaps, single slice rebinning could not be used to deposit the multi-ring 
data into sinograms for analysis. Therefore, each individual ring was analyzed according to NEMA 
and scatter fraction of the three-ring system was assumed to be the average of the three 
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individual rings, since the scatter fractions were the same for simulated 23-cm ring-segment and 
the 70-cm PennPET Explorer. Randoms were calculated based on a delay window, scatter was 
calculated as #𝑠𝑐𝑎𝑡𝑡𝑒𝑟 = 𝑆𝐹 ∗ (#	𝑝𝑟𝑜𝑚𝑝𝑡𝑠 − #	𝑑𝑒𝑙𝑎𝑦𝑠) , and trues were calculated as 
#	𝑡𝑟𝑢𝑒𝑠 = #𝑝𝑟𝑜𝑚𝑝𝑡𝑠 − #	𝑠𝑐𝑎𝑡𝑡𝑒𝑟 − #	𝑑𝑒𝑙𝑎𝑦𝑠 , where prompts include trues, random, and 
scattered events, while delays include only random events. 
 
Figure 23. Trues, randoms, scatter, and noise equivalent count rates (NECR) as a function of activity concentration 
for data collected on the PennPET Explorer at 18˚C. 
 
The count-rate performance is shown in Figure 23 for data collected with the system operating at 
18˚C (320 ps). These results demonstrate that the trues rate is linear over a wide range of activity, 
up to 45 kBq/cc—about 10 times that of a clinical 18F-FDG study. The calculated average scatter 
fraction is 32%. The noise-equivalent count rate continues to increase slowly beyond the point at 
which trues equal randoms (at 15 kBq/cc), reaching 1230 kcps at 45 kBq/cc. At 3.7 kBq/cc, the 
average concentration of a clinical patient, the NECR was 327 kcps. 
Timing resolution was measured using the count rate data based on the known line source 
position, as per NEMA 2018 for both the individual ring and the three-ring PennPET Explorer. 
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Timing resolution was estimated on a crystal by crystal basis and the mean and standard deviation 
was calculated across all the crystals. Timing resolutions as a function of activity concentration 
are shown for data taken at 18˚C and 5˚C in Figure 24. Timing resolutions at 18˚C and 5˚C are 
shown in for the three individual rings and for the PennPET Explorer prototype at 4.25 kBq/cc, the 
closest measured data point to the average clinical activity concentration of 3.7 kBq/cc. Overall, 
the line source timing resolution at the lower temperature is close to the measured point source 
timing resolution of 250 ps; however, at the warmer temperature, the timing resolution is 
markedly higher than the point source timing resolution of 320 ps. The timing resolution for the 
PennPET Explorer, compared to the individual rings, is higher and more sensitive to differences in 
activity concentration. The degradation of timing resolution on the PennPET Explorer is directly 
related to the total singles rate of the scanner. Additionally, the standard deviation of timing 
resolution is larger and more consistent at the warmer temperature. 
Table VII. Timing resolutions as measured at 4.25 kBq/cc 
 Timing resolution at 18˚C Timing resolution at 5˚C 
Ring 1 340 ± 27 ps 246 ± 19 ps 
Ring 2 352 ± 26 ps 257 ± 16 ps 
Ring 3 338 ± 21 ps 250 ± 21 ps 
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Figure 24. Timing resolution as a function of activity concentration for data collected at (A) 18˚C and (B) 5˚C for both 




Image quality data were acquired using both the standard NEMA sized spheres (“full sized 
spheres”) and the half size spheres developed for the harmonization initiative. Spheres were filled 
with an average contrast of 10:1. Both the full and half-sized sphere phantoms were centered 
axially in the FOV and data were collected 30 min and 40 min, respectively, to account for decay 
in order to collect the same number of total counts. List-mode data were shuffled and parsed into 
ten 3-min or 4-min statistically independent list files. Each list file was reconstructed using LM-
TOF-OSEM, and images are shown in Figure 25. Spherical VOIs with diameters equal to the size of 
the sphere were placed on the sphere in each image and twelve circular ROIs (37 mm diameter) 
were each placed in the background over a range of twenty slices. The means of the VOIs were 
used to calculate CRCs and the mean and standard deviation were taken across the ten replicates. 
The background variability was calculated as the standard deviation of the means of the 
background VOIs of a given diameter divided by the average of the means of the background VOIs. 
Both the CRC and background variability are plotted as a function of sphere size in Figure 26. 
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Overall, CRC and background variability curves are consistent due to careful preparation of 
aliquots and careful filling of the phantoms, within error bars, and the CRC values for the full-sized 
spheres agree well with simulation (Table IV). 
 




Figure 26. (A) Contrast recovery for both full-sized (blue) and half-sized (red) spheres as a function of sphere size and 
(B) background variability as a function of sphere size. 
 
Image Uniformity 
Reconstructed image uniformity is shown using a 20x120 cm uniform cylinder filled with water 
and 6 mCi of 18F and imaged for 1 hr. Data were reconstructed using LM-TOF-OSEM and a 15 cm 
ROI was placed in the center of the reconstruction image to measure mean counts and the 
10 mm sphere
8.5 mm sphere
Half sized spheres Full sized spheres
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standard deviation of counts in each axial slice. The image roughness was then calculated for each 
slice by dividing the standard deviation by the mean counts. The reconstructed image, uniformity, 
and image roughness are shown in Figure 27. Excluding five slices on the edges of the image, the 
% SD of the image uniformity is 2.2%. Overall, normalization correction compensates for axial 
sensitivity variations, and the excellent image uniformity is a key to achieving quantitative 
accuracy with phantom and human studies. The image roughness plot clearly shows four regions 
of increased noise corresponding to the dips in the axial sensitivity profile (Figure 21).  
 
Figure 27. (A) Coronal 2-mm slice of the reconstructed uniform cylinder. (B) Mean and standard deviation of counts 
in a 15 cm ROI as a function of axial position. (C) % SD of counts in a 15 cm ROI as a function of axial position shows 
image roughness. 
 
Summary of Results 
NEMA results from the 70-cm PennPET Explorer prototype reported a sensitivity of 55 kcps/MBq 
at 5˚C, a sensitivity of 41 kcps/MBq at 18˚C and a transverse spatial resolution of 4.0 mm, with an 
axial resolution degradation of 0.4 mm FWHM. The sensitivity measures reflect an 8x gain (at 
18˚C) compared to the single ring Philips Vereos data, and the consistency of the transverse spatial 
resolution with data reported by Philips implies that the redesign of the individual rings did not 
create any unforeseen errors.  Trues count rates were linear up to 45 kBq/cc and agreed well with 
GATE simulations. The system linearity at high count rates is unique to the detector design which 
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1:1-couples crystals to the SiPMs. The maximum NECR for the three-ring system was 1230 kcps at 
45 kBq/cc and 327 at 3.7 kBq/cc. The NECR gain of this system compared to a standard AFOV 
system is 11x, which is consistent with early work done by Poon et al. [101], who studied NECR 
gains for long AFOV scanners based on a Siemens mCT (described in Chapter 2). CRC of the 10-
mm sphere was 0.39 ± 0.02 and background variability was less than 10 % for even the smallest 
spheres. Image uniformity of a uniform cylinder was within 2 % and image roughness was less 
than 20 % with a maximum difference between peaks and troughs of 8 %. These results showcase 
that despite the axial data readout gaps in the scanner, we were able to reconstruct good quality 
quantitative images. 
HUMAN SUBJECT DATA MEASURED ON THE PENNPET EXPLORER 
Ten human subjects have been imaged on the PennPET Explorer prototype, including both normal 
human subjects, clinical patients, and subjects on research protocols. The goal of this work was 
to characterize imaging on our long AFOV system. Human subjects were imaged at ultra-late time 
points to push the limits of the increased sensitivity of our system. Data were also acquired to 
assess the effect of axial resolution degradation on the human brain. And dynamic data were 
acquired to study how the increased sensitivity of the system could be leveraged for finer 
temporal sampling and measurement of blood TACs in various locations. 
The details of all subjects imaged along with the times at which they were imaged and the 
corresponding scan durations for both the PennPET Explorer scans and clinical scans are included 
in Table VIII. Subjects # 1-4 and # 7 were normal humans injected with FDG and scanned on both 
the PennPET Explorer and a clinical scanner. Of those subjects, # 3 and # 7 were injected with FDG 
on the PennPET Explorer and imaged dynamically for 60 minutes. Subjects # 5 and # 10 were the 
same clinical patient with colorectal cancer imaged on the PennPET Explorer at two time points 
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in his treatment after a standard of care (SoC) clinical PET scan. Subjects # 6 and # 9 were clinical 
research subjects injected with research tracers and imaged on the PennPET Explorer after 
imaging on a clinical scanner according to the research protocol. Finally, subject #8 was a clinical 
patient with a neuroendocrine tumor injected with Ga-DOTATATE and imaged on the PennPET 
Explorer following her SoC PET scan. Data from subjects # 3 and # 7 are used for studies later in 
this thesis. Described below are results from a select number of these studies done using the 
human subject data collected on the PennPET Explorer. 








Penn PET Scan Clinical Scan 
Uptake Time Duration (min) Uptake Time Duration (min) 
1 62/F Normal Volunteer 26.5 18F-FDG 15.6 
1 hr 27 min 
3 hr 10 min 
5 hr 14 min 
7 hr 17 min 
9 hr 5 min 







45 min 20 
2 56/F Normal 
Volunteer 21.6 18F-FDG 15.1 1 hr 33 min  5 hr 0 min 10 15 57 min 15 
3 79/M Normal 
Volunteer 22.9 18F-FDG 14.9 
10 – 30 min [dyn] 
1 hr 44 min 
4 hr 21 min 
18 hr 40 min 
20 
30 
60 1 hr 9 min 15 
4 79/M Normal 
Volunteer 23.3 18F-FDG 14.0 
0 – 60 min [dyn] 
2 hr 23 min 
4 hr 52 min 
20 
25 NA  
5 60/M Clinical 
Patient 20.1 18F-FDG 13.4 2 hr 46 min 4 hr 12 min 10 10 60 min 15 
6 28/M Research Subject 23.7 18F-FNOS 5.9 1 hr 39 min 30 0-60 min [dyn]  
7 29/F Normal Volunteer 19.3 18F-FDG 13.5 
0 – 60 min [dyn] 
2 hr 13 min 
4 hr 57 min 
23 hr 2 min 
20 
30 
60 3 hr 0 min 15 





2 hr 21 min 
3 hr 32 min 20 20 1 hr 5 min 10 
9 48/M Research 
Subject 26.3 18F-FTP 6.1 2 hr 31 min-59 min [dyn] 
 
0-120 min [dyn]  
10 60/M Clinical 
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Low count statistics images are shown in Figure 28 for scan # 1 taken on subject # 1. Collected list-
mode data were subsampled down to 10-min, 5-min, 2.5-min, 75-s, and 38-s scan durations and 
reconstructed using LM-TOF-OSEM. Coronal 2-mm slices show low image noise for scan durations 
as short as 2.5 min and good distinction of small structures such as the individual ribs, wall of the 
aorta, the cervical spine, and lumbar spine in the 75-s image. When the data readout gaps are 
filled in on the PennPET Explorer, resulting in a 2x increase in sensitivity, similar image quality will 
be visible in a 38-s scan. Such short scans may allow for imaging of pediatric patients without 
general anesthesia, which has been suspected to cause developmental defects, breath-hold 
imaging of adult patients to minimize lesion blurring due to respiratory motion, and finer temporal 
sampling of dynamic data to more accurately estimate the blood curve and tracer delivery to the 
tissue. 
 
Figure 28. Coronal 2-mm slice images of subject # 1 scan # 1 at various scan durations: 20 min, 10 min, 5 min, 2.5 
min 75 sec, and 38 sec (left to right). Image roughness in the liver is reported for each scan duration [102].  
 
Ultra-late next day scans were taken on three subjects injected with FDG: subjects #1, #3, and #7 
at up to 24 hours post-injection. Images at various time points along with corresponding TACs for 
select organs are shown in Figure 29. Data were taken on the PennPET Explorer and reconstructed 
using the standard LM-TOF-OSEM. Randoms correction for the final time points was modified to 
account for the sparsity of data collected. Instead of binning randoms data into a sinogram and 
smoothing to remove noise, the randoms sinogram was set to a constant value to avoid averaging 
20 min scan
IR = 8.6 %
10 min scan
IR = 8.3 %
5 min scan
IR = 11 %
2.5 min scan
IR = 15 %
75 sec scan
IR = 20 %
38 sec scan
IR = 27 %
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with zeros thereby underestimating randoms due to the sparsity of measured delayed 
coincidences. VOIs were drawn over six brain regions, three myocardial regions, the liver, the lung, 
and the descending aorta and plotted after correcting for radioactive decay, scan duration, and 
scanner calibration factor. Resultant images show that uptake in the brain increases up to 2 hours 
post-injection and then decreases rapidly out to 24 hours. Conversely, uptake in the myocardium 
increases out to about five hours and then plateaus or decreases slightly by 24 hours. Uptake in 
the liver, lung, and blood pool slowly washes out over the course of the 24 hours. The fact that 
brain uptake decreases over time implies that the brain may have and use the enzyme to 
dephosphorylate FDG-6-phosphate. When applying a two-compartment analysis the activity of 
this enzyme is modeled by the k4 kinetic parameter (Chapter 2, Figure 4B). One further area of 
interest is to fit our data to a kinetic model and accurately quantify the presence of k4 in the brain 
and the absence of k4 in the myocardium. Spence et al. has previously reported an average k4 
value in the brain of 0.008 min-1 after imaging FDG patients out to 6-8 hrs [103]. From the subjects 
imaged, we quantified k4 in the brain to be 0.002, 0.0053, and 0.0017 min-1, lower than the 
average reported by Spence but implying that the dephosphorylation enzyme is active. 
Myocardial k4 values for the three subjects were zero on average. 
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Figure 29. (A) Select 2-mm coronal slices of subjects #1 (top), #3 (middle), #7 (bottom) at various time points (right 
to left). Insets show uptake in the brain and myocardium over time at an adjusted color scale. (B) Plots showing the 
24-hr time course of uptake in various organs for subjects #1 (left), #3 (middle), #7 (right). Uptake in the images and 
plots are both in kBq/cc and are directly comparable [104]. 
 
A clinical patient was imaged at two time points on the PennPET Explorer following an SoC PET/CT 
scan (subjects #5 and #10). Figure 30 shows coronal and axial slices of both clinical and PennPET 
Explorer images at both time points. The blue arrows point to a node above the diaphragm that 
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is not detectable on the clinical scan at the initial time point but is easily detectable on both 
PennPET Explorer scans. The red arrows point to disease spread along the peritoneum which is 
more sharply visible on the PennPET Explorer scans. Follow-up scans show the node is no longer 
visible on either scan (blue arrow) but that cancerous uptake along the peritoneum is more easily 
distinguishable on the PennPET Explorer scan compared to the clinical PET scan (yellow and red 
arrows). 
 
Figure 30. Axial (top) and coronal (bottom) 2-mm slices of a clinical patient with colorectal cancer imaged at an initial 
time point (subject #5) and a follow-up time point (subject #10) a few months later. Images are shown for the clinical 
PET/CT at the initial timepoint along with two subsequent scans on the PennPET Explorer, and for the clinical PET at 
the follow-up time point along with the PennPET Explorer scan [102]. 
 
The main benefit of long AFOV systems is the marked increase in sensitivity that can allow for 
imaging at lower radioactive doses, which is especially valuable for 68Ga-DOTATATE imaging. 
Galium-68 has a short half-life of 68 min compared to 18F (t1/2 = 110 min) and DOTATATE is injected 
at a much lower dose of 5.4 mCi maximum (54 µCi/kg, 3.78 mCi for a 70 kg person) compared to 
the 15 mCi at which FDG is injected. Subject #8 was a clinical patient with neuroendocrine tumors 
injected with 4.1 mCi of 68Ga-DOTATATE. She underwent an SoC clinical scan one-hour post-
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injection followed by two scans on the PennPET Explorer. At the times of imaging on the PennPET 
Explorer, the 68Ga-DOTATATE dose had decayed to 0.97 and 0.47 mCi; however, the resulting 
images still show good image quality and minimal noise (Figure 31). 
 
Figure 31. 68Ga-DOTATATE images of a clinical patient with neuroendocrine tumors imaged on the PennPET Explorer 
at two time points after an SoC clinical scan [102]. 
 
Another key advantage of imaging the whole body simultaneously is measuring TACs from 
multiple organs, lesions at various axial locations, and different blood sources simultaneously 
from a fully dynamic dataset. Subject #7 was injected with FDG on the table and imaged on the 
PennPET Explorer for 60 min and data were parsed into 70 frames (20x1s, 10x2.5s, 7x5s, 7x10s, 
9x30s, 5x1m, 6x3m, 6x5m) and each frame was reconstructed using LM-TOF-OSEM. Subject #7 
was a normal volunteer so there were no cancerous lesions to quantify; however, Figure 32B 
shows TACs for various organs over the 60-min time period along with TACs for a number of blood 
vessels during the first 50 s of imaging. Corresponding MIP images for early time points are shown 
in Figure 32A. Given that TACs reflect the raw data and are not smoothed or fit to any model, the 
time course shown is not noisy as might be expected, despite the fine sampling of the early frames 
PennPET Explorer: Scan # 1
2 hr 21 min post-injection
0.97 mCi at scan time
20 min scan duration
PennPET Explorer: Scan # 2
3 hr 32 min post-injection
0.47 mCi at scan time
20 min scan duration
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at 1 s. This would allow for collecting blood input functions for lesions based on the closest arterial 
source without adding noise to the data. 
 
Figure 32. (A) MIP coronal images of the early time course showing blood flow through the lungs and vasculature. 
(B) Time-activity curves of the full 60-min time course for all organs in the FOV (left) and for various blood vessels 
during the first 50-s after injection [102]. 
 
SUMMARY OF RESULTS 
These ten studies on the PennPET Explorer validated the successful implementation of many of 
the key design components and showcased some of the clinical and research capabilities of the 
system, underscoring the power and versatility of the sensitive scanner. Subsampled images from 
subject #1 showed good image quality and low noise for 1-2 min scans. Quick PET scans would be 
valuable for both pediatric imaging and breath hold imaging of lung cancers. The images from the 
patient with colorectal cancer showed improved visualization of cancer compared to a clinical 
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scan, due to the increased sensitivity of imaging on the PennPET Explorer which enabled delayed 
imaging. Delayed imaging of FDG is known to have increased lesion contrast since FDG remains 
trapped in cancer but washes out of background tissues. The images also detected a lesion that 
was not visible on the clinical scan. Better detectability of lesions is further studied in Chapter 4, 
but this showcases the value of long AFOV PET for standard clinical use. 68Ga-DOTATATE scans 
were acquired on the PennPET at < 1 mCi, but good quality images were still reconstructed. Low 
dose imaging is valuable for imaging research tracers and radiosensitive populations. Ultra-late 
scans acquired up to 24 hours after injection of FDG showed that uptake in the brain decreases 
over time, supporting the theory that FDG is dephosphorylated in brain tissue. The study of FDG 
over a 24-hour time frame represents a possible research study that can be done on long AFOV 
systems which was not possible on standard AFOV systems due to limited sensitivity. Finally, 
dynamic FDG scans on the PennPET Explorer were separated into 1 s frames, where TACs of 
various organs showed little noise. Additionally, blood input functions from various arterial 
sources were measured and TACs showed little noise for 1-s time frames. The fine temporal 
sampling made possible by the increased sensitivity of long AFOV imaging will be valuable for 
research of new dynamic tracers and has the potential to replace arterial sampling. Arterial 
sampling is currently the gold standard and also measures metabolites in the blood. Future 
investigations will examine the benefits of the full device with an even larger axial FOV and will 
refine quantitative methods for analysis, optimize imaging protocols, and study novel 
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CHAPTER 4: LESION DETECTABILITY 
ABSTRACT 
This chapter conducts a lesion detectability study using a numerical observer to characterize how 
the increased sensitivity of a long AFOV PET scanner impacts lesion detectability. Lesion 
detectability is an important clinical task performed by radiologists for both staging and follow-
up PET scans and our study uses embedded spheres to mimic lesions. Spheres are embedded at 
known uptakes in both simulated and measured data that range in complexity from a simple 
uniform cylinder to anthropomorphic and torso phantoms to a human subject. Data were 
simulated on the 23-cm ring-segment and the 70-cm PennPET Explorer and measured on the 70-
cm PennPET Explorer prototype. The lesion localization and detection task was quantified 
numerically using a generalized scan statistics methodology, which is conducted by a computer 
designed to emulate a human observer and doesn’t require a clinician’s time of to read many PET 
images and doesn’t rely on correlating the different expertise levels of multiple clinicians. 
Detectability was studied as a function of background activity distribution, scan duration for a 
single bed position, and axial location of the lesions. For the cylindrical phantom, the areas under 
the localization receiver operating curve (ALROCs) of lesions placed at various axial locations in 
the scanner were greater than 0.8 (i.e., 80% probability of detecting and correctly locating the 
lesion) for scan times of 60 s or longer for standard-of-care (SoC) clinical dose levels. For more 
complex background distributions like the torso phantom and human subject, a scan duration of 
60 s or longer was sufficient to achieve an ALROC of 0.8 for 10-mm 3:1-uptake spheres in the liver, 
while an ALROC of 0.8 or greater was achieved for 10-mm 6:1-uptake spheres in the lung at scan 
durations of 30 s or longer. These scan durations are impressively short and would support 
acquiring 60 s scans on a long AFOV scanner. ALROC results from the measured and simulated 
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uniform cylinders, the measured torso phantom, and the human subject show similar trends as a 
function of counts detected per axial location. These results will be used to guide decisions on 
imaging parameters, such as scan time and patient dose, when imaging patients in a single bed 
position on long AFOV systems; the results can be generalized to scanners with different AFOVs 
and sensitivities compared to the PennPET Explorer.  
INTRODUCTION 
Oncologic FDG PET scans represent the majority of clinical PET studies, where lesion detection 
and quantification is a primary clinical task performed by radiologists when characterizing the 
extent of disease on initial staging scans and when identifying possible new metastatic lesions on 
follow up scans [105]. In this chapter, we study the relationship between the increased sensitivity 
of long AFOV imaging and lesion detectability and localization. We especially study the 
relationship between sensitivity at a particular axial location, especially since the axial sensitivity 
profile of single-bed-position imaging is non-uniform, and this study would inform whether single 
bed position imaging is preferable on long AFOV scanners. We expect that the improved 
sensitivity of long AFOV systems will improve detectability of lesions, which is particularly 
important for small, low-uptake lesions that can represent inflamed lymph nodes, typically 1 cm 
in size, or foci of cancer, where lesions detectable on a CT scan can be as small as 3 mm. Lesions 
smaller than 1 cm suffer large partial volume effects of 50% or greater, depending on the scanner 
and the reconstruction algorithm, that prove challenging for both detectability and quantitation 
tasks, even with the improved TOF and spatial resolution of newer clinical systems. The increased 
sensitivity of long AFOV systems may provide the boost in performance necessary for small lesion 
detection and localization [57]. The improved lesion detectability will allow for better detection 
of low uptake cancer lesions and more accurate initial staging of disease spread and better 
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assessment of recurrence on follow-up scans. Alternatively, the higher sensitivity of long AFOV 
systems can be leveraged to reduce clinical scan times in an effort to improve clinical workflow, 
reduce patient motion artifacts, and allow for breath-hold imaging while maintaining acceptable 
detectability for clinically relevant lesions.  
The gold standard for quantifying lesion detectability is via a human reader study, where trained 
physicians are requested to read studies and detect and localize lesions; however, these studies 
are difficult to organize, require many hours of clinicians’ time, and are subject to variations in 
reader training. Therefore, numerical observer methodologies have been developed to efficiently 
perform this task. The most commonly used numerical observer methodology in PET imaging is 
the channelized hotelling observer (CHO) [106]. This technique as used in nuclear medicine has 
been shown to correlate with human observer performance, given a proper choice of channels 
[107, 108].  However, CHO only performs a detectability task, while the generalized scan statistics 
methodology, the numerical observer that we chose to use in this work, performs a detectability 
and localization task that more closely approximates the task performed by a physician. While 
results from the generalized scan statistics methodology have not been directly correlated with a 
human observer study, it is a physics-based metric based on how human observers detect and 
localize lesions. Additionally, qualitative observations by researchers in our group using the 
generalized scan statistics methodology appear to substantiate results. The generalized scan 
statistics methodology scans an image volume to determine the distribution of true (lesions) and 
false (background noise) signals from which lesion detection and localization can be directly 
estimated. Thus far, the generalized scan statistics methodology has only been implemented it in 
uniform activity distributions, whereas this work extends application of the technique in non-
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uniform activity distributions (e.g. human subjects) and in non-uniform organ regions, such as the 
lung [67, 68, 109-111]. 
The generalized scan statistics methodology was previously used to perform lesion detectability 
studies of long AFOV scanners from Monte Carlo simulations with simple cylindrical phantoms 
[68]. These studies demonstrated the benefit of longer AFOV and improved TOF resolution, 
indicating a potential factor of ten reduction in total scan time with a combination of increasing 
the AFOV by 4x from 18 cm to 72 cm and improving the TOF resolution from 600 ps to 300 ps [68]. 
This work presents a more extensive and systematic study of lesion detectability using the long 
AFOV PennPET Explorer that was developed in the last several years [85]. Importantly, the studies 
include more realistic activity distributions including anthropomorphic simulations, a torso 
phantom and a human subject. Both simulations and measurements on the PennPET Explorer are 
used to perform the numerical detection studies, and results from this work are generalizable to 




All simulations were run in GATE with a 10.9% energy resolution (450-613 keV window) and at 
100-ps timing resolution (4.02-ns coincidence window) that was later degraded to a 250-ps timing 
resolution to match the performance of the PennPET Explorer. The simulated scanner sensitivity, 
determined using the NEMA NU-2 methodology [89], was 90 kcps/MBq. Further details on the 
scanner geometry and performance, as well as details on the GATE implementation, can be found 
in Chapter 2 [85]. 
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Measurement 
The PennPET Explorer in its prototype form is composed of three 23-cm ring-segments, each with 
6.6-cm inactive regions due to current data readout limitations, and a 1-cm physical gap between 
ring-segments, thereby resulting in 64.4 cm AFOV. The data readout gaps were shown to decrease 
the total sensitivity by a factor of 2x. Once readout from the inactive regions has been established, 
the PennPET Explorer will have the same geometry as the simulated scanner. The measured 
scanner sensitivity in this prototype configuration using the standard 70-cm NEMA line source is 
55 kcps/MBq, timing resolution is 250 ps, and spatial resolution is 4.0 mm at the center of the 
scanner. The maximum axial acceptance angle is ±40°, which covers the axial extent of the 
scanner. Further details on the scanner geometry and performance can be found in Chapter 2 or 
Karp, et al. [85]. 
Axial sensitivity profile 
Axial sensitivity profiles were generated for a line source in a 20-cm attenuating cylinder to 
characterize how the extension of the AFOV and the inactive axial regions resulting from the data 
readout limitations affect the roughly triangular axial sensitivity profile seen in single-bed-position 
imaging. A 140-cm line source filled with 37 MBq of activity was simulated in a 20-cm diameter x 
140-cm long cold water-filled cylinder on the 70-cm scanner. List-mode events from a NEMA 
sensitivity line measured in air on the PennPET Explorer were statistically attenuated using the 
probability of attenuation along each LOR through a 20x70 cm water-filled cylinder. Each list-
mode event was then placed into the axial location from which that event most likely originated 
based on the TOF difference of the two annihilation photons and scanner geometry (Figure 33A 
[112]). This distribution reflects the relative sensitivity to activity at each axial location while 
including the effects of attenuation. We characterized how lesion detectability and localization 
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would depend on the axial location due to changes in the relative sensitivity with axial position as 
well as the degrading effects of axial parallax errors due to the large acceptance angle and 
presence of gaps in the data (or however you call this stuff with only oblique LORs).  
 
Figure 33. (A) Schematic of the most likely positioning algorithm used to calculate the axial sensitivity for each axial 
location. Events are deposited into their corresponding axial position, based on the TOF difference of arrival of the 
two annihilation photons. (B) Schematic illustrating the axial placement of spheres in cylinder measurements (Table 
IX, Study C) with respect to the inactive regions in the PennPET Explorer.  
 
  











103   
DATA ACQUISITION AND GENERATION.  
A number of simulated and measured phantoms were used in this chapter to study lesion 
localization and detectability. The phantoms used are outlined in Table IX and will be further 
described in the indicated sections.  
Table IX. List of phantom distributions used for studies in this chapter 
 Simulation or 
Measurement Scanner Geometry 
Lesion 
(number, size, contrast, locations) 
A. Cylinder 
(20 cm x 70 cm) Simulation 
23-cm ring-segment (1 bed) 
23-cm ring-segment (3 beds) 
70-cm PennPET Explorer (1 
bed) 
N = 16 | 8 per slice 
7-mm @ 2:1, 3:1, 4:1 uptake 
z = ± 6 cm 
B. Cylinder 
(20 cm x 70 cm) 
Simulation 70-cm PennPET Explorer (1 
bed) 
N = 80 | 8 per slice 
6 mm @ 4:1, 6:1 uptake 
10 mm @ 2:1, 3:1 uptake 
z = -30, -21, -9, -5, 0, 3, 11, 15, 23, 27 cm 
C. Cylinder 
(20 cm x 120 cm) Measurement 
3-ring prototype PennPET 
Explorer 
N = 72 | 8 per slice 
6 mm @ 4:1, 6:1 uptake 
10 mm @ 2:1, 3:1 uptake 
z = -21, -9, -5, 0, 3, 11, 15, 23, 27 cm 
D. Anthropomorphic 
child (XCAT) Simulation 
23-cm ring-segment (1 bed) 
23-cm ring-segment (3 beds) 
70-cm PennPET Explorer (1 
bed) 
N = 8 Liver 
7-mm @ 2:1, 3:1, 4:1 uptake 
E. Anthropomorphic 
adult female (XCAT) 
Simulation 70-cm PennPET Explorer (1 
bed) 
N = 8 Liver 
7-mm @ 2:1, 3:1, 4:1 uptake 
F. CTN phantom + 
cylinder 
(20 cm x 30 cm) 
Measurement 
3-ring prototype PennPET 
Explorer 
N = 39 | 22 Lung, 17 Liver 
6 mm @ 8:1 uptake in Lung, 4:1 uptake in Liver 
10 mm @ 6:1 uptake in Lung, 4:1 uptake in 
Liver 
G. Human Subject Measurement 3-ring prototype PennPET 
Explorer 
N = 43 | 27 Lung, 16 Liver 
6 mm @ 8:1 uptake in Lung, 4:1 uptake in Liver 
10 mm @ 6:1 uptake in Lung, 4:1 uptake in 
Liver 




Three activity distributions with lesions of increasing complexity were simulated in GATE and 
analyzed using the generalized scan statistics methodology. The three simulated distributions 
were a uniform 20 x 70 cm cylinder, a child anthropomorphic phantom, and an adult 
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anthropomorphic phantom (Figure 34). The cylinder was filled to reflect a background 
concentration of 0.1 µCi/cc of 18F and sixteen lesions were placed in the uniform cylinder, eight in 
each of two slices at ± 6 cm from the axial center of the 70-cm cylinder. Lesions were simulated 
as 7-mm spheres with 2:1-, 3:1-, and 4:1-uptake ratios compared to the cylinder background 
(Table IX, Study A). 
The anthropomorphic child phantom was generated using the 4D extended cardiac-torso (XCAT) 
phantom [97] and filled to reflect imaging one-hour after injection of 2.74 mCi of FDG, calculated 
based on weight (0.1 μCi/kg, 27 kg) [113]. Concentration of activity in each organ is listed in 
Chapter 3, Table V. Eight 7-mm lesions were placed in the liver, with five replicate simulations, 
and simulated at 2:1-, 3:1-, and 4:1-uptake ratios for a 180-s scan duration (Table IX, Study D).  
 
Figure 34. Images of phantoms used for preliminary data GATE simulations including (A) a uniform cylinder with 
lesions placed in a cylinder in slices at ±  6.0 cm, (B) an anthropomorphic child phantom of a 7-year-old female with 
lesion embedded in the liver, and (C) an anthropomorphic adult phantom of a 5’ 5” female with lesions embedded in 
the liver. 
 
The anthropomorphic adult phantom was generated using the XCAT simulation and filled to 
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concentration for each organ is listed in Chapter 3, Table V. Eight 7-mm in diameter spherical 
lesions were simulated within the liver with 2:1, 3:1, or 4:1 uptake relative to the liver background. 
For all three activity distributions, the background-only distributions were separately simulated, 
and simulated sphere events were added to the background-only list-mode data (Table IX, Study 
E). 
All three activity distributions were simulated on the 70-cm PennPET Explorer. Both the uniform 
cylinder and the anthropomorphic child phantom were also simulated on the 23-cm ring-segment 
in two configurations. The first was a single bed position where the liver was centered in the AFOV 
and the second scanned the liver in three overlapping bed positions to reflect the sensitivity of a 
standard AFOV scan, as opposed to a single bed-position dataset. 
Resulting list-mode data were reconstructed using LM-TOF-OSEM for scan durations of 15 s, 30 s, 
60 s, 90 s, 120 s, and 180 s, and analyzed using the generalized scan statistics methodology.  
Results from this work motivated the rest of the phantoms studied in this chapter. The uniform 
cylinder with lesions located at ± 6 cm motivated a study of lesions along the length of the AFOV 
of a uniform cylinder to see how differences in axial sensitivity effected lesion detectability. The 
anthropomorphic adult and child phantom motivated an extension of this work to lesion 
embedding studies in an anthropomorphic torso phantom and the human subject. 
Cylindrical phantom 
This work was then followed with simulations of a uniform cylinder and a cylinder with spherical 
lesions placed at a wider range of axial locations, as opposed to the more centrally-located lesions 
in the preliminary simulations, to better characterize the relationship between lesion detectability 
and slice sensitivity for single-bed-position imaging with a long AFOV scanner (Table IX, Study B). 
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This study was also designed to provide insight into the performance of the PennPET Explorer 
with axial inactive regions. A 20-cm diameter x 70-cm long water-filled cylinder was filled with 81 
MBq of FDG (3.7 kBq/cc), positioned in the center of the scanner, and imaged for 3 min. A second 
cylinder with spheres at four different configurations was similarly simulated, and replicate GATE 
simulations were run to generate ten statistically independent replicates of each cylinder 
configuration.  
Four different lesion uptakes and sizes were investigated: 6-mm spheres with 4:1 and 6:1-uptakes 
and 10-mm spheres with 2:1 and 3:1-uptakes. The sphere sizes and uptakes were chosen to be 
challenging based on visual detectability of reconstructed lesion images. Sphere sizes were also 
chosen to reflect clinically relevant sizes in oncologic PET imaging. Additionally, prior simulations 
showed good detectability for a 10-mm sphere with 3:1 uptake on a 72-cm AFOV scanner [68]; 
therefore, we chose to study a similar sphere along with a lower uptake as a more challenging 
case. Corresponding uptakes were selected for 6-mm spheres based on visual detectability.  
For each configuration eight lesions were placed -30, -21, -9, -5, 0, 3, 11, 15, 23, and 27 cm from 
the axial center of the FOV, positions that correspond to the maximum variations in axial 
sensitivity for the 70-cm PennPET Explorer prototype (Figure 35A). In each slice, eight lesions were 
placed at a radius of 7 cm for a total of 80 lesions per image. Figure 33B shows the positioning of 
the lesions. All datasets were also subsampled to shorter time frames, ranging from 180 s to 5 s 
prior to reconstruction.  
Measurements 
Data were separately acquired as background data and sphere-in-air data, which were then 
combined using the lesion embedding methodology, described below, to create list-mode data 
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containing lesions of known uptake. The distributions ranged from a simple cylindrical phantom 
to measurements of more complex backgrounds.  
Lesion Embedding 
Lesion embedding is a flexible method to synthetically add measured sphere list-mode data to 
human subject list-mode data and reconstruct an image of a human subject with a spherical lesion 
of known size and contrast. Lesion embedding has previously been used to study improved lesion 
detectability in oncologic patients using CHO, studying the improvement of measurement 
precision with TOF, and quantifying partial volume effects in a given scanner [114-116]. Sphere-
in-air data are acquired at the desired locations within the scanner, and the number of sphere list-
mode counts to embed (𝑁43@) in the background list-mode data (B) are selected based on the 
desired uptake ratio (𝑎:) and activity in the background image at the sphere location (BABC) as 
described in Equation II. BDE is the average whole-body concentration in counts/cm3, VABC is the 
volume of the sphere in cm3, NFGH is the number of total events in the sphere list-mode file, and 
𝐴;%' is the total activity in the sphere image. Equation II first calculates the desired total sphere 
activity (𝑎: ∙ 𝐵IJ ∙ 𝑉43@), subtracts the activity currently in the background image at that location 
(BABC), and scales by the ratio of 𝑁;%'/𝐴;%' to determine the number of sphere list-mode events 
to embed. Sphere list-mode events are then statistically attenuated using the probability of 
attenuation for each sphere event through the corresponding LOR in the background object. The 
attenuated sphere and phantom list-mode events are then merged and jointly reconstructed to 
create a dataset with spheres embedded with known uptake at the desired locations. A more 
thorough description of this methodology can be found in Daube-Witherspoon, et al. [116]. 
Details describing sphere sizes, uptakes, and background data specifics vary for each generated 
dataset, so those details are included below for each background distribution. 
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Equation II. Calculation of the number of sphere list-mode events to embed with desired uptake 
 𝑁43@ = A𝑎: ∙ 𝐵IJ ∙ 𝑉43@ − 𝐵43@B ∙ (𝑁;%'/𝐴;%') 
Spheres in air 
Data were collected of 6- and 10-mm diameter spheres filled with 37-74 MBq of activity at many 
locations in air on a pre-defined grid in order to overlap with the volumes of both liver and lung 
of a human subject placed within the scanner. The previously described lesion embedding 
methodology was used to add spheres to background data to create lesion present datasets. 
 
Figure 35. (A) Plot of the axial sensitivity profiles for both simulated and measured scanners along with the axial 
locations at which spheres were placed (diamonds). Shaded boxes below the plot indicate axial coverage of data 
active (blue) and inactive (gray) regions of the PennPET Explorer, while the red outlines indicate the axial coverage 
of the 70-cm simulated scanner. (B) Schematic of the simulated scanner and PennPET Explorer where shaded regions 
reflect axial LORs that pass through that region. The number of LORs that pass through any given axial location 
reflects the axial sensitivity at that location. 
 
Cylindrical phantom 
A 20-cm diameter x 120-cm long water-filled cylinder, constructed using an 8-inch diameter 
polyvinyl chloride pipe, was filled with 151 MBq of 18F, a concentration of 4.0 kBq/cc, and imaged 
for 21 min. The 21-min dataset was separated into seven independent 180-s datasets that were 
reconstructed as background images (Table IX, Study C). 
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Sphere data were embedded in the uniform cylinder data set in the same four size/uptake 
configurations as in the GATE simulations (6-mm spheres with 4:1 and 6:1-uptake and 10-mm 
spheres with 2:1 and 3:1-uptake). For each configuration, the axial and transverse locations were 
also similar to those in the GATE simulations (eight lesions each at positions -21, -9, -5, 0, 3, 11, 
15, 23, and 27 cm from the axial center of the FOV and at an average radial distance of 6 cm 
(range: 5.0 - 6.5 cm). The differences in sphere location axially between simulation and 
measurement (Figure 35A) show how the axial sensitivity varies across the various locations in 
which lesions were embedded. Locations were selected to sample the uneven sensitivity 
distribution of both the measured and simulated geometries. Due to small measurement and 
positioning differences, embedded measured lesions were not in the exact same locations in the 
measurement and simulation. Similar to the simulation, data were reconstructed for durations of 
5, 10, 15, 30, 60, 90, 120, and 180 s to characterize how measured lesion localization and 
detectability changes with scan time. 
CTN torso phantom 
We extended our measurements to anthropomorphic geometries with non-uniform regions to 
study the impact on lesion detectability in a more realistic but still well-defined distribution. 
Lesions were embedded in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 
Clinical Trials Network (CTN) torso phantom, a 30-cm-long torso phantom with both a uniform 
background region and two lung regions filled with Styrofoam to emulate the attenuation and 
activity of human lung (Chapter 3, Figure 12) [93]. To extend the axial extent of the activity 
distribution, a 20-cm diameter x 30-cm long cylindrical phantom, within which we could easily 
embed spheres, was placed directly inferior to the CTN phantom to act as a uniform liver region. 
Both phantoms were centered in the transverse FOV; the CTN phantom was centered in the axial 
 
 
110   
center of the FOV with the uniform cylinder placed directly inferior; this positioning resulted in 
only 16 cm of the 30-cm long cylinder being inside the AFOV. Because the CTN phantom has a 2-
inch lip, there is a gap between the two phantoms in reconstructed images. The described 
phantom positioning was meant to roughly emulate the positioning of human subjects in the 
PennPET Explorer, given differences in body structure, with the vertex aligned with the top edge 
of the scanner, lungs within the center of the AFOV, and the liver above the bottom edge of the 
scanner (Table IX, Study F). 
The CTN phantom was scanned 60 min after filling according to standard instructions [93]. 85 MBq 
of 18F were mixed into the 9.5-L water-filled background region of the CTN phantom for a 
concentration of 6.3 kBq/cc when imaging began, and the spheres included in the CTN phantom 
were filled with a 4.1:1-uptake. While liver FDG uptake in humans is typically twice that of 
background, for this study the uniform cylinder was filled with the same activity concentration as 
the CTN phantom background. The phantom setup was imaged for 60 min on the PennPET 
Explorer, and the full dataset was split into ten 360-s background datasets after randomly 
reordering the list-mode events to eliminate effects of radioactive decay and changing randoms 
fraction. The physical spheres in the CTN phantom (7-37 mm diameter) were not used in this 
study. 
Spheres were embedded into the lung and the liver regions in two configurations: 6-mm lesions 
were embedded into the lung at an 8:1-uptake and into the liver at a 4:1-uptake, and 10-mm 
lesions were embedded into the lung at a 6:1-uptake and into the liver at a 3:1-uptake. Uptake 
ratios were chosen to be challenging based on visual detectability for both liver and lung lesions. 
Twenty-two lesions were embedded into the lungs (12 right lung, 10 left lung) and 17 lesions were 
embedded into the liver region. There are slight positioning discrepancies between the 10-mm 
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and 6-mm spheres that are related to the sphere data acquisitions. Each of the 10 background 
datasets and 20 lesion datasets – 10 replicates for each sphere size including both the liver and 
lung – were subsampled and reconstructed at nine scan times ranging from 5 s to 6 min. 
Human subject 
Ten healthy human volunteers have been imaged thus far on the PennPET Explorer [102]. The 
protocol was approved by the University of Pennsylvania Institutional Review Board, and all 
subjects signed informed consent. For this work, we used one representative scan with a scan 
duration long enough to generate multiple independent realizations. We embedded lesions in the 
liver and lung of this human subject dataset. This builds on work done using the CTN phantom but 
also introduces some new challenges, such as imaging in a complex activity and attenuation 
distribution. While this work does not replicate respiratory motion that would blur lesions in both 
the lung and liver, the respiratory motion of the human subject does result in blurring and 
smoothing of the lung background. 
The subject was a normal 79-year-old male who was imaged 102 min following injection of 551 
MBq of FDG. The subject was positioned such that his vertex was aligned with the top edge of the 
AFOV, his lungs were in the center of the AFOV, and his liver was towards the bottom of the AFOV. 
Twenty min of data were collected, and the list-mode file was parsed into six 180-s background 
datasets, following random reordering of the list-mode events (Table IX, Study G). 
Both 6- and 10-mm lesions were embedded into the lung and liver using the same uptakes as 
described for the CTN phantom. Twenty-seven lesions were embedded into the lungs (18 right 
lung, 9 left lung) and 16 lesions were embedded into the liver. Each of the 6 background datasets 
and 12 lesion datasets – 6 replicates for each sphere size including both the liver and lung – was 
subsampled and reconstructed at eight scan durations ranging from 5 s to 3 min. 
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Image Reconstruction and Analysis 
Reconstruction 
All datasets were reconstructed using LM TOF-OSEM (up to 5 iterations x 25 subsets) with SSS-
TOF for scatter correction (see Chapter 2 for more details) [19, 30]. Because the PennPET Explorer 
did not have an in-line CT at the time of data acquisition, attenuation correction sinograms were 
generated from CT images acquired on our clinical PET/CT system and aligned to non-attenuation 
corrected (NAC) PET images from the PennPET Explorer using rigid body registration (MIM 
Software, Inc.). To aid in this registration, immobilizers commonly used in radiation oncology were 
used for the human subject scan to maintain body positioning between the PennPET Explorer PET 
scan and the clinical CT. Rigid body registration worked well to align the patient’s torso but often 
resulted in a small misalignment of the patient’s head. A non-rigid registration within MIM was 
tested but since it was designed for CT data, not PET data, it was difficult to implement 
reproducibly.  
Numerical lesion detection 
A generalized scan statistics methodology was used to quantify lesion localization and 
detectability [109]. The scan statistics methodology uses background images to measure local 
contrast over the background region and generate the corresponding lesion-absent probability 
distribution function (PDF), which reflects the probability of false positive detection. A schematic 
depiction of the generalized scan statistics methodology is shown in Figure 36. Contrast is 
calculated as H/B, where H is the mean counts within a spherical VOI(Figure 36, red circle) with a 
6- or 10-mm diameter, corresponding to the size of the lesion of interest, and B is the mean counts 
in a spherical shell (Figure 36, blue circle) with an inner diameter twice the embedded sphere 
diameter and a thickness of 1 cm. Background regions for the CTN phantom and human subject 
were defined using region masks drawn in MIM (MIM Software, Inc.). For lesion present images, 
 
 
113   
local contrast is measured for each sphere to generate the lesion PDF (Figure 2A). The area under 
the localization receiver operating curve (ALROC) is then calculated statistically from first 
principles making use of the lesion-present and lesion-absent contrast PDFs [117]. All results are 
shown for the image reconstruction iteration number that achieves maximum ALROC. The 
calculated ALROC value reflects the probability of correctly localizing and detecting the lesion. 
 
Figure 36. The generalized scans statistics model measures (A) local contrast of spheres in an image and (B) scans 
the background image to measure local at every voxel within the dashed circle to (C) generate the corresponding 
PDFs of contrast for the background (g(c )) and the sphere (g(c )). ALROC can then be calculated using the formula 




Results show ALROC plots as a function of time for the 20x70 cm uniform cylinder, the 
anthropomorphic child phantom, and the anthropomorphic adult phantom for lesions with 2:1, 
3:1, and 4:1 uptake (Figure 38). Both the uniform cylinder and the anthropomorphic child 
phantom also show detectability results for data simulated in three imaging protocols. The 23-cm 
ring segment was simulated in two bed position configurations – a single bed position and three 
bed positions with 50% overlap – in addition to detectability results on the 70-cm PennPET 
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Explorer simulation. Corresponding 2-mm coronal slices are shown in Figure 37 for the uniform 
cylinder and anthropomorphic child phantom for a 180 s per bed position scan duration, which 
can be used to visually assess the relative detectability of lesions (red arrows). Overall, lesions are 
more easily visible on higher uptake images and images from the 70-cm PennPET Explorer.  
 
Figure 37. Coronal 2-mm slices of the (A) 20 x 70 cm uniform cylinder and (B) anthropomorphic child phantom. Lesions 
were embedded at 2:1-, 3:1-, and 4:1-uptake and for simulations on the 23-cm ring-segment in a single bed position 
(top), three bed positions with 50% overlap (middle), and simulated on the 70-cm PennPET Explorer in one bed 
position (bottom). 
 
Table X. Measured contrast of the 7-mm spheres at the 180 s per bed position scan duration for the three simulated 
activity distributions 
 
20 x 70 cm Uniform 
Cylinder Anthropomorphic Child Anthropomorphic Adult 
 2:1 3:1 4:1 2:1 3:1 4:1 2:1 3:1 4:1 
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Measured contrast at 180 s is shown in Table X for all three phantoms and all three imaging 
protocols. Contrasts for spheres of a given uptake are similar across all three phantoms and 
imaging protocols. Average contrast values for the 2:1, 3:1, and 4:1-uptake spheres are 1.27, 1.55, 
and 1.82, respectively. Additionally, the standard deviation of the contrast measurement 
increases for data from the 23-cm ring-segment simulation compared to the 70-cm PennPET 
Explorer simulation due to the decrease in sensitivity. 
ALROCs from the 20 x70 cm uniform cylinder study (Table IX, Study A) are shown in Figure 38A. 
Overall, ALROC curves show that the 70-cm scanner performs better than the 23-cm ring-segment 
data taken in three bed positions, which in turn performs much better than the 23-cm ring-
segment data taken in a single bed position. An ALROC of 0.8 is used as a threshold for “good” 
lesion detectability throughout this chapter and can be understood as 80% of lesions are 
accurately detected and localized. An ALROC of 0.8 is achieved at 42 s for the 4:1-uptake sphere 
on the 70-cm PennPET Explorer. The same ALROC is achieved for data from the 23-cm ring-
segment imaged in three bed-positions at 75 s (1.8x ALROC gain calculated by the ratio of scan 
durations) and in one bed position at 120 s (2.9x). The times were estimated by linear 
interpolation from the plots (something like that). The ALROC gain is the factor by which the scan 
duration or dose can be lowered while maintaining the same detectability. Alternatively, it is the 
scale factor by which the scan duration on the 23-cm ring-segment should be increased to match 
the detectability on the 70-cm scanner. For the 3:1-uptake spheres, an ALROC of 0.8 is achieved 
at 90 s and 143 s (1.6x) for the 70-cm and 23-cm multi-bed-position datasets; the 23-cm single-
bed-position dataset does not reach an ALROC of 0.8 by the maximum scan duration studied but 
continues to rise and could be expected to reach this value with a longer scan time. The 2:1-uptake 
spheres were only detectable on the 70-cm scanner at a 180 s scan duration. Overall, imaging on 
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the 70-cm PennPET Explorer compared to the 23-cm ring segment results in an almost 2x 
detectability gain when imaging in three bed positions and a 3-4x detectability gain when imaging 
in one bed position. 
 
 
Figure 38. ALROC results for GATE simulations of phantoms used for preliminary data including (A) The 20 x 70 cm 
uniform cylinder (B) an anthropomorphic child phantom, and (C) the anthropomorphic phantom representing a 5’ 5” 
female adult. ALROC results are shown as a function of scan time per bed position for three lesion uptakes: 4:1 (red), 
3:1 (blue), and 2:1 (gray). The solid line reflects the 70-cm simulation of the PennPET Explorer, the dashed line reflects 
the 23-cm ring-segment simulation for three overlapping bed positions, and the dash-dot line reflects the 23-cm ring-
segment simulation for a single bed position. (D) ALROC for the 20 x 70 cm uniform cylinder as a function of counts 
for simulations on the 23-cm ring-segment in a single bed position (triangle) and the 70-cm PennPET Explorer (circle). 
 
Results from the anthropomorphic child phantom study (Table IX, Study D) are shown in Figure 
38B. ALROCs show better performance of the 70-cm PennPET Explorer compared to the 23-cm 
ring segment, but there is little improvement in detectability between the 23-cm system imaged 
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in multiple bed-positions versus a single-bed-position. The 4:1-uptake spheres achieve an ALROC 
of 0.8 at 12 s, 46 s (3.8x), and 54 s (4.5x) for the 70-cm, 23-cm multi-bed-position, and 23-cm 
single-bed-position data, respectively. For the 3:1-uptake spheres, an ALROC of 0.8 is achieved at 
51 s, 107 s (2.1x), and 129 s (2.5x) 70-cm, 23-cm multi-bed-position, and 23-cm single-bed-position 
data, respectively. The 2:1-uptake spheres do not reach an ALROC of 0.8 by the maximum scan 
duration studied but, like the cylinder, continue to rise and could be expected to reach this value 
with a longer scan time. Overall ALROCs, and thus gains in ALROC, are higher for the 
anthropomorphic child phantom compared to the uniform cylinder due to differences in 
attenuation of LORs through low attenuation organs such as the lungs. 
Results from the anthropomorphic adult phantom study (Table IX, Study E) are shown in Figure 
38C. Overall, because attenuation of LORs is increased compared to the anthropomorphic child 
phantom, ALROCs are lower than they were for the child phantom or the uniform cylinder. The 
70-cm scanner achieves an ALROC of 0.8 at scan times of 30 s and 80 s for the 4:1-uptake and 3:1-
uptake spheres respectively. The 2:1-uptake spheres only reach a maximum ALROC of 0.2 at a 
scan time of 180 s although it is possible that the ALROC would continue to increase with longer 
scan durations. 
ALROC results for the uniform cylinder are also shown as a function of detected counts at the axial 
position where the spheres were location (Figure 38D). The number of counts was calculated by 
placing events in their most likely position using TOF information (i.e. a histo-image with 1 view 
and 1 tilt, see Chapter 2) and calculating the total counts in the 2-mm slice where the lesions were 
placed. Detectability as a function of measured counts agrees well across all three imaging 
protocols for a given sphere uptake. In addition to looking at detectability gains, this further 
supports the supposition that ALROC is directly related to axial sensitivity.  
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Summary of Results 
Overall, these preliminary results show a strong relationship between detected counts (axial 
sensitivity improvements) and detectability. ALROC increases for higher uptake spheres; however, 
even at longer scan durations on the PennPET Explorer, 2:1-uptake spheres are difficult to detect 
and were not used in the following studies. On the 70-cm PennPET Explorer, an ALROC of at least 
0.8 can be achieved across all three activity distributions for scan durations of 60 s for a 4:1-uptake 
sphere and a 90 s for a 3:1 uptake sphere. The shorter, 23-cm ring-segment shows lower ALROC 
than the 70-cm PennPET Explorer and would require longer scan times to reach comparable 
ALROC. Lesions in these studies were placed near the center of the AFOV, so while dependence 
with scan time was well studied, the relationship between ALROC and the changing axial 
sensitivity of single-bed-position imaging was not well characterized. This was further investigated 
in the next set of experiments.  
AXIAL SENSITIVITY PROFILES 
Axial sensitivity profiles for a line source in a 20x70-cm cylinder are shown in Figure 35A for the 
simulated 70-cm scanner and the PennPET Explorer. The profile for the simulated scanner is 
roughly triangular with a slight decrease in expected axial sensitivity in the center of the AFOV 
due to attenuation effects. The inactive regions in the PennPET Explorer result in a roughly 2x 
decrease in total sensitivity with peaks and valleys seen in its axial sensitivity profile. The peaks 
and valleys reflect axial positions with the greatest and fewest LORs passing through that position, 
respectively, as illustrated in Figure 35B. 
CYLINDRICAL PHANTOM 
Contrast measures for the 180-s cylindrical phantom dataset with spheres at multiple axial 
locations from both the simulation and PennPET Explorer measurement (Table IX, Study B and 
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Study C) are shown as a function of axial position in Figure 39. Average contrast values at 180 s 
over all axial positions are shown for all sphere configurations and activity distributions in Table 
XI. The mean contrast values are consistent across simulation and measurement and do not vary 
over the AFOV; the standard deviation is systematically larger on the PennPET Explorer due to the 
lower sensitivity. Contrast results for the spheres are also consistent with values calculated using 
the NEMA image quality phantom [89, 93].  
 
Figure 39. Contrast vs. axial position for (A) 6-mm and (B) 10-mm spheres embedded in a 20-cm cylindrical phantom. 
(Top) Higher uptake and (bottom) lower uptake spheres are shown for both the simulation in red and measurement 
in blue. Scanner detector geometries for the 3 ring segments are shown in shaded boxes: simulation (red) and 
measurement (blue). The measurements cover 64 cm AFOV due to inter-ring data gaps indicated with lighter shading 
in the schematics. 
 
Simulated (left) and measured (right) ALROCs for the 6-mm, 6:1-uptake spheres are shown in 
Figure 40 as a function of axial location for scan times ranging from 5 s to 180 s. These results 
demonstrate the trends seen with all four sphere configurations studied. For the simulated 
scanner, ALROC saturates at 1.0 in the center of the scanner for scan durations of 60 s or longer; 
for measured data, an ALROC > 0.75 is maintained at most axial locations for scan times longer 
than 90 s.   
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Table XI. Average measured contrast over all axial positions 
 
a. Cylindrical phantom 
 
6 mm Spheres 10 mm Spheres 
 
4:1 uptake 6:1 uptake 2:1 uptake 3:1 uptake 
Simulation 1.59 ± 0.10 2.02 ± 0.12 1.43 ± 0.06 1.88 ± 0.09 
Measurement 1.61 ± 0.15 2.03 ± 0.17 1.43 ± 0.09 1.89 ± 0.11 
 
b. CTN phantom and human subject 
6 mm Spheres 10 mm Spheres 
Liver (4:1) Lung (8:1) Liver (3:1) Lung (6:1) 
CTN Phantom 1.62 ± 0.18 2.45 ± 0.53 1.92 ± 0.12 2.97 ± 0.60 
Human Subject 1.54 ± 0.15 2.15 ± 0.34 1.92 ± 0.20 2.84 ± 0.54 
 
 
Figure 40. ALROC vs. axial position for 6-mm spheres embedded at 6:1 uptake in the cylindrical phantom at scan 
times ranging from 5-180 s. Scanner detector geometries for (A) simulation and (B) measurement are shown by 
shaded boxes. 
 
The results in Figure 40 further reinforce the results shown in Figure 38 that changes in ALROC 
correspond with changes in axial sensitivity. This is especially true for shorter scan times in Figure 
40. To further probe this relationship, we plotted ALROC as a function of counts originating from 
different axial locations for all sphere configurations in Figure 41. Counts originating from 
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different axial locations were estimated using most likely positioning of events using TOF 
information along the LOR of each event, as was done for the axial sensitivity profile 
determination (Figure 33A) and simulated cylinder with central spheres (Figure 5D). Results show 
a strong relationship between the measured counts, which varies axially for long AFOV scanners, 
and ALROC for a given sphere size/uptake combination, as well as good agreement between 
measurement and simulation. As noted earlier, the two contributing factors to ALROC are the 
lesion contrast and background image noise. Since there is no change in measured contrast axially 
(Figure 39), the ALROC only varies as a function of measured counts, which does vary axially. The 
lowest number of counts at which the ALROC is 1.0 is 0.85 Mcts and 0.30 Mcts for the 4:1- and 
6:1-uptake 6-mm spheres, respectively, and 0.80 Mcts and 0.25 Mcts for the 2:1- and 3:1-uptake 
10-mm spheres, respectively. 
 
Figure 41. ALROC for (A) 6-mm and (B) 10-mm spheres in the cylindrical phantom as a function of counts. Note that 
each data point corresponds to a different axial location and counts were determined by the most likely positioning 
algorithm. Data from the simulation (red) and measurement (blue) are included for both the higher uptake (square) 
and lower uptake (star) spheres. 
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Figure 42. (A) Representative images from the CTN phantom with (top) 6-mm and (bottom) 10-mm embedded 
spheres for a scan times ranging from 360 s (left) to 5 s (right) and (B) the corresponding ALROC plot as a function of 
scan duration including 6-mm (dashed) and 10-mm (solid) lesions in both the liver (green) and lung (blue). There were 
22 spheres embedded in the lung (6 visible in the 2-mm thick coronal image shown) and 17 spheres in the liver (3 
visible) distributed volumetrically throughout each organ region. The embedded lesions are circled to identify them 
from the physical CTN spheres. 
 
CTN PHANTOM  
Results from the CTN phantom lung region show the first known implementation of the 
generalized scan statistics methodology in a non-uniform background (Table IX, Study F). 
Representative coronal slices of data embedded with both 6-mm and 10-mm spheres at all nine 
scan times as well as corresponding ALROC curves as a function of scan time are shown in Figure 
42. In the plots shown in Figure 42B, ALROC plateaus at 0.90 for 10-mm lung lesions with scan 
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than 90 s. Results for the 6-mm liver lesion show the ALROC steadily increasing with scan time up 
to an ALROC of 0.94 at 360 s. ALROC curves for the 6-mm lung lesion plateau at 0.4 (0.38-0.44) for 
scan durations of 90 s and longer and are unlikely to reach an ALROC of 1.0 with longer imaging 
times. Corresponding visual lesion detectability can be seen in the representative coronal image 
slices (Figure 42A).  
 
 
Figure 43. (A) Representative images from the human subject with (top) 6-mm and (bottom) 10-mm embedded 
spheres for a scan times ranging from 180 s (left) to 5 s (right) and (B) the corresponding ALROC plot as a function of 
scan duration including 6-mm (dashed) and 10-mm (solid) lesions in both the liver (green) and lung (blue). There were 
27 spheres embedded in the lung (5 visible in the 2-mm thick coronal image shown) and 16 spheres in the liver (3 
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HUMAN SUBJECT 
Representative coronal slices of the human subject datasets (Table IX, Study G) with 6-mm and 
10-mm embedded lesions and the corresponding quantitative ALROC results are shown in Figure 
43. The 10-mm sphere results show ALROCs of 0.8 or greater at scan times longer than 30 s and 
60 s for the lung and liver spheres, respectively. The 6-mm lung and liver spheres have ALROCs 
that increase steadily up to values of 0.66 and 0.39 at 180 s, suggesting that the ALROC will 
continue to increase at longer scan times. 
 
Figure 44. ALROC for the (a) 4:1-uptake 6-mm spheres and (b) 3:1-uptake 10-mm spheres as a function of measured 
axial counts for the cylindrical phantom (red and blue squares), CTN phantom (yellow diamonds), and human subject 
(green diamonds) with corresponding trend curves. 
 
Figure 44 compares simulated and measured ALROC results as a function of measured axial counts 
from all three distributions studied – the cylinder (faded squares), the CTN phantom (yellow 
diamonds), and the human subject (green diamonds) – and shows that they follow similar trends. 
The 6-mm sphere with 4:1-uptake (hard to detect) and the 10-mm sphere with 3:1-uptake (easy 
to detect) in the liver were specifically selected for Figure 44 to allow direct comparison of both 
the CTN phantom and human subject results to results from the cylindrical phantom. Trend lines 
were drawn through the cylinder data (solid) along with the CTN and human data (dashed). In 
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these plots the measured axial counts for the CTN phantom and human subject were calculated 
using a weighted average over slices in which spheres were embedded, based on the number of 
spheres in each slice. 
DISCUSSION 
For scan times of 30 s or less, the curves of ALROC as a function of axial position for the simulated 
cylindrical phantom (Figure 40A) roughly follow the shape of the axial sensitivity profile (Figure 
35A), which peaks in the center of the scanner and decreases towards the edges of the AFOV, 
confirming that ALROC is closely related to the number of counts collected per axial location. This 
correspondence is especially pronounced for the 30-s scan duration. The relationship of ALROC 
with axial sensitivity is also apparent for the measured cylinder results (Figure 40B) where dips in 
the ALROC correspond directly to dips in the axial sensitivity profile of the PennPET Explorer. 
These results demonstrate the compromise of imaging with a single bed position, which can 
provide simultaneous coverage of the organs of interest, but not with uniform sensitivity. This 
variation is highlighted with the 70-cm PennPET Explorer. The axial sensitivity, and therefore 
ALROC will become more uniform with axial location as the scanner is extended to a longer AFOV 
with additional ring segments, as will be described later.  
The cylindrical phantom results are in agreement with past Monte Carlo simulation work done by 
Surti and Karp on a long AFOV scanner [68]. They simulated a 72-cm AFOV scanner with 4x4x20 
mm3 LYSO crystals and a 300-ps timing resolution with a 35-cm cylindrical phantom, meant to 
represent a heavy patient, with 10-mm 3:1-uptake lesions in the center of the AFOV. After 
adjusting for both scan time and background distribution, our ALROC results are consistent with 
those results: for adjusted scan times at 60 and 30 s, Surti and Karp report ALROCs of 0.92 and 
0.73 while our ALROCs are 0.98 and 0.74 at scan durations of 30 and 15 s. The factor of 2x 
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difference in scan times is likely due to the lower attenuation in the current work due to the use 
of a 20-cm diameter cylinder as well as differences in simulated scanner sensitivity (higher in 
previous work). 
The PennPET Explorer measurements were taken in its prototype 3-ring configuration with two 
axially inactive regions between ring segments that make up 23% of the axial detector extent for 
each ring. Because long AFOV scanners will prove costly to build, axial gaps can be part of the 
scanner design to maximize the AFOV for a given number of detectors [118], but it is important 
to consider the implications of introducing such gaps for quantitative metrics such as lesion 
detectability. First, the total sensitivity is reduced by about a factor of 2, and the axial sensitivity 
profiles, measured using a line source attenuated in a 20-cm cylinder (Figure 35A), show that 
there are significant variations in sensitivity corresponding to the different numbers of cross-
coincidences accepted at these axial positions (Figure 35B). The normalization correction leads to 
uniform images and the lesion contrast values are not affected by the inactive regions or the low 
points of the sensitivity measurement, although the measurement uncertainty (error bars) shows 
a slight increase at the axial locations related to the decrease in collected counts. Since ALROC is 
dependent on measured axial counts (Figure 41), however, decreased axial sensitivity does 
translate to poorer lesion localization and detectability in these regions of lower sensitivity (Figure 
40).  
The plots of ALROC vs. axial counts in Figure 41 show similarities between the two sphere sizes, 
due to the similarities in measured contrast of these spheres. For the higher uptake spheres – 10-
mm with 3:1-uptake and 6-mm with 6:1-uptake spheres – the curves plateau at a similar point 
(0.25 vs. 0.30 Mcts, see section 3.2) where the average contrast measured for these spheres is 
similar, (1.88 ± 0.09 vs. 2.02 ± 0.12, see Table XIa). This is also true for the two lower uptake 
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spheres – the 10-mm with 2:1-uptake and 6-mm with 4:1-uptake spheres – with contrasts of 1.43 
± 0.06 and 1.60 ± 0.10 where ALROC equals 1.0 at 0.80 and 0.85 Mcts, respectively.  
Table XII. Minimum scan duration* with ALROC ≥ 0.80 
  
6 mm Spheres 10 mm Spheres 
CTN Phantom 
Lung (360 s)** 26 s 
Liver 239 s 53 s 
Human 
Subject 
Lung (180 s)§ 28 s 
Liver (180 s)§ 60 s 
* Scan time estimated by linear interpolation from curves in Figure 42B and Figure 43B. 
** ALROC curves reached a plateau at 0.42 and would not be expected to reach 0.80 at any scan 
duration. 
§ ALROC curves had not reached 0.80 by 180 s but were continuing to rise and would be expected to 
reach 0.80 at scan times longer than 180 s. 
  
As can be seen in the images in Figure 42 and Figure 43, images with ALROCs ≥ 0.80 have good 
visual detectability of the lesions. Note that a single replicate is displayed and is only 
representative of the many replicates used to calculate the ALROC. For the CTN phantom and 
human subject, 10-mm liver spheres have an ALROC of 0.8 or better for scan times greater than 
60 s, whereas for the 10-mm lung spheres, ALROC is greater than 0.8 for scan times longer than 
30 s for both the CTN phantom and human subject (Table XII. Minimum scan duration* with 
ALROC ≥ 0.80). In comparison, for the smaller 6-mm sphere the ALROC exceeds 0.8 only in the 
liver of the CTN phantom at 360 s. While not being equivalent to a trained clinician reading the 
images, a visual observation of images indicates that, qualitatively, images with ALROC values of 
0.80 or higher would generally lead to a very high confidence in the lesion detection and 
localization task. Using this value (ALROC=0.8) as a cut-off, we see in Figure 41 that the measured 
axial counts for a 6-mm diameter sphere with 6:1 uptake in a uniform background can be lowered 
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from the measured 0.69 Mcts at the axial center of the PennPET Explorer for a 180-s scan to 0.25 
Mcts. This means, that either the scan time or patient dose can be lowered by a factor of 2.8 on 
the 70-cm PennPET Explorer in its current configuration while maintaining “good” detectability 
for lesions of this size in the central plane.  
In Figure 44, all datasets – the cylindrical phantom, the CTN phantom, and the human subject –  
follow similar trends; however, the CTN phantom ALROC values at a given count level are 
systematically higher than those for the cylindrical phantom, while the human subject results are 
systematically lower than the cylindrical phantom data, although the differences are less 
pronounced for the 10-mm sphere. The differences for the 6-mm sphere curves could be due to 
differences in measured contrast. While contrast measures for the 10-mm 3:1-uptake spheres are 
relatively similar for the cylinder, CTN phantom, and human subject (see Table XII), the contrasts 
for the 6-mm 4:1-uptake spheres do vary. The average contrast for the 6-mm 4:1-uptake spheres 
in the CTN phantom is slightly higher than that for the cylinder, both simulated and measured, 
and the contrast measures for the human subject is slightly lower than that for the cylinder. 
Additionally, the spread of these contrast measures is larger for both the CTN phantom and 
human subject when compared to the cylindrical phantom. While further study will be necessary 
to more systematically quantify these differences, the results offer insight into the performance 
of long AFOV systems for varying activity distributions. 
A few limitations of this work are noted. One limitation is the design of the lung in the CTN 
phantom, which makes the detectability results of small spheres in the lung of this phantom 
difficult to interpret. The ALROC for the 6-mm 8:1-uptake lung lesions in the CTN phantom reaches 
a plateau at an ALROC of 0.4 (0.38-0.44) for 90 - 360 s scan times, implying that increasing the 
number of counts collected would not improve the ALROC. We believe these results are 
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confounded by the design of the lungs in the CTN phantom, constructed using Styrofoam peanuts, 
which does not represent the structure of human lung parenchyma on FDG PET scans even though 
it does approximate the typical attenuation and uptake in the lung. This is further supported by 
ALROC results from 6-mm lung lesions in the human subject that continue increasing from 90 to 
180 s with a trajectory that should reach an ALROC of 1.0 at longer scan times. The human results 
demonstrate that the scan statistics methodology can work in a non-uniform region such as the 
lung, whereas the non-uniformity seen in the lung in the CTN phantom is clinically unrealistic for 
detectability studies. Also note that our work confines the background region to a specific organ 
in the CTN phantom and human subject studies. This correspondingly constrains the localization 
and detection task to a specific organ, while the traditional clinical task requires the reader to 
scan the full body.  
For the studies in this work, the embedded lesions did not include respiratory motion and 
therefore the results for short scans for lung lesions may be relevant for breath-hold studies, 
which need to be 30 s or shorter. ALROC results for the 10-mm 6:1-uptake lung lesions in both the 
CTN phantom and the human subject can be reduced to 30 s while maintaining detectability with 
ALROC > 0.8 (ALROC = 0.86 ± 0.03 and 0.82 ± 0.03, respectively). However, for smaller lesions 
such as the 6-mm 8:1-uptake lesions, ALROC at 30 s is quite poor: 0.28 ± 0.04 and 0.27 ± 0.03 for 
the CTN and human subject, respectively. Overall, this implies that the scan duration could be 
reduced to 30 s with minimal detectability losses for lesions 10 mm and larger, but future studies 
would be needed to consider the feasibility and benefits of such studies. To maintain good image 
quality, current clinical imaging protocols are only as short as 60 s per bed position for low BMI 
patients, a time span potentially unreasonable for breath-hold imaging on patients with lung 
disease for whom even a 30-s scan may be too long.  
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CONCLUSION 
In this work, we quantified the lesion detectability and localization task using the generalized scan 
statistics methodology in a cylindrical phantom, the anthropomorphic CTN phantom, and a 
human subject on the PennPET Explorer, a long AFOV system. ALROC results showed that scan 
times on our long AFOV system can be reduced to 60-90 s for a single bed position static image 
with “good” detectability, ALROC > 0.8. ALROC results on both the simulated 70-cm scanner and 
the PennPET Explorer correspond with variations in axial sensitivity due to axial location. The 
relationship between ALROC and axial counts for spheres of a given size can be used to design 
imaging protocols for the PennPET Explorer for single-bed acquisitions that lower dose or scan 
time, depending on the application. Compared to the PennPET Explorer in its prototype 3-ring 
configuration, the extended 6-ring (1.4-m) system will lead to a high sensitivity over a large axial 
range, extending beyond the liver and lungs, that is greater or equal to the maximum sensitivity 
for the shorter AFOV system studied in this work. Thus, the results of ALROC of this work near the 
central axial locations can be used to guide the design of imaging protocols for the larger AFOV 
PET scanner. Moreover, once differences in sensitivity are accounted for these results can also be 
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CHAPTER 5: DYNAMIC IMAGING: QUANTIFYING BIAS AND PRECISION OF KINETIC PARAMETER ESTIMATION 
ABSTRACT 
This chapter studies how the increased sensitivity of single-bed-position dynamic imaging on a 
long AFOV system affects kinetic parameter estimation. We designed both a simulation and 
measurement study to probe this question with the following studies: (1) a dynamic GATE 
simulation of [18F]-fluorothymidine (FLT) in a modified NEMA IQ phantom and (2) a lesion 
embedding study of spheres in the lung and liver of a human subject dynamically imaged with 
[18F]-fluorodeoxyglucose (FDG) on the 70-cm PennPET Explorer prototype system. Both studies 
were designed using published kinetic data of lung and liver cancers. Average K1, k2, and k3 values 
for both studies were 0.14 ± 0.05 ml/ccm/min, 0.30 ± 0.25 min-1, and 0.19 ± 0.11 min-1, 
respectively. Average k4 values for the FLT study were 0.027 ± 0.016 min-1, while k4 was assumed 
to be zero for the FDG study. Data were reconstructed at various emulated administered doses in 
order to study how the increased sensitivity of a long AFOV scanner impacts the accuracy and 
precision of kinetic parameter estimation at low doses. Sphere time-activity curves (TACs) were 
measured on resulting dynamic images, and TACs were fit using only a two-tissue-compartment 
model (k4≠0) for the FLT study and both a two-tissue-compartment model (k4=0) and Patlak 
graphical analysis for the FDG study to estimate values of flux (Ki) and delivery (K1) parameters. 
Quantification of flux and K1 shows lower bias and better precision for both radiotracers when 
imaging on the long AFOV scanner, especially at low doses. Dynamic imaging on a long AFOV 
system can be achieved for a greater range of injected doses, as low as 0.5-2 mCi depending on 
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INTRODUCTION 
Dynamic PET imaging offers biologic information beyond what is available from static images; 
however, several factors can impact the resultant accuracy of parameters. Such factors include 
count statistics, lesion size relative to system spatial resolution, target uptake relative to 
background, and patient motion, including respiratory and gross motion. Uncertainties in 
estimating kinetic parameters from dynamic images also depend on inaccuracies in the measured 
blood input function, which can be due to inadequate temporal sampling, inaccurate radiotracer 
metabolite corrections, or partial volume errors when using small vessels for the blood input 
function [119].  
Improving the quantitative accuracy of the underlying dynamic image data should enable more 
reliable kinetic parameter estimates. To increase the count statistics and improve quantitative 
accuracy, scanner sensitivity can be increased by extending the axial field-of-view (AFOV) of the 
scanner to capture a larger fraction of the coincident gammas or lines of response (LORs) [57]. 
This also enables dynamic studies in a single bed position covering the majority of the organs of 
interest. In this study, we investigated how improved count statistics from imaging on a long AFOV 
system affect kinetic parameter estimation using two tracers, [18F]-fluorothymidine (FLT) and 
[18F]-fluorodoxyglucose (FDG), which are modeled using two-tissue compartment models with 
trapping (k4 is small or 0) [120]. In contrast to static imaging, dynamic information from both 
tracers have been shown to have added clinical value. Dynamic FDG data has been shown to 
improve the ability to measure cancer response to treatment over static imaging at 60 min post-
injection (the usual clinical protocol), especially for low uptake tumors [121]. Although the clinical 
impact of FLT imaging is still under investigation, dynamic FLT imaging has shown to more strongly 
correlate with a pathologic marker of cellular proliferation compared to static imaging [120, 122]. 
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Additionally, research tracers with trapping are of interest since flux for such tracers is correlated 
with uptake at a later time point, which can help transition a dynamic tracer to practical clinical 
usage. We are interested in quantifying kinetic parameter estimation so future studies on long 
AFOV scanners of tracers with similar behavior can be anticipated and used for design of imaging 
protocols.   
As previously mentioned in Chapter 2, the total sensitivity of long AFOV scanners increases by a 
factor of 20-40x compared to a commercial scanner due to the longer axial extent of the detectors 
and the increased axial acceptance angle. However, the sensitivity at a single axial position (i.e. 
point source sensitivity) in an attenuating medium such as a patient only improves by 2-3x as a 
result of attenuation of oblique LORs [123]. Because this gain in sensitivity is mostly realized by 
an AFOV of 70-cm [123, 124], gains based on sensitivity for dynamic imaging on a long AFOV 
scanner can be tested on a scanner with an axial length of 70 cm and applied to longer devices.  
Little work has been done to quantify dynamic images acquired on long AFOV systems. Thus far, 
UC Davis has shown dynamic images with good image quality for time frames as short as 1 s for 
the whole body and 100 ms for the heart [77]. While the images from these systems are 
qualitatively striking, the impact of the increased sensitivity of long AFOV systems in comparison 
to clinical scanners on image quantitative accuracy, including kinetic parameter estimation, has 
not been studied.  
Herein, we present a series of studies using both simulated and measured data from the early 70-
cm PennPET Explorer prototype to understand how imaging on long AFOV systems impacts kinetic 
parameter estimation of dynamic studies. We compare kinetic parameter estimates from a 70-
cm long AFOV system to a single-ring system, meant to represent a clinical scanner, in simulation, 
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and demonstrate the accuracy and precision of kinetic parameter estimation from measurements 
on the prototype PennPET Explorer. We examine the accuracy and precision of kinetic parameter 
estimation for dynamic imaging as a function of count statistics (i.e. injected dose), lesion size, 
and modeling methodology for two tracers, [18F]-fluorothymidine (FLT) and [18F]-
fluorodoxyglucose (FDG).  
METHODS 
We performed two studies to primarily assess the relationship between improved count statistics 
and kinetic parameter estimation. The first is a simulation study of the modified NEMA image 
quality phantom designed to emulate dynamic imaging of [18F]-fluorothymidine (FLT). The second 
is an experimental study where measured lesions are dynamically embedded into a dataset of a 
normal human subject injected with [18F]-fluorodoxyglucose (FDG) and dynamically imaged on the 
PennPET Explorer. Both tracers can be modeled using two-tissue-compartments with trapping. 
FLT was selected to represent a generic two-tissue-compartment dynamic tracer with trapping, 
and FDG was selected to study a well characterized dynamic tracer. Both tracers had sufficient 
literature reports on dynamic imaging with estimated kinetic parameters to design these studies 
[120, 125-129], and measured dynamic patient data were readily available.  
DYNAMIC FLT PHANTOM MONTE CARLO SIMULATION 
Scanner geometry and GATE simulations 
GATE simulations of the modified image quality phantom were run for both the 23-cm ring-
segment and the 70-cm AFOV PennPET Explorer (Chapter 3, Figure 9B and Figure 9C). Simulations 
were run with a timing resolution of 320 ps to match the Philips Vereos timing resolution when 
operated at room temperature [85]. A timing resolution of 320 ps was used, as opposed to the 
250 ps timing resolution of the prototype scanner, because the simulations were run prior to 
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determining that a 250 ps timing resolution would be achievable. There may be additional gains 
from improving the TOF from 320 ps to 250 ps. 
Generation and reconstruction of dynamic FLT phantom data 
To generate the ideal time-activity curves (TACs) for dynamic simulations, rate constants from 
prior studies of the PET proliferation tracer [18F]-fluorothymidine (FLT) were utilized [120]. FLT is 
an analog of thymidine, a building block for DNA. Measures of FLT flux through thymidine kinase, 
a rate-limiting enzyme for thymidine incorporation into DNA, have been shown to correlate with 
measures of tumor proliferation, including Ki-67 values, a marker of cellular proliferation 
determined from tumor biopsy material [130]. As such, FLT flux provides a measure of tumor 
growth that can be used to assess response to therapy. The dynamic behavior of different organs 
in the FLT simulations was based on published dynamic FLT data from lung cancer patients. Kinetic 
parameters were selected to emulate low, medium, and high flux lung tumors based on these 
published series [120, 125]. Kinetic parameters for the background were based on muscle tissue 
from the same lung cancer patient studies [120, 125]. The blood input function was based on the 
left ventricular blood pool measured in dynamic FLT images from a breast cancer patient after a 
4 mCi (148 MBq) injection of FLT, fit to a tri-exponential model. For this study, we ignored the 
metabolites in the blood. This blood input function, along with the selected kinetic parameters, 
was used to generate representative ideal time-activity curves for low, medium, and high flux 
tumors using a two-tissue-compartment model and the Stella Architect software package (isee 
systems inc., Lebanon, NH). Because the measured fit blood curve was assumed to be the true 
FLT plasma input function that was used to generate the tissue curves as inputs to the simulation, 
any metabolites in this curve will not affect results of the study. The selected kinetic parameters 
are shown in Table XIII. 
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Table XIII. Kinetic Parameters for the dynamic Fluorothymidine simulation 
 Low Flux Medium Flux High Flux Bkgd (muscle) 
vB 0.05 0.05 0.05 0.05 
K1 0.074 0.135 0.2 0.0235 
K1/k2 0.35 0.68 1.3 0.58 
k3 0.21 0.175 0.15 0.03 
k4 0.04575 0.02015 0.01525 0.019 
Flux 0.0369 0.0632 0.0987 0.01 
 
The simulated dynamic FLT phantom was modified from a NEMA image quality (IQ) phantom 
(axial extent: 21 cm) [89]. The six spheres in the phantom were modified to represent small lung 
lesions: three with a 10 mm diameter and three with a 13 mm diameter. Each of the three spheres 
of each size was simulated with uptake profiles to emulate the dynamic behavior of low, medium, 
and high flux lesions following their ideal TACs (Figure 45). The lung insert in the center of the 
phantom was altered to have the attenuation of water and was dynamically simulated to emulate 
the blood TAC while the background region was dynamically simulated to emulate the muscle or 
background TAC. For purposes of the simulation, these curves were discretized into 500 ms 
segments. The phantom was placed in the center of the AFOV for the simulations. The phantom 
was simulated for 60 min on both the 23-cm ring-segment and the 70-cm PennPET Explorer 
simulation (Chapter 3, Figure 9B and Figure 9C) and coincidence data written into list-mode files.  
The list-mode data were parsed into 45 frames (16x5s, 7x10s, 5x30s, 5x60s, 5x180s, 7x300s) [125]. 
Each frame was then subsampled from a full dose of 4.0 mCi (148 MBq) into one-half, one-quarter, 
one-eighth, and one-sixteenth the dose, roughly corresponding to emulated doses of 2.0, 1.0, 0.5, 
and 0.25 mCi (74, 37, 18.5, and 9.25 MBq, respectively). Each of these five datasets was then 
bootstrapped using list-mode bootstrapping with replacement to generate 20 statistical replicates 
per dataset [100]. The list-mode data were reconstructed using a blob-based TOF-LM-OSEM 
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algorithm (4 iterations, 25 subsets) and binned into 2 mm3 isotropic voxels [30]. All corrections 
including scatter, randoms, attenuation, and normalization corrections were applied. Scatter 
correction was estimated using 3D time-of-flight single-scatter-simulation [19], while randoms 
correction was estimated using a delayed timing window. 
 
Figure 45. Ideal simulated FLT time-activity curves for the low, medium, and high uptake lesions (blue) in the modified 
NEMA image quality phantom along with the blood input function (red). Images (2-mm slice) of the modified IQ 
phantom for the full-dose dataset are shown at the top. An early frame clearly (at 22 s, 5 s duration) shows blood 
pool uptake and a later frame (at 32 min, 5 min duration) shows uptake in the low (top), medium (middle), and high 
(bottom) flux lesions and the difference between the 13 mm (left) and 10 mm (right) lesions. Example data points 
from a single dynamic phantom simulation, are shown in gray for the 10-mm spheres at full dose (4 mCi, 148 MBq). 
 
Data analysis for simulated dynamic FLT phantom images 
Spherical volumes of interest (VOIs, diameter equal to the physical sphere diameter) were 
centered over all spheres and circular regions of interest (ROIs) were drawn over several slices of 
the lung insert. The mean value of each region was corrected for scan duration, decay, and partial 
volume effects. A separately simulated uniform cylinder was used to determine the scanner 
calibration factor to convert image counts per voxel per time into activity concentration units 
(Bq/cc). 
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Partial volume correction (PVC) was based on the known ideal contrast for each frame and the 
measured contrast recovery coefficient (CRC) value for a given sphere size. Partial volume effects 
are defined as the ratio of the measured contrast (𝐻/𝐵 ) over the actual contrast (𝑎 ). We 
calculated 𝐻/𝐵  using the known contrast and rearranging the CRC equation so that 𝐻/𝐵 =
𝐶𝑅𝐶 ∗ (𝑎 − 1) + 1. The multiplicative PVC was then defined as 𝑎/(𝐶𝑅𝐶 ∗ (𝑎 − 1) + 1). CRC for 
a given sphere size was measured on a uniform cylinder dataset with embedded spheres 
reconstructed using the same DIRECT algorithm. Therefore, this PVC uses the CRC for a known 
sphere size to estimate the measured contrast as opposed to using the known contrast to 
perfectly correct measured VOIs back to desired values. 
The generated TAC data were fit using PMOD v3.7 (PMOD Technologies LLC, Zurich, Switzerland). 
The same two-tissue-compartment model used for data simulation was applied to the resulting 
simulated image data with model estimation starting values of 0.05 mL/g, 0.2 mL/g/min, 2.0 mL/g, 
0.2 min-1, and 0.02 min-1 for vB, K1, K1/k2, k3, and k4, respectively, based on prior work with 
thymidine tracers [125, 131]; all parameters were fit in the model. Calculated weighting was 
applied to the model using Poisson weighting derived from the measured value, frame duration, 
and decay based on the frame mid-time. 
For each of the six spheres and five emulated doses, the mean (?̅?) and standard deviation (?̅?) of 
both flux (KFLT) and delivery (K1) were calculated across the 20 bootstrapped replicates. Bias was 
calculated as 100% ∗ (?̅? − 𝜇)/𝜇 and percent standard deviation (% SD) was calculated as 100% ∗
?̅?/𝜇, where 𝜇 is the known value of the kinetic parameter or flux for the corresponding simulated 
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DYNAMIC FDG LESION EMBEDDING STUDY 
Spheres measured in air were embedded into each frame of a dynamic dataset from a human 
FDG subject acquired on the PennPET Explorer to emulate a human study with lesions.  
Scanner geometry 
All data were taken on the 70-cm PennPET Explorer prototype system (Chapter2, Figure 6D). 
Details of the scanner geometry can be found in Chapter 3. For reference, the PennPET Explorer 
has a measured spatial resolution of 4.0 mm, energy resolution of 12%, sensitivity of 54 kcps/MBq, 
and a timing resolution of 250 ps [85].  
Human subject data acquisition 
Dynamic lesion embedding was performed for an FDG study. To obtain the background dynamic 
tissue biodistribution data for this study, a normal human subject was injected with 500 MBq of 
FDG and imaged dynamically for 60 min on the PennPET Explorer. The subject was positioned 
such that the top of her head aligned with the edge of the scanner and the head, torso, and 
abdomen were within a single bed position. List-mode data were parsed into 70 frames (20x1s, 
10x2.5s, 7x5s, 7x10s, 9x30s, 5x1min, 6x3min, 6x5min) to accurately capture the bolus injected 
into the patient (i.e. a quick 2-s injection). For attenuation correction, CT data were acquired on 
a clinical PET/CT system and registered to the PET dataset using rigid body registration [102]. 
Sphere-in-air data acquisition 
Sphere-in-air data from Chapter 4 were used for dynamic embedding of lesions into the subject’s 
dataset. Note that sufficient counts were acquired in list-mode at each location such that the 
desired number of list-mode events could be filtered and embedded in the data to represent a 
lesion with given uptake. A 6-mm sphere was chosen, in addition to a 10-mm sphere, to further 
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test the improved spatial resolution and sensitivity of the scanner. Twenty-six sphere locations 
(10 liver, 8 right lung, 8 left lung) were selected to embed dynamically into the human subject 
dataset, as described below. The spheres in this lesion embedding study were placed over a large 
axial range in the scanner where axial sensitivity is not constant. Spheres for the previously 
described GATE simulation were placed in the center of the AFOV, which ensured maximum 
sensitivity benefits of the 70-cm scanner compared to the 23-cm scanner.  
Generation and reconstruction of dynamic FDG data with embedded lesions 
Generation of ideal dynamic FDG lesion TACs was based on a 2-tissue-compartment/3-parameter 
model of FDG kinetics. As in the FLT simulations, published literature kinetic values for dynamic 
FDG lung and liver cancer studies were used to select a set of kinetic parameters to represent low, 
medium, and high uptake lesions. Kinetic parameters selected for lung lesions were derived from 
published patient data with a variety of lung cancers, and parameters for liver lesions were 
acquired from FDG PET data of patients with metastatic liver cancer of colorectal origin (see Table 
II) [126-129]. Ideal low, medium, and high flux TACs in the lung and liver were generated using 
the human subject’s left ventricular (LV) blood curve fit to a tri-exponential model, and a two-
tissue-compartment model with trapping (k4 = 0) was assumed for all lesions using STELLA (Figure 
46). FDG kinetic parameters were independently selected to fall within the biologic range of 
dynamic FDG data, but variations will not impact the study since they were used to generate the 
lesion TACs and set as ground truth. 
Lesions were embedded independently in each of the 70 frames using a modified lesion 
embedding methodology. Similar to lesion embedding in Chapter 4 and based on previously 
published work, the number of list-mode events for each sphere was calculated using the desired 
contrast and local background uptake at that time point [116]. List-mode events from the 
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different spheres were merged together on a frame-by-frame basis and then statistically 
attenuated using the probability of attenuation of each LOR through the human subject from the 
subject’s attenuation image. 
 
Figure 46. Ideal TACs for FDG lesion embedding for the lung (left) and liver (right). 
 
Table XIV. Kinetic parameters for the dynamic fluorodeoxyglucose study 
 Lung Lesions Liver Lesions 
 Low Flux Medium Flux High Flux Low Flux 
Medium 
Flux High Flux 
vB 0.170 0.170 0.170 0.200 0.170 0.120 
K1 0.100 0.178 0.133 0.119 0.194 0.086 
k2 0.219 0.550 0.044 0.487 0.782 0.031 
k3 0.074 0.250 0.070 0.113 0.279 0.404 
k4 0 0 0 0 0 0 
Ki 0.0253 0.0556 0.0817 0.0224 0.0510 0.0799 
 
Prior work with the list-mode-based lesion-embedding methodology only embedded lesions with 
uptake higher than background and the attenuated sphere-in-air events were merged with the 
background events prior to reconstruction [116]. With dynamic data, sphere TACs are at times 
lower than the measured background organ TACs (Figure 46). This is because the early portion of 
the lesion TACs, which are driven by delivery of tracer to the lesion, were designed based on 
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has a dual blood supply, where ~25% of blood is supplied by the hepatic artery while ~75% of 
blood comes from the portal vein, resulting in the blunted and broadened early blood peak of the 
measured human subject data. Therefore, events needed to be removed from the background at 
the embedded lesion location to obtain an accurate TAC for the embedded lesions. Because list-
mode event data can only be added, not removed, we instead implemented lesion embedding in 
histo-image format, a sinogram-like binned representation of the data, described in more detail 
in Chapter 2 [31]. Both sphere-in-air and human subject list data were binned into 4-mm histo-
images (144 x 144 x 160 slices x 40 views x 9 tilts), where the sphere-in-air list-mode data were 
first statistically attenuated. Histo-images of the lesions were then added to or subtracted from 
the human subject histo-image for each frame to create a histo-image with embedded lesions for 
each frame. Each frame was then reconstructed using direct image reconstruction for time-of-
flight PET (DIRECT), an iterative time-of-flight reconstruction algorithm based on the histo-image 
data format (50 iterations; row-action maximum likelihood – RAMLA – update [31]), into 4 mm3 
voxels [132]. The reconstruction used 2.0-mm line-of-response modeling and image filtering to 
match the image noise of the blob-based TOF-LM-OSEM reconstruction used for the simulated 
data. Scatter, attenuation, normalization, and randoms corrections were applied [32]. Images 
were then resampled in the spectral domain to create 2 mm3 images to allow more accurate 
definition and placement of the evaluated VOIs. We have observed that resampling decreases the 
measured CRC of small spheres by only 1-2% compared with reconstructing directly into 2-mm3 
voxels but with reduced reconstruction time due to the smaller image matrix size. 
This method of lesion embedding was applied to generate six datasets at a 13.5 mCi (500 MBq) 
FDG dose that included two sphere sizes (6 mm and 10 mm) and three fluxes. The six list-mode 
datasets of the combined lesion and background FDG data were also subsampled to emulate FDG 
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doses of 9.0, 4.5, 2.25, 0.9, and 0.45 mCi (333, 167, 83.3, 33, and 16.7 MBq, respectively), similar 
to the approach used for the FLT phantom simulations, to create 30 more datasets that were 
similarly deposited into histo-images and reconstructed using DIRECT. 
Data analysis for dynamic FDG data with embedded lesions 
From their known locations, VOIs were drawn over each sphere, corrected for scan duration, 
decay, and partial volume effects. TACs were created using the VOI mean. PVC for dynamic FDG 
data was implemented using the known contrast at each time point and CRC for a given sphere 
size, as described for the simulation analysis. The 10 liver spheres and 16 lung spheres were used 
as replicates. The blood input function was measured from the left ventricle and fit to a tri-
exponential for each dataset. 
Data were fit in PMOD using both the Patlak graphical method [133] and the two-tissue-
compartment (FDG) model with vB and k4 fixed at 0.15 and 0, respectively, where 0.15 falls within 
the range of the ideal vB values and a k4 of 0 was used to generate the ideal TACs. Parameter 
estimation starting values for K1, k2, and k3 were 0.102 mL/ccm/min, 0.13 1/min, 0.062 1/min 
respectively; no weighting was applied during fitting. For each dataset the mean and standard 
deviation for the 10 liver spheres and 16 lung spheres were determined to estimate the bias and 
% SD of the kinetic parameters, as previously described. 
RESULTS 
DYNAMIC FLT PHANTOM MONTE CARLO SIMULATION 
Representative images of the modified IQ phantom are shown in Figure 47 for both the 23-cm 
and 70-cm scanners. Early time point images at 22 s highlight the blood peak in the central rod of 
the phantom. Later images at 32 and 60 min highlight the six spheres representing embedded 
 
 
144   




Figure 47. (A) Representative images of the modified image quality phantom at full-dose on both the 23-cm (top) and 
70-cm scanners (bottom) at various time points: 22 sec (5 s duration), 32 min (5 min), 60 min (5 min) and summed 
19-60 min (left to right). (B) TACs with measured data at full-dose for all sphere sizes and fluxes for both the 23-cm 
scanner (left) and the 70-cm scanner (right). 
 
The bias and % SD of FLT flux (KFLT) fit using a two-tissue-compartment model are shown in Figure 
48 for the six spheres on the 23-cm and 70-cm geometries at doses ranging from 4 mCi (148 MBq) 
to 0.25 mCi (9.25 MBq). Overall, results from the IQ phantom study show that bias is close to zero 
for medium and high flux lesions at higher doses, but larger at lower doses. Bias is consistently 
large for the low flux lesions regardless of dose or lesion size, although the 70-cm scanner has less 


































































145   
bias than the 23-cm scanner. Precision for the 70-cm scanner geometry is generally better (i.e. 




Figure 48. Bias (A) and % SD (B) results quantifying flux (KFLT) fit using a two-tissue-compartment model. Data are 
from the FLT simulation for the 23-cm ring-segment (red) and the 70-cm PennPET Explorer simulation (blue). Results 
are shown for the low, medium, and high (left to right) flux spheres and for the 10 mm (top) and 13 mm (bottom) 
spheres. 
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Figure 49. Bias (A) and % SD (B) results quantifying delivery (K1) fit using a two-tissue-compartment model. Data were 
measured from the FLT simulation for both the 23-cm ring-segment (red) and the 70-cm PennPET Explorer simulation 
(blue). Results are shown for the low, medium, and high (left to right) flux spheres and for the 10 mm (top) and 13 
mm (bottom) spheres. 
 
The bias and % SD of the estimated FLT delivery parameter (K1) fit using the two-tissue-
compartment model are shown in Figure 49. Overall, delivery (K1) (1) has a bias close to zero for 
the medium and high flux spheres, (2) has a lower bias than that for flux for all spheres, and (3) 
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has slightly lower bias for the 70-cm scanner geometry compared to that for the 23-cm scanner 
geometry. Precision measures show little difference between the 23-cm and 70-cm scanner 
lengths when estimating K1, and overall, % SD is 10% for high flux spheres and 20% or lower for 
medium and low flux spheres at all doses. 
DYNAMIC FDG LESION EMBEDDING STUDY 
Maximum intensity projection images of lesions embedded in the lung and liver of the human 
subject are shown to visualize the medium flux spheres in Figure 50 at three time points. Lesions 
were placed volumetrically through the image; 10 liver lesions and 13 lung lesions are visible. 
Measured TACs for these lesions (Figure 51) at full dose (13.5 mCi, 500 MBq) reflect the accuracy 
of the lesion embedding methodology. 
 
Figure 50. Maximum intensity projection images showing early, middle, and late (left to right) frames for the medium 
flux lesion datasets. 10 lesions are visible in the liver, 7 lesions are visible in the right lung, and 6 lesions are visible in 
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Figure 51. Plots depicting the correspondence between measured sphere data (colored x’s) and ideal curves (black 
lines) for embedded spheres in the lung (A) and liver (B). Data shown are for the 10-mm spheres from the 15 mCi 
dose dataset. Also shown are the measured blood curve (red), background lung curve (sky blue), and background liver curve (olive 
green). 
 
Bias and % SD results for flux (Ki) and delivery (K1) are shown in Figure 52-Figure 54. Results are 
shown for 6- and 10-mm spheres embedded in the liver and lung at low, medium, and high flux 
as a function of emulated activity. Because a subset of lesions and the left ventricular blood pool, 
the source of the blood input function, were located in the axial range of the PennPET Explorer’s 
data readout inactive regions, single ring analyses could not be done. However, to compare results 
with a single ring scanner, one can compare PennPET Explorer results to values at one-third the 
emulated dose, since the sensitivity of a clinical scanner (23-cm length) at any axial location is 
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Figure 52. Bias (A) and % SD (B) results quantifying flux (KFDG) using Patlak graphical analysis as measured from the 
FDG PennPET Explorer emulation for the 6-mm sphere (medium blue) and the 10-mm sphere (dark blue). Results are 
shown for the low, medium, and high (left to right) flux spheres for the lung (top) and liver (bottom). Note the y-axis 
for the liver plots of % SD has a maximum of 80% as opposed to 40% for all other % SD plots. 
 
Results quantifying bias and % SD of flux using Patlak graphical modeling are shown in Figure 52. 
Results show bias is close to zero and stable until the lowest doses, while % SD for the 6-mm 
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sphere is higher than that of the 10-mm sphere, as expected. Bias and precision both improve (i.e. 
lower bias and % SD) as the dose increases, showing similar trends across all spheres. 
 
 
Figure 53. Bias (A) and % SD (B) results quantifying flux (KFDG) using a two-compartment fit as measured from the 
FDG PennPET Explorer emulation for the 6-mm sphere (lighter blue) and the 10-mm sphere (dark blue). Results are 
shown for the low, medium, and high (left to right) flux spheres and for the lung (top) and liver (bottom). 
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Figure 54. Bias (A) and % SD (B) results quantifying delivery (K1) using a two-compartment fit as measured from the 
FDG PennPET Explorer emulation for the 6-mm sphere (medium blue) and the 10-mm sphere (dark blue). Results are 
shown for the low, medium, and high (left to right) flux spheres and for the lung (top) and liver (bottom) spheres. 
 
Figure 53 shows the bias and % SD of FDG flux estimated using a two-tissue-compartment model. 
Results show a systematic non-zero positive bias (20-25% lung, 10-15% liver) in the estimation of 
flux that is independent of dose. Precision measurements at low doses are better using a two-
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tissue-compartment model than those obtained using Patlak analysis and are largely independent 
of dose except for the lowest activities. The % SD decreases with higher flux and is greater for the 
6-mm spheres compared to the 10-mm spheres, as expected, with both Patlak and two-tissue-
compartment fit. 
Figure 54 shows the bias and % SD of the FDG delivery parameter (K1) estimated using a two-
tissue-compartment fit. K1 values show a systematic negative bias (25% lung, 25-50% liver) for the 
low and medium flux spheres that increases at lower doses. The high flux lung and liver lesions 
show biases closer to zero for all emulated doses. The % SD of K1 is low except for the 6-mm 
sphere in the lung, which had relatively high % SD at low and medium fluxes. The % SD does not 
show a systematic trend as a function of dose but does show a slight decrease for higher flux 
spheres. 
DISCUSSION 
Through a series of simulation studies, we have demonstrated improvements in the estimation of 
quantitative kinetic parameter estimation with a long AFOV scanner compared to a scanner with 
a standard (23-cm) AFOV. We then studied the performance of such a system in quantifying tracer 
kinetics using embedded lesions in a healthy patient with decreasing administered activities and 
smaller lesion size. 
The dynamic FLT simulations (Figure 48 & Figure 49) demonstrate overall better kinetic parameter 
estimation — both improved bias and precision of delivery and flux estimates — with the 70-cm 
scanner geometry compared to the 23-cm simulated scanner. Improvements were particularly 
accentuated in low flux lesions and at lower administered activities. With the 70-cm scanner, the 
bias of flux is near zero for medium and high flux lesions. The precision of flux estimation is better 
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over a wide range of emulated doses for the 70-cm scanner geometry compared to the 23-cm 
scanner geometry, with some noticeable loss of precision for doses less than 1 mCi. 
A dynamic FDG study with embedded lesions was then used to study the measured performance 
of a long AFOV scanner. Patlak graphical analysis of dynamic data (Figure 52) shows a near-zero 
bias and low % SD for all fluxes over a wide range of doses. The combination of the increased 
sensitivity afforded by the PennPET Explorer and Patlak graphical analysis allows for quantitatively 
accurate dynamic imaging with low administered activity that would be especially desirable in 
certain populations, such as patients participating in research trials that require multiple static 
and dynamic scans. Although technical constraints did not allow single-ring analysis of these 
embedded lesions, we estimate that a clinical system with a standard AFOV would need three 
times the administered activity to achieve the same quantitative accuracy as the PennPET 
Explorer, underscoring the benefits of a long AFOV scanner. 
Patlak analysis allows for quantification of flux but cannot estimate delivery of FDG (K1). K1 has 
been shown to have clinical prognostic value (e.g. K1 has been shown to be predictive for breast 
cancer response assessment [134]). As such, we also fit the FDG data using a standard two-tissue-
compartment model capable of estimating K1 in addition to flux. Results (Figure 53) show a 
systematically positive bias in flux with the two-tissue-compartment model for all spheres that 
was stable over nearly the entire range of doses, but with lower % SD compared to Patlak analysis. 
The positive bias remained when fitting using calculated weighting (Poisson weighting of the 
measured value, frame duration, and decay based on the frame mid-time) or various fixed blood 
fraction values (not shown). These results suggest that the observed bias in estimated FDG flux 
was not due to poor parameter optimization. Although the bias of flux in the liver improved when 
the blood fraction value was floated (i.e. the model was allowed to fit for the value of the blood 
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fraction), the corresponding bias of K1 values increased to 50-100%. Bias results similarly show a 
larger dynamic dose range over which patients can be imaged on long AFOV scanners compared 
to clinical scanners with one-third of the axial sensitivity. Additionally, flux estimates using Patlak 
analysis demonstrated consistently less bias than those obtained with the two-compartment 
model underscoring the robustness of this graphical method. 
The K1 estimates from the dynamic FDG study with lesion embedding fit using a two-tissue-
compartment model (Figure 54) show a negative bias for the low and medium flux spheres but 
very little bias for the high flux spheres. Because fitting K1 depends on the early portion of the 
TAC, these inaccuracies may result from noise in the lesion TAC of the 1-s time frames during the 
first few minutes. Since uptake is higher for the high flux spheres in the early time points, these 
spheres were more accurately measured, resulting in less noise and more accurate quantification 
of K1. This conclusion is further supported by noting that the K1 estimates from the FLT simulation, 
which were sampled with 5-s frames, show a bias close to zero for higher flux spheres and a 
systematic negative bias for low flux spheres, implying that coarser time sampling may be 
necessary for accurate estimation of K1. Therefore, although 1-s time frames allow us to capture 
the peak of the blood input curve, longer time frames may be necessary to accurately quantify K1 
in small, low-uptake dynamic lesions.  
This work extended the lesion embedding methodology that has previously been implemented in 
list-mode to an implementation in histo-images, which allowed for embedding of spheres that 
have uptakes both higher and lower than background. This method is similar to the original lesion 
embedding method in sinogram space but preserves the TOF information of the spheres. Contrary 
to the GATE simulations of the modified NEMA IQ phantom, where dynamic uptake of the spheres 
was inherent in the simulation, the lesion embedding study relied on this modified methodology 
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to properly embed lesions in the measured dataset. After applying a partial volume correction 
and scanner calibration factor to the reconstructed images from the lesion embedding study, 
identical to the GATE simulations, results show proper recovery of the ideal TACs (Figure 51) with 
some noise across the various lesions. Potential sources of variation for the lesion embedding 
study could stem from the larger variations in axial sensitivity (and, therefore, image noise) over 
the axial range where lesions were placed. In contrast, spheres in the simulation study were only 
placed in the central of the AFOV where the axial sensitivity is peaked (Chapter 4, Figure 35A). 
Lower emulated doses for both studies were based on uniformly subsampling list-mode data 
based on the number of counts. However, when injecting lower radiotracer doses, there are also 
count rate effects that we did not model by subsampling. Most notably, the number of random 
events detected would decrease quadratically compared to the number of true events detected, 
which decrease linearly, resulting in a higher true event fraction at lower doses [135]. This would 
generally improve image quality and quantification of kinetic parameters, so the results obtained 
in this study are a conservative measure of the improvement obtained in actual dynamic studies. 
Only tracers fit to a two-tissue-compartment model were studied in this work. While results from 
fitting using a single-tissue model may be similar to a two-tissue model, and results for fitting 
using the Logan graphical analysis may be similar to Patlak results, further work would be needed 
to verify the performance of these other models. This would be valuable when designing protocols 
for dynamic imaging on long AFOV scanners. 
Both studies were processed using a partial volume correction (PVC) that relied on the known size 
of the lesion that would not be available for an actual dynamic study. Our PVC correction was 
unique to this study and could not be used for dynamic human studies on the PennPET Explorer. 
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Our method depended on knowing the true contrast to background ratio of the lesion in each 
frame and the lesion size. This was necessary for our study to avoid introducing bias in the 
measurement of the TACs; however, while tumor size could be estimated from a CT, the true 
contrast of the lesion would not be known for a real dynamic study. An alternative method that 
could be employed for measured dynamic data is to use the measured contrast of the sphere and 
the CRC for a lesion of that size to estimate the true sphere contrast. However, that method 
greatly increases noise in the measured TACs and the PVC we used was designed to avoid 
compounding noise from measurement. 
CONCLUSION 
The improved sensitivity of a long AFOV scanner permits improvement of accurately modeling the 
kinetic parameters across a range of injected activities. This leads to reduced bias and higher 
precision, depending on lesion size and uptake. In addition, we demonstrated the ability to lower 
the dose on these scanners without compromising bias or precision, which will reduce patient 
exposure for dynamic studies that are often experimental research protocols or ease production 
requirements for less commonly used radiopharmaceuticals for both research and clinical use. 
Since many research tracers are injected at around 5 mCi (185 MBq) due to organ dose limitations 
or radiopharmaceutical production limits, imaging these tracers on a long AFOV scanner will 
particularly benefit quantification of kinetic parameters for research studies. Finally, these results 
are also directly applicable to AFOVs longer than 70-cm since the axial sensitivity gain in an 
attenuating medium is similar for a 70-cm scanner and longer AFOV scanners. This would allow 
for accurate kinetic parameter estimation of dynamic studies with multiple lesions in organs 
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CHAPTER 6. DYNAMIC MODELING OF FLUOROGLUTAMINE AND DUAL-TRACER MODELING 
ABSTRACT 
Dual-tracer imaging involving serial injections of dynamic tracers in the same imaging session can 
be used to quantify information about oncologic tumors using two complementary tracers. 
Implementation of dual-tracer imaging may be possible on long AFOV systems due to the 
increased sensitivity of such scanners, which we have shown to be capable of low dose imaging 
with accurate quantification of kinetic parameters in Chapter 5. We propose injecting a lower 
dose of fluoroglutamine (FGln) followed by a higher dose of FDG. FGln is a volume-of-distribution 
tracer that measures the glutamine pool size. The combination of FGln and FDG is of special 
interest since triple-negative breast cancer (TNBC) tumors tend to use glutamine as an energy 
source, in addition to glucose. In an effort to determine which model best fit data collected and 
the known biology of FGln, dynamic mouse FGln data were analyzed using a single-compartment 
model, two-compartment model with trapping (k4=0), the Logan graphical analysis, and the Patlak 
graphical analysis. The two graphical approaches offer insight into the behavior of the tumors. A 
well fit Logan plot indicates a reversible tracer, while a well fit Patlak plot indicates a tracer that 
is trapped in the second compartment. Poisson noise was then added in statistical simulations to 
fit representative mouse curves to study the accuracy and precision of estimating VD using one-
compartment and two-compartment models. Results showed good fits from the one-
compartment model, two-compartment model with trapping (k4=0), and Logan plot, but a poor 
fit of the Patlak model, implying that the tracer is not trapped. Additionally, the trapped 
component of the tracer in the two-compartment model gave results that were inconsistent with 
the expected values from other testing, suggesting the one-compartment reversible model is best 
for this tracer. Poisson noise studies showed that VD has low bias and better precision estimated 
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using a one-compartment model, with a % standard deviation (SD) of 11.9 %, versus a two-
compartment model with trapping (k4=0), with a % SD of 32.9 %. A dual tracer study was designed 
where lesions were dynamically embedded as described in Chapter 5 to emulate an injection of 
FGln followed by an injection of FDG. The kinetic parameters from the mice were used to design 
the FGln portion of the dual-tracer study, while FDG literature data described in Chapter 5 was 
used to design the FDG portion of the study. Preliminary results from studying various times 
between serial injections of FGln and FDG show that 30-60 min between injections results in less 
noisy TACs from which VD may be accurately quantified. We have not yet been able to fit dual 
tracer TACs since both tracers need to be fit simultaneously and account for residual activity from 
the first tracer into the second. When implemented, we plan to quantify VD for FGln and flux for 
FDG and use the accuracy and precision of these metrics to guide decisions about both the interval 
between injections and dose of the FGln study to design an imaging protocol with these tracers 
for a long AFOV system. 
INTRODUCTION 
Dual tracer imaging has the potential to be a valuable method to gather complementary dynamic 
information on cancerous lesions in a single imaging session so that the physiologic state of the 
patient remains constant. Dual-tracer imaging of two tracers imaged simultaneously has been 
previously studied in single photon emission computed tomography (SPECT) using radioisotopes 
with different energies and in PET using isotopes with different half-lives. We propose dual tracer 
imaging of two 18F-labeled tracers: fluoroglutamine (FGln) and FDG, where FGln is injected at a 
lower dose and is expected to wash out, as opposed to tracers like FDG that trap radiotracer,  
followed by a higher dose injection of FDG to minimize the effects of residual radioactivity from 
the first tracer. Both tracers are dynamically imaged so both static metrics like SUV and dynamic 
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metrics like volume of distribution can be used to characterize the cancerous lesions. We propose 
to perform dual tracer imaging with FGln and FDG since a growing body of research suggests that 
glutaminolysis as measured by FGln, the conversion of glutamine to glutamate via the glutaminase 
enzyme, offers complementary information about the cellular energy source when compared 
with glycolysis, as measured by FDG (Figure 55) [136].   
In addition to glucose, cancers may consume glutamine, the most abundant amino acid in plasma 
[137], as an energy source. While glutamine is used for a variety of normal biologic processes [82, 
138-140],   numerous cancer types have been shown to use glutamine as an energy source via the 
tricarboxylic acid (TCA) cycle [139]. Cancer reliance on glutamine is a vulnerability that has been 
exploited for therapeutic gain, and the first step in glutaminolysis is a prime target to inhibit the 
entire pathway [141-143]. The glutaminase inhibitor CB-839 (Calithera Biosciences) has 
demonstrated antiproliferative activity in cell lines with accelerated glutamine metabolism, 
including triple-negative breast cancer (TNBC) cell lines. Glutamine pool size at baseline is 
inversely related to glutaminase activity [81], and after treatment with a glutaminase inhibitor, 
there was an increase in intracellular glutamine levels and a decrease in glutamate. Compared to 
estrogen-receptor positive (ER+) cell lines, TNBC cell lines, with generally increased glutaminase 
activity, were more susceptible to treatment with a glutaminase inhibitor [143].  
The complementary nature of FDG and FGln as energy sources for cancer cells is highlighted in 
Figure 55. While the use of FDG is based on cancer cells increasing the flux of glucose through 
glycolysis and preferring the pyruvate to lactate shunt for energy, cells can also upregulate use of 
glutamine through glutaminolysis to produce energy via the TCA cycle. In the same way that FDG 
measures flux of glucose utilization through hexokinase, and not the pyruvate to lactate 
conversion directly, we propose that FGln measures the pool size of glutamine in the intracellular 
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space and not the direct conversion of glutamine to glutamate, supported by the lack of 
metabolism of glutamine in tumor cells. To that end, we hypothesize that FGln can be modeled 
using a single-compartment model to measure pool size, as opposed to modeling FGln using a 
two-compartment model to measure flux based on known biology of the tracer.  
The PET radiotracer [18F](2S,4R)4-Fluoroglutamine (FGln) has been developed as an in vivo 
measure of tumor glutamine metabolism [144].  FGln utilizes the same cellular transporters as 
native glutamine but is minimally metabolized [81, 145, 146].  In cell uptake studies and early 
animal data, FGln generally washes out over time, suggesting reversible transport [81, 145].  These 
properties make FGln an ideal radiotracer for measuring glutamine pool size. However, the 
optimal method for PET dynamic acquisition and kinetic image analysis has not been established 
for this experimental radiotracer. 
FDG, on the other hand, has a vast amount of literature characterizing the utility of dynamic and 
static information for a variety of tumors. Dynamic studies of FDG are usually imaged for the first 
60-120 min after injection. During this time period, FDG is modeled using a two-compartment 
model with trapping (k4=0) for most organs. FDG is also well modeled using the Patlak graphical 
analysis method to quantify flux. The value of quantifying both flux and flow using FDG has been 
well established [129], and SUV, the current clinical metric of uptake, is an analogue for FDG flux 
in lesions [147, 148]. In certain tissues, specifically the liver and primary tumors arising from the 
liver, FDG is known to have a small k4 which represents the de-phosphorylation of FDG6P back 
into FDG [149]. This was discussed in more detail in Chapter 3. Using the two-compartment model 
with trapping (k4=0) along with literature of both lung lesions and colorectal cancer metastases to 
the liver, we designed a dynamic lesion embedding study of FDG in Chapter 5. 
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Figure 55. Metabolic pathways of glucose and glutamine along with their corresponding PET radiotracers FDG and 
FGln. FGln enters the cell through a transporter and a small portion may be metabolized into proteins and 
macromolecules. Glutamine enters the cell and can be metabolized into proteins and macromolecules or enter the 
mitochondria. Glutamine in the mitochondria can then be metabolized to glutamate via glutaminase (GLS). 
Glutaminolysis can be inhibited via the drug CB-839. Glutamate then enters the tricarboxylic cycle (TCA). Glucose 
enters the cell through a transporter and is then converted to pyruvate through a series of steps. In cancerous cells, 
conversion of pyruvate to lactate is preferred as an energy source. In healthy cells pyruvate is converted into acetyl 
CoA in the mitochondria and enters the TCA cycle. FDG enters the cell through a non-specific transporter and is 
converted to FDG6P via hexokinase (HK). Further metabolism of FDG does not occur due to increased specificity of 
enzymes. GLS refers to glutaminase, HK refers to hexokinase, G6P refers to glucose-6-phosphate, FDG6P refers to 
FDG-6-phosphate, a-KG is alpha-ketoglutarate, OAA is oxaloacetic acid. CB-839 is a glutaminase inhibitor. 
 
In this chapter, we first show results from modeling preclinical data of mice with both TNBC and 
ER+ tumors dynamically imaged with FGln. We model the kinetics of FGln using both graphical 
and compartmental approaches, and based on these pre-clinical data [81], we hypothesize that 
the volume of distribution (VD) of FGln is a marker of tumor glutamine pool size, which can be 
used to infer levels of tumor glutaminolysis.  Computer simulations were used to study the 
mathematical properties of the model, building a theoretical foundation for human PET imaging 
interpretation of FGln as this radiotracer moves into early clinical trials. Kinetic parameters from 
imaging mice with FGln were then used to design a dual-tracer lesion embedding study using 
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of kinetic parameter estimation as a function of injected dose and time between serial injections 
of FGln followed by FDG, with the goal of lowering injected dose and shortening the time between 
injections without compromising kinetic parameter estimation. 
METHODS 
MOUSE MODELS 
Prior work done at the University of Pennsylvania with collaborators on this project established 
human breast cancer xenografts in mice as previously described [81].  Briefly, xenografts from 
HCC1806 (triple-negative breast cancer cell line) and MCF-7 (receptor-positive breast cancer cell 
line) were implanted in mice. Six HCC1806 xenografts and six MCF-7 xenografts were analyzed.  In 
each subtype, 3 mice were treated with CB-839, a glutaminase inhibitor supplied by Calithera 
Biosciences (South San Francisco, California, USA), and 3 mice were treated with vehicle solution.  
Two mice were scanned at baseline, then after vehicle treatment, and subsequently treated with 
CB-839 and scanned. The initial pre-treatment scan was treated as the baseline for the post-
treatment scan for these mice. 
FGln PET Studies 
All mice were dynamically imaged before and after treatment on a dedicated small animal PET 
scanner (A-PET [150]). A-PET is a completely three-dimensional scanner with a 2 mm x 2 mm x 10 
mm lutetium yttrium orthosilicate (LYSO) crystals with 2.3-mm pitch.  The transverse spatial 
resolution measures 2.3 mm and axial spatial resolution measures 2.4 mm. The entire mouse was 
fit in the scanner with a 19.7 cm diameter and a length of 11.6 cm. A 3-D row-action maximum 
likelihood algorithm (3D RAMLA) was used for reconstruction with 1 mm3 image voxels. Images 
were decay corrected; scatter and attenuation correction were not used, noting the relatively 
small size of a mouse.   
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Dynamic imaging was obtained for all scans; the same imaging protocol was used for all mice. PET 
imaging was initiated immediately prior to FGln injection. FGln (300–350 µCi) was injected into 
the tail vein.  The first ten minutes of dynamic imaging were acquired in list mode.  For these 
studies, the following sequential frame durations were used (10 seconds x 6 frames, 60 second x 
9 frames).  Non-list mode PET data was collected for the remaining 50 minutes of scanning in 
10x300 s frames. 
FGln Imaging Analysis 
MIM version 6.7.10 was used to view PET images and find the centers of a spherical VOI (volume 
= 16 mm3) that maximized the mean of the VOI within a given search area. The centers of a box 
shaped VOI (volume = 8 mm3) were similarly placed and used for the image derived input function. 
The coordinates of the center of each VOI found in MIM were used in Matlab to draw the VOIs, 
accounting for partial voxel coverage of the VOI, and TAC curves were constructed from mean 
values in the VOI.  TACs were corrected for frame duration.  Tumor-to-blood ratios were also 
calculated for the final imaging frame using the same VOIs described above.   
Quantitative Analysis   
Tumor and blood time activity curves derived above were input into PMOD Version 3.7 (PMOD 
Technologies, LLC, Zurich, Switzerland).  For compartmental modeling, a two-compartment model 
with irreversible trapping (k4 = 0) with a single blood input was used (Chapter 2, Figure 4B).  Here, 
k3 represents the rate constant of incorporation of tissue glutamine into macromolecules. Note 
that FGln is minimally metabolized to FGlutamate  [146], and only a small fraction of FGln is 
incorporated into macromolecules [81]. The inclusion of k3 to account for this minor effect was 
examined mathematically in this work.  The volume of distribution of the reversible compartment 
of the radiotracer (tissue glutamine) in a two-compartment model equals 𝑉< = 	𝐾"/(𝑘! +
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𝑘8)	and equals 𝑉< 	= 	𝐾"/𝑘! for a single-compartment model (i.e setting k3 = 0). Blood fraction 
was fixed at 5% for these models and not estimated. A blood fraction of 5% is within the range of 
estimated values from a prior mouse xenograft studies [151] and similar to the 4% blood fraction 
used in prior studies of FDG in locally advanced breast cancer in humans [152]. PMOD was also 
used for graphical analysis of data using Patlak and Logan analyses, where the slope of the fit for 
the Logan analysis is equal to the VD.   
Adding Poisson noise to simulations 
A simulation was designed to assess the bias and precision of kinetic parameter estimation, 
namely VD, using a one-compartment reversible model and two compartment irreversible model. 
The mean and standard deviation of all kinetic parameters from the imaged mice were input into 
STELLA 1.9.1 (isee systems, Lebanon, NH) along with the fit blood curve from a single mouse, to 
generate 250 TACs that spanned the range of kinetic parameters seen in the mice, for a 1-
compartment model and a 2-compartment model with trapping. For each of the 250 TACs from 
STELLA, delay, frame duration, and decay were then applied to the tumor TAC to reflect counts 
collected in the tumor. Poisson noise was then independently added to each datapoint to 
generate 100 noise realizations of each curve, and all data were fit in PMOD. The mean and 
standard deviation across the 100 noise realizations were calculated for each of the 250 TACs and 
the true kinetic parameter and the estimated parameters were then plotted. 
DUAL-TRACER LESION EMBEDDING STUDY 
The data from imaging mice with FGln were then used to design a dual-tracer study using dynamic 
human subject imaging data from the 70-cm PennPET Explorer prototype. The methodology of 
dynamic lesion embedding from Chapter 5 was extended to a multi tracer study where the first 
injected tracer was FGln and the second injected tracer was FDG. Three emulated tracer doses 
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and four scan durations were studied for FGln: 1, 3, and 6 mCi injected dose and 30, 45, and 60 
min scan durations. The current human FGln imaging protocol at the University of Pennsylvania 
has injected FGln doses of range of 5 - 6.5 mCi. Since results from Chapter 5 showed good 
quantitation of kinetic parameters at doses as low as 1-2.5 mCi, we chose to design the FGln study 
to emulate a 1-3 mCi injected dose. The FGln injection was followed by a 15 mCi FDG injection 
with imaging for 60 min. Residual activity from the FGln study was modeled in the data. Based on 
mouse TACs in Figure 58, TACs appear to have reached steady state by 30-45 min, so the 30-45 
min scan duration may be sufficient to estimate VD. It is important to note that the scan durations 
of FGln also reflect the interval between injections, which in turn affects the total time that the 
subject is being scanned. Having a longer interval between injections results in more FGln TAC 
data points, with potentially better estimation of FGln kinetic parameters, and less residual 
activity from the FGln in the FDG study. 
The kinetic parameters used for lesion embedding are shown in Table XV, and representative TACs 
are shown for a medium flux lesion in Figure 56. The left ventricular blood pool was measured 
from subject #7 and fit using a tri-exponential mode. Since dynamic data of subject #7 were only 
acquired for 60 minutes, the tri-exponential coefficients from the fit were used to calculate the 
blood curve out to two hours. This ideal blood curve was then input into STELLA to generate two-
hour-long ideal TACs using the FGln kinetic parameters and a one-compartment model. The ideal 
TACs for FDG are the same as in Chapter 5 and were generated using the first hour of the blood 
curve and kinetic parameters input into a two-compartment model with trapping (k4=0) in STELLA. 
Total lesion and total blood curves were calculated by adding individual lesion and blood curves 
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Table XV. Kinetic parameters for FDG and FGln used to create true TACs for the dual-tracer study 
  Fluorodeoxyglucose (FDG)   Fluoroglutamine (FGln) 
  Low Flux Med Flux High Flux   Low VD Med VD High VD 
VB 0.170 0.170 0.170  VB 0.100 0.100 0.100 
K1 0.100 0.178 0.133  K1 0.088 0.100 0.121 
k2 0.219 0.550 0.044  k2 0.087 0.070 0.059 
k3 0.074 0.250 0.070      
k4 0 0 0      
KFDG 0.0253 0.0556 0.0817  VD 1.0115 1.4286 2.0508 
 
 
Figure 56. TACs for the dual tracer study with 3 mCi injections of FGln for medium flux lesions. TACs are shown for 
both a 30 min interval between injections and a 45 min interval between injections. 
 
Dynamic FDG human subject data from imaging subject #7 on the 70-cm PennPET Explorer 
prototype were used as the background dataset for both the dynamic FGln and dynamic FDG 
portions of the dual tracer study, since we were unable to acquire dynamic FGln data on the 
PennPET Explorer due to research restrictions. However, dynamic FGln and static FDG images 
have been acquired in the same patient with ER+ breast cancer and images in Figure 57 show 
similar uptake in normal tissues for both tracers, so the dynamic FDG study from the PennPET 
Explorer is a suitable analogue for dynamic FGln data, which will be acquired on the PennPET 
Explorer once operational in our clinical space. Additionally, the behavior of the lesions modeled 
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is based on FGln mice data and we are only interested in characterizing the embedded lesions, 
not the background. Ten-mm spheres were embedded in 16 lung locations using the total lesion 
TAC to calculate the number of events to embed. The methodology of lesion embedding using 
histo-images was described in Chapter 5. For frames before the FDG injection, the methodology 
is identical to that employed in Chapter 5. For frames after the FDG injection, residual data in the 
background is modeled by scaling the final frame from the FGln injection for scan duration, 
applying radioactive decay, and adding the resulting histo-image to the sphere and background 
histo-images. Data were reconstructed using DIRECT into 2-mm3 images. Framing of data varied 
depending on the time between injections. Data from the FGln injection were framed into 64, 67, 
and 70 frames for scan durations of 30, 45, 60 min, respectively. The first 58 frames (20x1s, 
10x2.5s, 7x5s, 7x10s, 9x30s, 5x1m) were similar across all four FGln datasets. The final frames for 
the 30, 45, and 60 min dataset were 6x3m, 6x3m & 3x5m, and 6x3m & 6x5m. Data from the FDG 
injection were framed into 70 frames (20x1s, 10x2.5s, 7x5s, 7x10s, 9x30s, 5x1m, 6x3m, 6x5m), as 
described in Chapter 5.  
 
Figure 57. Coronal and axial slices of a patient with ER+ breast cancer imaged with FGln (left) and FDG (right). 
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VOIs with diameters equal to the embedded sphere size were drawn over the spheres in each 
frame, and resulting TACs were corrected for scan duration, radioactive decay, and partial volume 
errors, as described in more detail in Chapter 5. TACs will then be fit in PMOD. 
RESULTS 
MOUSE MODELS 
The results from the mouse study described below were used to model FGln in the subsequent 
dual-tracer lesion embedding study. Specifically, the range of kinetic parameters from the mice 
data were used to create representative FGln TACs. 
Blood and Tissue Time Activity Curves 
Representative blood and tissue time activity curves are shown in Figure 58. Uptake of the FGln 
was as expected based on prior mouse studies of tumor extracts and with FGln PET evaluating 
tumor-to-blood ratios [81, 143]. At baseline, TNBC xenografts (Figure 58A), with inherently high 
glutaminase activity, demonstrate low FGln uptake compared to an ER+ xenograft (Figure 58C) 
with inherently low glutaminase activity.  Upon glutaminase inhibition with CB-839, there is 
increased radiotracer uptake in the TNBC tumor (Figure 58B) reflecting an increase in glutamine 
pool size that is expected with the inhibition of glutaminolysis.  In the ER+ tumor xenograft (Figure 
58D), only a minimal increase in radiotracer uptake was observed after glutaminase inhibition, 
reflecting known low glutaminase activity in this breast cancer subtype. 
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Figure 58.  Static images of TNBC (A, B) and ER+ (C, D) tumor xenografts and the response to glutaminase inhibition 
(post-CB-839 images in the right-hand column).  Tumor and blood time activity curves demonstrate adequate 
temporal sampling of radiotracer uptake over time [153]. 
 
Compartmental Kinetic Analysis 
The two representative mice with typical time activity curves shown above in Figure 58 were then 
selected for mathematical investigation of radiotracer uptake.  Both a single-compartment and a 
two-compartment model with trapping were investigated. The one-compartment fit is shown in 
Figure 59A,C  and the two-compartment fit is shown Figure 59B,D.  Dashed lines in the two-
compartment model demonstrate the contribution from each compartment to the overall model 
curve. 
The overall model curve for the one- and two-compartment models fit the data well.  The single-
compartment model for the ER+ tumor underestimates FGln uptake at later time points owing to 
the inability to retain tracer in a non-reversible compartment.  The two-compartment model 
estimates k3 at 0 min-1 for the TNBC mouse and 0.006 min-1 for the ER+ mouse data.  For the ER+ 
two-compartment model, 27% of the total radioactivity is estimated to be contained in the 
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TNBC mouse has no contribution from the trapped compartment.  This estimate is inconsistent 
with the 10% ± 4% of radiotracer incorporated into the pellet versus supernatant of tumor 
extracts in prior work from our group [81].  Moreover, increased counts in the irreversible 
compartment in the ER+ tumor compared to the TNBC tumor is inconsistent with the known level 
of glutamine metabolism in these tumors if the irreversible compartment is thought to represent 
downstream glutamine metabolites.  These results suggest that k3 is poorly estimated and the 
resultant model is not biologically reasonable based upon the xenograft tissue analysis.  The 
relatively low values of k3 also suggest that such a term could be omitted. 
 
Figure 59. Single-compartment model fit (A, C) and two-compartment model fit (B, D) of the same representative 
time-activity curves for the ER+ and TNBC mice prior to treatment. The two-compartment fit separately shows the 
time course of the individual compartments [153]. 
 

















TNBC Mouse: 2-Compartment fit

















TNBC Mouse: 1-Compartment fit




















ER+ Mouse: 1-Compartment fit


































171   
The models were then evaluated using Akaike information criterion (AIC). The AIC for the TNBC 
mouse data fit using a single-compartment model was 60.9, more favorable than the AIC of a two-
compartment model of 63.5; the penalty of fitting an extra term in the two-compartment model 
more than offset the improved goodness of fit by the two-compartment model.  The AIC for the 
ER+ tumor data fit using a single- and two-compartment model were nearly equal: 34.4 and 33.8, 
respectively, noting the errors in this model described above. The benefits of omitting the second 
compartment are further supported by examining the accuracy and precision estimates of 
estimating k3 as described below. 
 
Figure 60. (A) Logan graphical analysis and (B) Patlak graphical analysis of the same representative time-activity 
curves for the ER+ and TNBC mice prior to treatment [153]. 
 
Graphical Analysis 
The same data from the TNBC mice were analyzed using Patlak and Logan graphical approaches 
(Figure 60). Results from the ER+ mouse are not depicted but show similar results. The Logan plots 
demonstrated late linearity, consistent with minimal radiotracer trapping and largely reversible 
tracer exchange between the tumor and the blood. R2 values for the fits of the TNBC and ER+ mice 
data were 0.997 and 0.999, respectively, reflecting good quality linear fits.  In contrast, the Patlak 
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plot, where all data plotted should be roughly linear (see Chapter 2, Figure 4C), demonstrates a 
poor fit and refutes a component of significant radiotracer trapping.  Graphical analyses support 
the use of the VD as calculated by the slope of the best fit line in the Logan graphical analysis as a 
measure of glutamine pool size. The use of Logan analysis is corroborated by the suitable fits of 
the single-compartment model.  
Mathematical Simulations 
Simulations to analyze the accuracy and precision of VD estimation were then extended to 
simulate time activity curves across the range of kinetic parameter estimates from all tumors. 
Figure 61 shows estimation of VD versus the true VD value from the ideal Stella curve. Error bars 
reflect the standard deviation over 100 noise realizations generated based on the ideal Stella 
curve and fit using PMOD. The black line is the line of identity. Results clearly demonstrate more 
accurate and precise recovery of the true VD across the range of kinetic parameters seen in all 
studied mice.  The standard deviation of VD using a one-compartment model is less than that of 
the two-compartment model representing better precision.  Improved accuracy of the one 
compartment model is demonstrated with a smaller deviation of mean VD recovered for each 
noise realization from the line of identity compared to the two-compartment model.  The average 
% SD, calculated as %	𝑆𝐷 = 100 ∗ 𝑠/?̅? for each data point, where 𝑠 is the standard deviation and 
?̅? is the mean, is 11.9% for the one-compartment model and 32.9% for the two-compartment 
model with trapping.  Poor precision and accuracy of the two-compartment model is particularly 
apparent for VD. This further supports modeling of FGln using a single-compartment model. 
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Figure 61. Comparison of true vs estimated VD values for a one-compartment (left) and a two-compartment model 
with trapping (right) [153]. 
 
Comparison of Volume of Distribution Obtained by Kinetic Modeling Approaches and Tumor-
to-Blood Ratios from Static Images 
VD estimates from the 26 dynamic FGln imaging datasets of mice (10 mice imaged before and 
after treatment and 2 mice imaged before treatment, after Vehicle treatment, and after CB839 
treatment) were compared with tumor-to-blood ratios, a surrogate of volume of distribution that 
can be obtained from static images (Figure 62). Tumor-to-blood (T/B) ratios were obtained from 
the final imaging time point, well after the slope of the time activity curve had stabilized.  Strong 
correlations were seen between T/B ratios, VD as estimated by Logan plot, and VD as estimated by 
a single-compartment model. Strong correlations were not seen when VD of the two-
compartment model was compared to VD estimated by a single-compartment model, Logan plot, 
or T/B ratios, underscoring the inaccuracy of using a two-compartment model to estimate the 
underlying biology of FGln. 
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Figure 62. Comparison of volume of distribution of FGln by compartmental and graphical analysis, as well as tumor-
to-blood ratios [153]. 
 
DYNAMIC LESION EMBEDDING STUDY 
Figure 63 shows images from the final frames of the FGln portions of the dual-tracer study along 
with an early and late FDG frame. The early FDG frame shows residual activity from the FGln 
injection. Corresponding measured TACs for the spheres are shown in Figure 64. Data are only 
shown for the 3 min FGln injection and medium flux embedded spheres. Measured sphere values 
are slightly lower than the true sphere TACs for both the FDG and FGln portions of the study. The 
30 min and 45 min interval may be sufficient to accurately and precisely quantify VD, since TACs 
show little noise at later time points. While fit VD values can be compared to true values, they can 
also be compared to the VD values from fitting data with 60 min between injections, since 60 min 
data were used to validate the mouse model. This work is currently in progress, and we are 
working on a means to fit dual tracer data using existing tools. 
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Figure 63. Coronal 2-mm slices showing the last frames for the FGln injection with 30 min, 45 min, and 60 min (top, 
left to right) between injections and for an early and late FDG frame (bottom, left to right). The early frame (shown 
in maximum intensity projection, MIP) shows residual activity from the FGln injection. Data are shown for medium 
flux embedded spheres and a 3 mCi injection of FGln. 
  
 
Figure 64. TACs with measured sphere contrasts for the dataset with (A) 30 min and (B) 45 min interval between 
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DISCUSSION 
This chapter examined the kinetics of a novel PET imaging agent [18F](2S,4R)4-Fluoroglutamine 
(FGln) in mouse models of human breast cancer to provide a theoretical framework for PET image 
analysis and used results from that work to design a dual tracer study with serial injections of FGln 
and FDG to garner complementary information on energy sources used by cancer cells and the 
optimal treatment targets. Mouse studies were used in lieu of human studies, which are currently 
underway at the University of Pennsylvania. Our model of FGln and the range of kinetic 
parameters will be updated once analysis of the human patient study is complete. Preliminary 
analysis of early human patient studies shows good agreement of kinetic parameters with mice 
data. The overall goal of the dual tracer study was to minimize the time between injections of 
FGln and FDG and FGln dose, while accurately measuring kinetic parameters of interest, namely 
volume of distribution for FGln and flux for FDG. 
Previous work has related the uptake of FGln to tumor cellular glutamine pool size and 
demonstrated a change in glutamine pool size after targeted glutaminase inhibition [81]. The 
distinct kinetics of FGln necessitate specific model and image analysis approaches distinct from 
those used for other cancer tracers such as FDG. We first demonstrated the reconstructed images 
recapitulated the previously described patterns of uptake—baseline FGln uptake was inversely 
related to glutaminase activity and FGln uptake increased in a highly glutaminolytic tumor after 
glutaminase inhibition [81].  Typical mouse time activity curves were then selected to model the 
radiotracer behavior and mathematically test the model for plausibility. 
In two representative tumors, both a one-compartment and a two-compartment model with 
irreversible trapping modeled the representative time activity curves well.  The AIC favored a 
single compartment model for the TNBC tumor; for the ER+ tumor, the AIC values were nearly 
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equal.  The two-compartment model, though, greatly overestimated the percentage of 
radiotracer incorporated into macromolecules in an ER+ mouse with marked FGln uptake when 
compared with prior data [81] suggesting that the k3 estimation is inaccurate.   Furthermore, the 
TNBC model, with inherently high glutaminase expression, had only negligible trapping.  This 
discordance between known glutamine metabolism and irreversible uptake suggests that the 
trapping compartment does not represent metabolism of FGln to FGlutamate, concordant with 
minimal metabolism of FGln [81, 145, 146], and in keeping with the model proposed here.   
Graphical analysis supported the adequacy of the single-compartment model. The Logan plot 
demonstrated late linearity, consistent with minimal radiotracer trapping and reversible exchange 
between tumor and blood.  This result is concordant with a recent study in mouse glioma 
xenografts [154].  Of note the Logan plot does not discriminate between the number of 
compartments in a model, as long as each compartment is reversible.  As such, late linearity of a 
Logan plot would also support a two-compartment model with reversibility of all the 
compartments (that is a k4 ¹ 0) as recently proposed [155]. Such a compartment model, though, 
is not biologically plausible since incorporation of FGln into macromolecules and then 
disassociation in the one-hour imaging interval is highly unlikely.  Consistent with the observation 
of largely reversible uptake, the Patlak plot demonstrated a poor fit. These approaches suggest 
nearly entirely reversible model for FGln.   
Mathematical simulations provided additional support for omitting k3 from the final model.  When 
noise typical of a PET scan was added to idealized TACs constructed from known kinetic 
parameters, a single-compartment model was able to better recover the true VD—both the 
precision and accuracy of the recovery suffered with the two-compartment model. Additionally, 
correlation plots for VD for all tumors studied further support a single-compartment model. 
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Relatively poor correlation was seen when the VD of the two-compartment model was plotted 
against VD as estimated by both the single-compartment model and Logan analysis. These results 
underscore the inability of the two-compartment model to appropriately place the contribution 
of FGln to the reversible and irreversible compartment, with associated deviations from reference 
standard tissue studies.  This inability to estimate kinetic parameters translates to errors in VD 
estimates, our parameter of biologic interest. 
The strong correlation between tumor-to-blood ratios and VD of a single-compartment model or 
a Logan plot suggests that a static image may capture relevant glutamine biology, possibly 
eliminating the need for dynamic imaging.  An abridged protocol consisting only of a single late 
static image, once validated in humans, may allow direct translation to the clinic.  Such a protocol 
would be akin to commonly used radiotracers in the clinic, including FDG.  Furthermore, tumor-
to-blood ratios were previously shown to correlate with glutamine pool size by magnetic 
resonance spectroscopy (MRS) [81], indirectly supporting volume of distribution measures as a 
glutamine pool size. 
There are several limitations to the broad application of this small animal imaging study.  
Subcutaneously implanted tumors may have different intrinsic biologic properties than human 
breast tumors, precluding direct translation.  For example, cellularity is not a factor in mice 
xenografts, but may complicate the interpretation of VD in humans, possibly necessitating a 
normalization factor.  Mouse imaging estimates of TACs are less accurate than human TACs owing, 
in part, to differences in scale, especially for estimates of the blood input function.  An image-
derived blood input function was used without metabolite correction. Minimal metabolism of 
FGln in the blood supports such an input function [81], although others have used corrected input 
functions [154, 155].  We do not expect this difference to change our conclusions, but human 
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dynamic studies will refine our model.  Lastly, we have a limited reference standard of glutamine 
pool size and glutaminase activity [81, 143].  None of the tumors reported here had direct 
measurements of glutamine pool size to directly correlate PET measures to a reference standard.  
An ongoing human trial in patients with breast cancer, will include such tissue correlation.  Lastly, 
the identity of the macromolecule(s) that FGln is incorporated into is also unknown at this point, 
although we suspect this is in the form of protein. 
The data from the mouse model of FGln were then used to design a dual tracer study where FGln 
was first injected at a lower dose and imaged for an abbreviated time before injecting a standard 
FDG dose and imaging for the standard 60-min duration. Early results show that uptake in the 
spheres is close to the true values and next steps include fitting data to a multi-tracer model in 
PMOD. The accuracy and precision of kinetic parameters, namely VD for FGln and flux for FDG, will 
inform how best to implement dual tracer imaging on the PennPET Explorer. Additionally, work 
in this chapter showed that FGln uptake at a later time point is strongly correlated with VD of FGln, 
and that this implies that FGln can be translated to static clinical imaging. Our dual-tracer study 
can similarly identify two time points at which FDG and FGln can be sequentially injected and 
imaged with minimal wait time and minimal dose for the patient, while still measuring both 
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 
This work quantified and characterized the benefits of long AFOV imaging in both clinical and 
research contexts using both simulations and measurements on the PennPET Explorer. First, 
NEMA performance standards were analyzed on simulations of the 16.4-cm Philips Vereos, 23-cm 
ring-segment, and 70-cm PennPET Explorer, followed by select NEMA measurements on the 70-
cm PennPET Explorer prototype system. The 16.4-cm Philips Vereos and 23-cm ring-segment both 
represent standard AFOV systems, while the 70-cm PennPET Explorer simulation and prototype 
system represent long AFOV scanners. We then designed studies to represent clinical and 
research imaging on the PennPET Explorer and other long AFOV systems. A lesion detectability 
study was designed to reflect the clinical task performed by radiologists when reading oncologic 
staging and follow-up scans. We used this study to interrogate how the non-uniform axial 
sensitivity of single bed position imaging, which we expect to be commonplace when imaging on 
long AFOV scanners, effects the lesion detectability of the system at different axial locations. 
Dynamic studies were designed to represent potential research studies that would be 
advantageous to implement on long AFOV systems as opposed to standard AFOV systems. 
Dynamic simulation was used to study the direct benefits of the 70-cm PennPET Explorer to the 
23-cm ring-segment and measurement was used to study how the dose lowering capabilities of 
the 70-cm PennPET Explorer prototype. Finally, a dual tracer study was designed to push the 
boundaries of the capabilities of a long AFOV system to dynamically image two complementary 
radiotracers, FGln and FDG, within a single imaging session. Together this work offers a basis of 
information to design both static and dynamic imaging protocols to image a variety of research 
and clinical tracers on long AFOV scanners. 
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The total line source sensitivity of the three simulated scanners – the 16.4-cm Philips Vereos, 23-
cm ring-segment, and 70-cm PennPET Explorer – were 5.5, 10.8, and 90.5 kcps/MBq, where the 
sensitivity gain of the 70-cm scanner is 8x compared to the 23-cm ring segment and 16x compared 
to the Philips Vereos. The total line source sensitivity of the 70-cm PennPET Explorer prototype is 
55 kcps/MBq, roughly half of the simulated sensitivity due to the data readout gaps in the scanner. 
These gains in sensitivity reflect the factor by which the dose injected into a patient or the total 
scan time of a PET acquisition can be reduced while maintaining image quality.  
The axial sensitivity profiles for simulated scanners are shown in Chapter 3, Figure 13 and the axial 
sensitivity profile for the prototype scanner is shown in Chapter 3, Figure 21. The axial sensitivity 
profile reflects the per-organ or per-lesion sensitivity gain for an organ or lesion at every axial 
location. Compared to the 23-cm ring-segment the 70-cm simulated PennPET Explorer achieves 
2.5x the sensitivity at the center of the AFOV of the scanner. The axial sensitivity profile of the 
prototype scanner is non-uniform due to data readout gaps in the scanner and the peak axial 
sensitivity at the center of the scanner is 35% less than the simulated value which doesn’t model 
the gaps. 
Spatial resolution results showed a transverse spatial resolution of 4.0 mm FWHM in simulation 
4.0 mm FWHM in measurement, which agrees with the spatial resolution of the Philips Vereos, 
showing that the prototype scanner was properly constructed and did not lead to unforeseen 
degradations in transverse axial resolution. The axial spatial resolution degradation due to axial 
parallax error was 0.5 mm FWHM and 2 mm FWTM in simulation and 0.4 mm FWHM and 1.6 mm 
FWTM in measurement, when comparing the three-ring system to a single-ring system. This 
degradation in axial resolution will result in a slight blurring of small objects such as individual 
brain regions or small lung nodules. The degradation in the axial resolution is small compared to 
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standard radial resolution degradation (usually 1-2 mm FWHM at a radius of 10-20 cm); however, 
the degradation in the FWTM does result in a corresponding decrease in measured contrast 
recovery values of hot spheres with diameters less than 13-mm in the image quality phantom.  
Count rate capabilities measured on the 70-cm PennPET Explorer prototype show linearity of the 
trues rate up to 45 kBq/cc, where the highest activity concentrations measured on the scanner 
was a bolus injection of FDG which is roughly equivalent to 35-45 kBq/cc based on singles rates 
from one ring. The deviation from linearity at 40 kBq/cc is 16 % without any deadtime correction 
considered. This wide range of count-rate capabilities means that we can image at both very low 
and very high rates on the PennPET Explorer. The NECR at 3.7 kBq/cc, the average concentration 
of an FDG human scan, and 40 kBq/cc, the concentration of a bolus study, were 327 kcps and 
1220 kcps, both of which are very high compared to current PET/CT scanners with a standard 
AFOV (e.g., 36 kcps at 3.7 kBq/cc and 151 kcps at 40 kBq/cc for the Philips Vereos).  
Lesion detectability results from Chapter 4 showed that ALROC is directly related to the axial 
sensitivity of a lesion at the corresponding axial location, and that differences in axial sensitivity 
can be used to scale results to scanners with different axial lengths and gap geometries. An ALROC 
of 0.8 can be achieved for 10-mm spheres embedding in the lung and liver of the human subject 
at scan durations of 26 s and 53 s, respectively. These scan durations are short enough to support 
future breath-hold imaging studies on clinical patients.  
An ALROC of 0.8 was not achieved for 6-mm spheres at the longest scan duration studied (180 s); 
however, based on the trendline in Chapter 4, Figure 44, one can estimate the scan duration at 
which ALROC would equal 0.8 for the 6-mm 4:1-uptake spheres in the liver. Based on that trend 
line, an ALROC of 0.8 could be achieved by increasing the scan time from 180 s to 240 s. This 
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implies that a four-minute scan on the 70-cm PennPET Explorer prototype, significantly shorter 
than the standard clinical 10-20 min scan duration, would be sufficient to visualize 6-mm lesions, 
including the 8:1-uptake lung lesions since those ALROCs are higher than the 4:1-uptake liver 
lesions.  
These results can also be extrapolated to the PennPET Explorer with additional rings. Due to 
attenuation of oblique lines-of-response (LORs) in the body, the point source sensitivity in the 
center of AFOV does not increase significantly for scanners longer than 70 cm (Chapter 2, Figure 
6C). Therefore, the advantage of the longer AFOVs is not a drastic increase in axial sensitivity, but 
a larger axial range over which this improved sensitivity is maintained. When imaging with these 
longer AFOVs, “good” detectability can thus be maintained while imaging with an additional 
reduction in scan time or dose by these same factors. Nonetheless, collecting data from the data 
readout gaps currently in the prototype scanner would lead to a 2x increase in overall sensitivity 
and a 1.9x increase in peak sensitivity. 
The dynamic FLT simulation in Chapter 5 showed lower bias of KFLT when imaging on the 70-cm 
scanner compared to the 23-cm ring-segment for low flux spheres, and estimation of K1 is slightly 
improved when imaging on the 70-cm scanner. The dynamic FDG lesion embedding study was fit 
using both a Patlak compartmental fit and a two-compartment model. Overall, results from both 
models support dynamic imaging at doses as low at 0.5 -2 mCi.  Patlak showed little to no bias in 
measurement of KFDG and low precision at low doses, while the two-compartment model results 
showed a systematic non-zero positive bias in the flux estimation and a systematic non-zero 
negative bias in the K1 estimation for low and medium flux spheres. K1 estimation of high flux 
spheres showed little to no bias. These results can be used to lower injected radioactive doses 
when imaging on long AFOV scanners to reduce patient exposure for dynamic studies that are 
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often experimental research protocols and to ease production requirements for less commonly 
used radiopharmaceuticals. The results were directly used to determine how low to lower the 
dose of the FGln injection for the dual-tracer lesion embedding studies described in Chapter 6. 
Additionally, since the axial sensitivity gain in an attenuating medium does not increase as the 
AFOV of scanners is extended past 70 cm (Chapter 2, Figure 6C), these results are also directly 
applicable to scanners longer than 70-cm. This would allow for accurate kinetic parameter 
estimation of dynamic studies with multiple lesions in organs spread throughout an even larger 
axial extent.  
Analysis of FGln mouse data in Chapter 6 showed that the one-compartment model best 
represented the biology while the two-compartment model either over- or underestimated the 
expected percentage of macromolecules based on other testing (Chapter 6, Figure 59). Poisson 
noise studies of both the one- and two-compartment models showed that VD was more accurately 
and precisely estimated using a single-compartment model (Chapter 6, Figure 61). Based on these 
conclusions, kinetic parameters from the FGln mice were used, in lieu of human data which is still 
in the process of being acquired and analyzed, to design a dual-tracer lesion embedding study 
using data from the 70-cm PennPET Explorer prototype. Measured lesion TACs from a 3 mCi 
injection of FGln followed by a 14 mCi injection of FDG are shown in Chapter 6, Figure 64 for two 
different scan durations of FGln. Resulting TACs imply that 30-60 min interval between injections 
may be sufficient to accurately quantify both VD of FGln and flux of FDG. This study is possible on 
long AFOV scanners because the increased sensitivity allows for low-dose dynamic imaging so 
FGln can be accurately quantified at a low dose, and a higher dose of FDG can be injected to 
swamp the residual FGln signal and minimize contamination from FGln when modeling FDG. 
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Based on the optimal FGln dose and timing interval between injections, we will design a protocol 
for dual tracer imaging on the 140-cm PennPET Explorer once installed in our clinical space.  
EXTENSION OF WORK TO OTHER RESEARCH 
There are a few specific examples where work done in this thesis is currently being used for 
collaborations. First, graduate student Rhea Chitalia, along with her advisor Dr. Despina Kontos, 
is using the dynamic FLT simulation from Chapter 5 to develop a machine learning algorithm that 
can separate PET data based on different time courses. She used the simulation to develop and 
hone an algorithm, called Rad-FIT, to segment the low, medium, and high flux spheres in the 
simulation (Figure 65A) and successfully applied the Rad-FIT algorithm to dynamic FDG human 
subject data (Figure 65B). Figure 65B shows a case where she successfully segmented three 
unique time courses within a breast cancer tumor that was recurrent, compared to a non-
recurrent tumor where the three segmented regions had identical time courses [156]. 
 
Figure 65. (A) Development of a segmentation algorithm using dynamic FLT simulation data from Chapter 5 showing 
representative center slice images (top) and average per-region TACs (bottom) of true segmentation labels (left) and 
segmentation results using Rad-FIT clustering (right). (B) Application of the Rad-FIT clustering algorithm to 
segmenting primary breast cancer tumors of FDG patients dynamically imaged showing axial slice images of a late 
frame (left), subregions identified using the Rad-FIT algorithm (middle) and corresponding TACs for each identified 
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Second, the XCAT phantom, which was developed to study the accuracy and precision of CRC as 
a function of scan duration in Chapter 2 and was then used for early lesion detectability studies 
in Chapter 4, is currently being used by Dr. Yusheng Li and Dr. Samuel Matej to develop an 
algorithm that can reconstruct an attenuation corrected PET image without attenuation 
information from an external source (CT-less reconstruction). This is valuable for imaging 
radiosensitive populations like pediatric patients or can avoid acquiring additional CT scans during 
longitudinal studies, where patients are imaged serially over time (Figure 66A) [157]. 
 
Figure 66. (A) Axial and coronal 2-mm slices of the XCAT phantom reconstructed using standard PET reconstruction 
with known attenuation correction (left) and reconstructed using CT-less PET reconstruction (right). (B) Axial and 
coronal 2-mm slices of the dynamic FDG human subject data reconstructed with analytic DIRECT, iterative DIRECT 
and 4D-DIRECT (left to right). Courtesy of Drs. Yusheng Li and Samuel Matej 
 
Third, Dr. Yusheng Li and Dr. Samuel Matej are using the dynamic FDG lesion embedding dataset 
from Chapter 5 to develop a 4D reconstruction algorithm that internally applies the Patlak 
graphical analysis to effectively constrain the reconstruction and outputs an image where the 
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voxel values are equal to the calculated flux. The FDG dataset with dynamically embedded lesions 
is uniquely valuable since the true flux of the lesions is known and can be used to validate the 
quantitative accuracy of the algorithm (Figure 66B). 
 
Figure 67. (A) Axial spatial resolution of point sources and (B) CRC of a 6-mm sphere as a function of axial location 
for a  GATE simulation of a 140-cm 6-ring scanner [158]. 
 
Finally, there are two ongoing projects that utilize simulations to study sparse detector 
configurations and their effect on quantitative metrics. Dr. Margaret Daube-Witherspoon used a 
GATE simulation of a 140-cm long scanner, based on simulations presented in this thesis, to study 
how large axial gaps affect the spatial resolution and contrast recovery. Results from these 
simulations show further degradation of the FWTM of the spatial resolution and the 
corresponding decrease in CRC when moving from the edge of the scanner, where the axial 
parallax is minimal, to the center of the scanner, where the axial parallax is greatest (Figure 67) 
[158]. Additionally, graduate student Maya Abi Akl and her advisor, Dr. Stefaan Vandenberghe, 
are studying how best to design a PET scanner that has gaps to minimize cost. Unlike the study 
with only large axial gaps, they have designed simulations to study a PET scanner with a 
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checkerboard pattern of detectors, where every other detector is missing in both the transverse 
and axial directions [159]. 
FUTURE DIRECTIONS 
Using dynamic datasets generated in this thesis, there are a few simple studies that are of interest 
for us to perform that are outside the scope of this thesis. The first is to complete analysis of the 
dual-tracer lesion embedding dataset to quantize the lowest dose and shortest imaging interval 
possible without compromising accuracy of kinetic parameters. The second is to use the dynamic 
FDG lesion embedding dataset created in Chapter 5, and study if flux and delivery can still be 
accurately quantified when using less than the full 60-min dynamic FDG dataset. One can 
potentially shorten the total time a patient would spend in the clinic while also quantifying 
delivery (K1) and flux of FDG in addition to estimating the 60-min SUV values. The third study is to 
complete the analysis of ultra-late time point images shown in Chapter 3. We aim to fit the TACs 
shown and quantify k4, the dephosphorylation of FDG, for various organs in the 24-hour time 
period we imaged.  
Five rings of the PennPET Explorer have currently been built in our clinical space and point source 
data have been acquired and reconstructed (Figure 68). We will be extending the scanner to six 
rings (140-cm) shortly, and work is currently underway to read out data from the final two rows 
of tiles from each ring so that there are no longer data readout gaps in the scanner. We will then 
need to extend the NEMA protocols to the 140 cm scanner. At this time, we are planning on using 
1.5-m long aluminum tubes for the sensitivity measurement, although three sleeves (instead of 
five as prescribed by NEMA) should be sufficient to extrapolate sensitivity at an attenuation of 
zero. The implementation of spatial resolution and image quality measurements will be the same, 
although spatial resolution measurements may need to be acquired at multiple axial locations. 
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There is an opportunity to extend the count rate phantom to twice its current length (70-cm to 
1.5 m) to accurately reflect the count rate performance of imaging an adult human patient, who 
is likely to fill the AFOV of the scanner. Because we measured the normalization for the 70-cm 
PennPET Explorer prototype using a rotating radioactive line source in a light-weight carbon fiber 
tube, we will simply extend the length of the tube to 1.5 m to fully cover the axial extent of the 
six-ring 140-cm scanner. Measuring uniformity of the scanner is slightly more challenging, since 
we used a 1.2-m water-filled pipe phantom to measure uniformity on the 70-cm PennPET Explorer 
prototype, and we experienced difficulty in uniformly mixing such a large volume of water. While 
imaging a large volume pipe phantom is not outside the realm of possibility, more practical 
options include either imaging a small 20 cm diameter x 30 cm long cylindrical phantom in five 
positions throughout the scanner or imaging five such cylinders placed back to back to assess 
uniformity of the 140-cm PennPET Explorer. 
 
Figure 68. (A) Image of the 5-ring PennPET Explorer and attached CT scanner. (B) MIP coronal image of nine point-
sources imaged on the 5-ring PennPET Explorer. Point sources are 12 cm apart and the full axial length of the scanner 
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Prior to imaging clinical patients on the PennPET Explorer, we will need to establish quantitative 
calibrations through standard phantom testing (e.g. testing according to the American College of 
Radiology) beyond NEMA performance testing. Once we transition to imaging clinical patients on 
the PennPET Explorer, we are interested in implementing a number of studies that build on prior 
work done. These include standard FDG imaging of adult and pediatric patients, imaging clinical 
radiotracers with short half-lives like 68Ga-DOTATATE or 68Ga-PSMA, dynamic imaging new cancer 
research tracers like 18F-Flurothanatrace (FTT), imaging of low uptake brain tracers like nicotine 
receptor tracers, and dual-tracer imaging with FGln and FDG. Additionally, some of our colleagues 
at the University of Pennsylvania are interested in studying how the dynamics of liver cancer 
metastases vary, studying lung cancer and lung inflammation in patients, and implementing pelvic 
imaging of 68Ga-PSMA so that regions in the pelvis and abdomen, which are most likely to have 
disease, are imaged longer. Neuroradiologists would like to image opioid receptors in the brain 
and throughout the whole body, while cardiologists want to image disease states that affect both 
the heart and kidney and quantify blood flow in both organs simultaneously. A few of the studies 
of interest that have not already been discussed are described in more detail here.  
An early study we are interested in is imaging patients with suspicious lung findings on CT who 
get PET scans for staging and characterization. These patients would be imaged on the PennPET 
Explorer either shortly before or after a clinical FDG PET scan. On the PennPET Explorer, we would 
first acquire 30 – 60 s breath hold images followed by a 20-min static acquisition. Based on lesion 
detectability studies in Chapter 4 of 10- and 6-mm spheres embedded into the lung of the human 
subject, we can image for 26 s and 240 s, respectively, to achieve an ALROC of 0.8. Both static 
acquisitions could then be assessed for lesion detectability metrics. The breath hold image would 
mitigate the blurring effects of respiratory motion and indicate whether there is value in pursuing 
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further breath hold imaging when compared to the 20-min scan. Additionally, the 20-min static 
image could be parsed into 1-min dynamic frames to assess if FDG uptake is increasing or 
decreasing over the period of time and create an FDG slope image to complement the SUV uptake 
image. Rhea’s work assessing heterogeneity of lesions using dynamic datasets could then be 
extended to these semi-dynamic datasets as well. 
The ability to achieve good detectability (ALROC ≥ 0.8) of 10-mm spheres on the 144-cm PennPET 
Explorer for scan durations of 60 s or less has applications for pediatric imaging. Because young 
pediatric patients are prone to motion during long scans, they are typically anesthetized for the 
duration of the scan. However, general anesthesia is suspected to cause neurodevelopmental 
issues, so there is an effort to move away from use. In that vein, short PET scans (1-2 min) that 
still achieve the same diagnostic quality are of benefit since patients are less likely to move during 
that time. Although this may not be an early study on the PennPET Explorer, we do anticipate 
moving forward with pediatric imaging, and perhaps implementing CT-less PET image 
reconstruction so the added dose from the CT will not be required. 
Finally, we are also interested in understanding the value of being able to measure finely sampled 
blood input functions from PET data for dynamic imaging. This could potentially replace arterial 
sampling which is the current gold standard. Early data from the prototype system shown in 
Chapter 3 shows low noise blood TACs with 1-s frames.  The higher sensitivity of the PennPET 
Explorer should result in reduced noise and better temporal sampling of the blood input curve. 
The lower noise of the curve and the ability to measure the blood input function near the lesion 
of interest may assist in more accurately quantifying the kinetics of a tracer within a lesion. 
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Within a few months of opening the PennPET Explorer to research studies, we expect to begin 
dynamic imaging studies of radiotracers in development along with other studies described. 
Continuing this work should offer a better understanding of the clinical impact that follows the 






193   
REFERENCES 
[1] M. V. Liberti, J. W. Locasale, "The Warburg effect: how does it benefit cancer cells?," 
Trends in biochemical sciences, vol. 41, no. 3, pp. 211-218, 2016. 
[2] T. Ido, C. N. Wan, V. Casella, J. Fowler, A. Wolf, M. Reivich et al., "Labeled 2-deoxy-D-
glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose 
and 14C-2-deoxy-2-fluoro-D-glucose," Journal of Labelled Compounds and 
Radiopharmaceuticals, vol. 14, no. 2, pp. 175-183, 1978. 
[3] M. Reivich, D. Kuhl, A. Wolf, J. Greenberg, M. A. Phelps, T. Ido et al., "The [18F] 
fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in 
man," Circulation research, vol. 44, no. 1, pp. 127-137, 1979. 
[4] M. Phelps, S. Huang, E. Hoffman, C. Selin, L. Sokoloff,  D. Kuhl, "Tomographic 
measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-
deoxy-D-glucose: validation of method," Annals of Neurology: Official Journal of the 
American Neurological Association and the Child Neurology Society, vol. 6, no. 5, pp. 371-
388, 1979. 
[5] K. Kubota, "From tumor biology to clinical PET: a review of positron emission tomography 
(PET) in oncology," Annals of nuclear medicine, vol. 15, no. 6, pp. 471-486, 2001. 
[6] P. S. Conti, D. L. Lilien, K. Hawley, J. Keppler, S. T. Grafton,  J. R. Bading, "PET and [18F]-
FDG in oncology: a clinical update," Nuclear medicine and biology, vol. 23, no. 6, pp. 717-
735, 1996. 
[7] N. C. Gupta, G. M. Graeber,  H. A. Bishop, "Comparative efficacy of positron emission 
tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 
cm), and large (> 3 cm) lymph node lesions," Chest, vol. 117, no. 3, pp. 773-778, 2000. 
[8] M. M. Graham, X. Gu, T. Ginader, P. Breheny,  J. J. Sunderland, "68Ga-DOTATOC imaging 
of neuroendocrine tumors: a systematic review and metaanalysis," J Nucl Med, vol. 58, 
no. 9, pp. 1452-1458, 2017. 
[9] S. Landau, B. Thomas, L. Thurfjell, M. Schmidt, R. Margolin, M. Mintun et al., "Amyloid 
PET imaging in Alzheimer’s disease: a comparison of three radiotracers," EJNMMI, vol. 41, 
no. 7, pp. 1398-1407, 2014. 
[10] L. Saint-Aubert, L. Lemoine, K. Chiotis, A. Leuzy, E. Rodriguez-Vieitez,  A. Nordberg, "Tau 
PET imaging: present and future directions," Molecular neurodegeneration, vol. 12, no. 1, 
p. 19, 2017. 
[11] B. L. Zaret, H. W. Strauss, N. D. Martin, H. P. Wells Jr,  M. Flamm Jr, "Noninvasive regional 
myocardial perfusion with radioactive potassium: study of patients at rest, with exercise 
and during angina pectoris," NEJM, vol. 288, no. 16, pp. 809-812, 1973. 
[12] O. Manabe, T. Kikuchi, A. J. Scholte, M. El Mahdiui, R. Nishii, M.-R. Zhang et al., 
"Radiopharmaceutical tracers for cardiac imaging," J Nucl Card, vol. 25, no. 4, pp. 1204-
1236, 2018. 
[13] G. V. Heller, D. Calnon,  S. Dorbala, "Recent advances in cardiac PET and PET/CT 
myocardial perfusion imaging," J Nucl Card, vol. 16, no. 6, p. 962, 2009. 
[14] K. L. Gould, "Clinical cardiac PET using generator-produced Rb-82: a review," 
Cardiovascular and interventional radiology, vol. 12, no. 5, pp. 245-251, 1989. 




194   
[16] J. Strydhorst, I. Buvat, "Redesign of the GATE PET coincidence sorter," Phys Med Biol, vol. 
61, no. 18, pp. N522–N531, 2016. 
[17] M. Conti, L. Eriksson, "Physics of pure and non-pure positron emitters for PET: a review 
and a discussion," EJNMMI physics, vol. 3, no. 1, p. 8, 2016. 
[18] O. Klein, Y. Nishina, "Über die Streuung von Strahlung durch freie Elektronen nach der 
neuen relativistischen Quantendynamik von Dirac," Zeitschrift für Physik, vol. 52, no. 11-
12, pp. 853-868, 1929. 
[19]  M. E. Werner, S. Surti,  J. S. Karp, "Implementation and evaluation of a 3D PET single 
scatter simulation with TOF modeling," in Nuc Sci Symp, 2006, vol. 3: IEEE, pp. 1768-1773.  
[20] J. S. Karp, G. Muehllehner, H. Qu,  X.-H. Yan, "Singles transmission in volume-imaging PET 
with a 137Cs source," Physics in medicine and biology, vol. 40, no. 5, p. 929, 1995. 
[21] M. Daube-Witherspoon, R. E. Carson,  M. V. Green, "Post-injection transmission 
attenuation measurements for PET," IEEE Transactions on Nuclear Science, vol. 35, no. 1, 
pp. 757-761, 1988. 
[22] P. Kinahan, D. Townsend, T. Beyer,  D. Sashin, "Attenuation correction for a combined 3D 
PET/CT scanner," Medical physics, vol. 25, no. 10, pp. 2046-2053, 1998. 
[23] C. Burger, G. Goerres, S. Schoenes, A. Buck, A. Lonn,  G. Von Schulthess, "PET attenuation 
coefficients from CT images: experimental evaluation of the transformation of CT into PET 
511-keV attenuation coefficients," EJNMMI, vol. 29, no. 7, pp. 922-927, 2002. 
[24] D. L. Bailey, D. W. Townsend, P. E. Kinahan, S. Grootoonk,  T. Jones, "An investigation of 
factors affecting detector and geometric correction in normalization of 3-D PET data," 
IEEE Trans Nuc Sci, vol. 43, no. 6, pp. 3300-3307, 1996. 
[25] M. E. Casey, E. J. Hoffman, "Quantitation in positron emission computed tomography: 7. 
A technique to reduce noise in accidental coincidence measurements and coincidence 
efficiency calibration," Journal of computer assisted tomography, vol. 10, no. 5, pp. 845-
850, 1986. 
[26] J. Radon, "On the determination of functions from their integral values along certain 
manifolds," IEEE Trans Med Img, vol. 5, no. 4, pp. 170-176, 1986. 
[27] C. A. Johnson, Y. Yan, R. E. Carson, R. L. Martino,  M. E. Daube-Witherspoon, "A system 
for the 3D reconstruction of retracted-septa PET data using the EM algorithm," IEEE 
Transactions on Nuclear Science, vol. 42, no. 4, pp. 1223-1227, 1995. 
[28] R. M. Lewitt, S. Matej, "Overview of methods for image reconstruction from projections 
in emission computed tomography," Proceedings of the IEEE, vol. 91, no. 10, pp. 1588-
1611, 2003. 
[29] S. Matej, R. M. Lewitt, "Practical considerations for 3-D image reconstruction using 
spherically symmetric volume elements," IEEE Trans Med Img, vol. 15, no. 1, pp. 68-78, 
1996. 
[30]  L. M. Popescu, S. Matej,  R. M. Lewitt, "Iterative image reconstruction using geometrically 
ordered subsets with list-mode data," in Nuc Sci Symp, 2004, vol. 6: IEEE, pp. 3536-3540.  
[31] S. Matej, S. Surti, S. Jayanthi, M. E. Daube-Witherspoon, R. M. Lewitt,  J. S. Karp, "Efficient 
3-D TOF PET reconstruction using view-grouped histo-images: DIRECT—Direct image 
reconstruction for TOF," IEEE Trans Med Img, vol. 28, no. 5, pp. 739-751, 2009. 
[32] M. Daube-Witherspoon, S. Matej, J. Karp,  R. Lewitt, "Application of the row action 
maximum likelihood algorithm with spherical basis functions to clinical PET imaging," IEEE 
Trans Nuc Sci, vol. 48, no. 1, pp. 24-30, 2001. 
 
 
195   
[33]  N. A. Karakatsanis, V. Garibotto, O. Rager,  H. Zaidi, "Continuous bed motion vs. step-and-
shoot acquisition on clinical whole-body dynamic and parametric PET imaging," in IEEE 
NSS/MIC, 2015: IEEE, pp. 1-6.  
[34] J. S. Karp, G. Muehllehner, D. A. Mankoff, C. E. Ordonez, J. M. Ollinger, M. E. Daube-
Witherspoon et al., "Continuous-slice PENN-PET: a positron tomograph with volume 
imaging capability," J Nucl Med, vol. 31, no. 5, pp. 617-627, 1990. 
[35] S. R. Cherry, M. Dahlbom,  E. J. Hoffman, "3D PET using a conventional multislice 
tomograph without septa," Journal of computer assisted tomography, vol. 15, no. 4, pp. 
655-668, 1991. 
[36] R. L. Wahl, H. Jacene, Y. Kasamon,  M. A. Lodge, "From RECIST to PERCIST: evolving 
considerations for PET response criteria in solid tumors," Journal of nuclear medicine, vol. 
50, no. Suppl 1, pp. 122S-150S, 2009. 
[37] J. S. Karp, S. Surti, M. E. Daube-Witherspoon,  G. Muehllehner, "Benefit of time-of-flight 
in PET: experimental and clinical results," Journal of Nuclear Medicine, vol. 49, no. 3, pp. 
462-470, 2008. 
[38] S. Surti, J. S. Karp, "Advances in time-of-flight PET," Physica Medica, vol. 32, no. 1, pp. 12-
22, 2016. 
[39] M. Conti, "State of the art and challenges of time-of-flight PET," Physica Medica, vol. 25, 
no. 1, pp. 1-11, 2009. 
[40] S. Vandenberghe, E. Mikhaylova, E. D’Hoe, P. Mollet,  J. Karp, "Recent developments in 
time-of-flight PET," EJNMMI physics, vol. 3, no. 1, p. 3, 2016. 
[41] M. Conti, L. Eriksson, H. Rothfuss, T. Sjoeholm, D. Townsend, G. Rosenqvist et al., 
"Characterization of 176Lu background in LSO-based PET scanners," Physics in Medicine 
and Biology, vol. 62, no. 9, p. 3700, 2017. 
[42] H. Rothfuss, V. Panin, A. Moor, J. Young, I. Hong, C. Michel et al., "LSO background 
radiation as a transmission source using time of flight," Phys Med Biol, vol. 59, no. 18, p. 
5483, 2014. 
[43] B. Jakoby, Y. Bercier, M. Conti, M. Casey, B. Bendriem,  D. Townsend, "Physical and clinical 
performance of the mCT time-of-flight PET/CT scanner," Physics in medicine and biology, 
vol. 56, no. 8, p. 2375, 2011. 
[44] J. A. Kolthammer, K.-H. Su, A. Grover, M. Narayanan, D. W. Jordan,  R. F. Muzic, 
"Performance evaluation of the Ingenuity TF PET/CT scanner with a focus on high count-
rate conditions," Physics in medicine and biology, vol. 59, no. 14, p. 3843, 2014. 
[45] M. Teräs, T. Tolvanen, J. Johansson, J. Williams,  J. Knuuti, "Performance of the new 
generation of whole-body PET/CT scanners: Discovery STE and Discovery VCT," European 
journal of nuclear medicine and molecular imaging, vol. 34, no. 10, pp. 1683-1692, 2007. 
[46] M. Casey, R. Nutt, "A multicrystal two dimensional BGO detector system for positron 
emission tomography," IEEE Trans Nuc Sci, vol. 33, no. 1, pp. 460-463, 1986. 
[47] H. O. Anger, "Sensitivity, resolution, and linearity of the scintillation camera," IEEE Trans 
Nuc Sci, vol. 13, no. 3, pp. 380-392, 1966. 
[48] S. Surti, J. Karp, R. Freifelder,  F. Liu, "Optimizing the performance of a PET detector using 
discrete GSO crystals on a continuous lightguide," IEEE Trans Nuc Sci, vol. 47, no. 3, pp. 
1030-1036, 2000. 
[49] S. Surti, A. Kuhn, M. E. Werner, A. E. Perkins, J. Kolthammer,  J. S. Karp, "Performance of 
Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging 
capabilities," J Nucl Med, vol. 48, no. 3, pp. 471-480, 2007. 
 
 
196   
[50] J. A. Kolthammer, K.-H. Su, A. Grover, M. Narayanan, D. W. Jordan,  R. F. Muzic, 
"Performance evaluation of the Ingenuity TF PET/CT scanner with a focus on high count-
rate conditions," Phys Med Biol, vol. 59, no. 14, pp. 3843-3859, 2014. 
[51] B. Jakoby, Y. Bercier, M. Conti, M. Casey, B. Bendriem,  D. Townsend, "Physical and clinical 
performance of the mCT time-of-flight PET/CT scanner," Phys Med Biol, vol. 56, no. 8, pp. 
2375-2389, 2011. 
[52] V. Bettinardi, L. Presotto, E. Rapisarda, M. Picchio, L. Gianolli,  M. Gilardi, "Physical 
performance of the new hybrid PET/CT Discovery-690," Med Phys, vol. 38, no. 10, pp. 
5394-5411, 2011. 
[53] M. Miller, J. Zhang, K. Binzel, J. Griesmer, T. Laurence, M. Narayanan et al., 
"Characterization of the vereos digital photon counting PET system," Journal of Nuclear 
Medicine, vol. 56, no. supplement 3, pp. 434-434, 2015. 
[54] J. J. van Sluis, J. de Jong, J. Schaar, W. Noordzij, P. van Snick, R. Dierckx et al., "Performance 
characteristics of the digital Biograph Vision PET/CT system," J Nucl Med, vol. 60, no. 7, 
pp. 1031-1036, 2019. 
[55] T. Pan, S. A. Einstein, S. C. Kappadath, K. S. Grogg, C. Lois Gomez, A. M. Alessio et al., 
"Performance evaluation of the 5-Ring GE Discovery MI PET/CT system using the National 
Electrical Manufacturers Association NU 2-2012 Standard," Med Phys, vol. 46, no. 7, pp. 
3025-3033, 2019. 
[56] I. Rausch, A. Ruiz, I. Valverde-Pascual, J. Cal-González, T. Beyer,  I. Carrio, "Performance 
evaluation of the Vereos PET/CT system according to the NEMA NU2-2012 standard," J 
Nucl Med, vol. 60, no. 4, pp. 561-567, 2019. 
[57] S. R. Cherry, T. Jones, J. S. Karp, J. Qi, W. W. Moses,  R. D. Badawi, "Total-body PET: 
Maximizing sensitivity to create new opportunities for clinical research and patient care," 
J Nucl Med, vol. 59, no. 1, pp. 3-12, 2018. 
[58] S. R. Cherry, R. D. Badawi, J. S. Karp, W. W. Moses, P. Price,  T. Jones, "Total-body imaging: 
Transforming the role of positron emission tomography," Science translational medicine, 
vol. 9, no. 381, 2017. 
[59] G. Borasi, F. Fioroni, A. Del Guerra,  G. Lucignani, "PET systems: the value of added length," 
ed: Springer, 2010. 
[60]  B. A. Spencer, J. Schmall, E. Berg, N. Omidvari, E. Leung, Z. Deng et al., "Performance 
evaluation of the EXPLORER Total-body PET/CT scanner based on NEMA NU-2 2018 
standard with additional tests for extended geometry," in IEEE NSS/MIC, Manchester, UK, 
2019.  
[61] L. Eriksson, D. Townsend, M. Conti, M. Eriksson, H. Rothfuss, M. Schmand et al., "An 
investigation of sensitivity limits in PET scanners," Nuclear Instruments and Methods in 
Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated 
Equipment, vol. 580, no. 2, pp. 836-842, 2007. 
[62] M. Couceiro, N. Ferreira,  P. Fonte, "Sensitivity assessment of wide axial field of view PET 
systems via Monte Carlo simulations of NEMA-like measurements," Nuclear Instruments 
and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and 
Associated Equipment, vol. 580, no. 1, pp. 485-488, 2007. 
[63] L. Eriksson, M. Conti, C. Melcher, D. Townsend, M. Eriksson, H. Rothfuss et al., "Towards 
sub-minute PET examination times," IEEE Transactions on Nuclear Science, vol. 58, no. 1, 
pp. 76-81, 2011. 
 
 
197   
[64] J. K. Poon, M. L. Dahlbom, W. W. Moses, K. Balakrishnan, W. Wang, S. R. Cherry et al., 
"Optimal whole-body PET scanner configurations for different volumes of LSO scintillator: 
a simulation study," Physics in medicine and biology, vol. 57, no. 13, p. 4077, 2012. 
[65] S. Surti, J. Karp, "Impact of detector design on imaging performance of a long axial field-
of-view, whole-body PET scanner," Physics in medicine and biology, vol. 60, no. 13, p. 
5343, 2015. 
[66] J. P. Schmall, J. S. Karp, M. Werner,  S. Surti, "Parallax error in long-axial field-of-view PET 
scanners—a simulation study," Phys Med Biol, vol. 61, no. 14, p. 5443, 2016. 
[67] S. Surti, M. Werner,  J. Karp, "Study of PET scanner designs using clinical metrics to 
optimize the scanner axial FOV and crystal thickness," Phys Med Biol, vol. 58, no. 12, p. 
3995, 2013. 
[68] S. Surti, J. Karp, "Impact of detector design on imaging performance of a long axial field-
of-view, whole-body PET scanner," Phys Med Biol, vol. 60, no. 13, p. 5343, 2015. 
[69] X. Zhang, J. Zhou, S. R. Cherry, R. D. Badawi,  J. Qi, "Quantitative image reconstruction for 
total-body PET imaging using the 2-meter long EXPLORER scanner," Physics in Medicine 
and Biology, vol. 62, no. 6, p. 2465, 2017. 
[70] X. Wang, Z. Xu,  C.-H. Miao, "Current clinical evidence on the effect of general anesthesia 
on neurodevelopment in children: an updated systematic review with meta-regression," 
PloS one, vol. 9, no. 1, p. e85760, 2014. 
[71] A. Taebi, B. Roudsari, C. Vu, S. Cherry,  E. Roncali, "Hepatic arterial tree segmentation: 
Towards patient-specific dosimetry for liver cancer radioembolization," J Nucl Med, vol. 
60, no. supplement 1, pp. 122-122, 2019. 
[72] S. A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold et al., "Chimeric 
antigen receptor–modified T cells for acute lymphoid leukemia," New England Journal of 
Medicine, vol. 368, no. 16, pp. 1509-1518, 2013. 
[73] M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg et al., "T cells with chimeric 
antigen receptors have potent antitumor effects and can establish memory in patients 
with advanced leukemia," Science translational medicine, vol. 3, no. 95, pp. 95ra73-
95ra73, 2011. 
[74] D. L. Porter, B. L. Levine, M. Kalos, A. Bagg,  C. H. June, "Chimeric antigen receptor–
modified T cells in chronic lymphoid leukemia," New England Journal of Medicine, vol. 
365, no. 8, pp. 725-733, 2011. 
[75] R. Boellaard, R. Delgado-Bolton, W. J. Oyen, F. Giammarile, K. Tatsch, W. Eschner et al., 
"FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0," European 
journal of nuclear medicine and molecular imaging, vol. 42, no. 2, pp. 328-354, 2015. 
[76] X. Zhang, Z. Xie, E. Berg, M. Judenhofer, W. Liu, Y. Lv et al., "Total-Body Parametric Imaging 
using Kernel and Direct Reconstruction on the uEXPLORER," J Nucl Med, vol. 60, no. 
supplement 1, pp. 456-456, 2019. 
[77]  X. Zhang, Z. Xie, J. Bao, H. Li, S. R. Cherry, R. D. Badawi et al., "Fast Dynamic Total-Body 
PET Imaging on EXPLORER," in IEEE NSS/MIC, Manchester, UK, IEEE, Ed., 2019.  
[78] X. Zhang, S. R. Cherry, Z. Xie, H. Shi, R. D. Badawi,  J. Qi, "Subsecond total-body imaging 
using ultrasensitive positron emission tomography," Proceedings of the National 
Academy of Sciences, 2020. 
[79] A. Pantel, M. Makvandi, R. Doot, L. Schwartz, R. Greenberg, F. Simpkins et al., "A pilot 
study of a novel poly (ADP-ribose) polymerase-1 (PARP) PET tracer ([18F] 
 
 
198   
FluorThanatrace) in patients with ovarian carcinoma," J Nucl Med, vol. 58, no. supplement 
1, pp. 386-386, 2017. 
[80] C. E. Edmonds, M. Makvandi, B. P. Lieberman, K. Xu, C. Zeng, S. Li et al., "[18F] 
FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer," 
American journal of nuclear medicine and molecular imaging, vol. 6, no. 1, p. 94, 2016. 
[81] R. Zhou, A. R. Pantel, S. Li, B. P. Lieberman, K. Ploessl, H. Choi et al., "[18F](2S, 4R) 4-
fluoroglutamine PET detects glutamine pool size changes in triple-negative breast cancer 
in response to glutaminase inhibition," Cancer research, vol. 77, no. 6, pp. 1476-1484, 
2017. 
[82] C. T. Hensley, A. T. Wasti,  R. J. DeBerardinis, "Glutamine and cancer: cell biology, 
physiology, and clinical opportunities," The Journal of clinical investigation, vol. 123, no. 
9, pp. 3678-3684, 2013. 
[83]  T. Frach, G. Prescher, C. Degenhardt, R. de Gruyter, A. Schmitz,  R. Ballizany, "The digital 
silicon photomultiplier—Principle of operation and intrinsic detector performance," in 
IEEE NSS/MIC, 2009: IEEE, pp. 1959-1965.  
[84] A. Perkins, "Personal communication," ed, 2017. 
[85] J. S. Karp, V. Viswanath, M. Geagan, G. Muehllehner, A. Pantel, M. Parma et al., "PennPET 
Explorer: Design and preliminary performance of a whole-body imager," J Nucl Med, vol. 
61, no. 1, pp. 136-143, 2019. 
[86]  P. R. A. Trindade, A. Andreyev, A. E. Perkins, M. Miller, J. Griesmer, J. Ye et al., "GATE 
simulation of the Philips Vereos digital photon counting PET system NEMA NU2-2012 
characterization," in IEEE NSS/MIC, San Diego, California, 2015: IEEE.  
[87] J. Schmall, M. Geagan, M. Werner, M. Parma, V. Viswanath, T. McDermott et al., 
"Characterizing the TOF performance of the PennPET Explorer scanner," J Nucl Med, vol. 
59, no. supplement 1, pp. 96-96, 2018. 
[88]  C. Degenhardt, G. Prescher, T. Frach, A. Thon, R. de Gruyter, A. Schmitz et al., "The digital 
silicon photomultiplier—A novel sensor for the detection of scintillation light," in IEEE 
NSS/MIC, 2009: IEEE, pp. 2383-2386.  
[89] NEMA Standards Publication NU-2-2001: performance measurements of positron 
emission tomography. Rosslyn, VA: National Electrical Manufacturers Association, 2001. 
[90] J. S. Karp, M. E. Daube-Witherspoon, E. J. Hoffman, T. K. Lewellen, J. M. Links, W.-H. Wong 
et al., "Performance standards in positron emission tomography," J Nucl Med, vol. 32, no. 
12, pp. 2342-2350, 1991. 
[91] S. Strother, M. Casey,  E. Hoffman, "Measuring PET scanner sensitivity: relating countrates 
to image signal-to-noise ratios using noise equivalents counts," IEEE Trans Nuc Sci, vol. 
37, no. 2, pp. 783-788, 1990. 
[92] J. Sunderland, P. Kinahan, J. Karp, D. Byrd, J. Scheuermann, J. Panetta et al., "Development 
and testing of a formalism to identify harmonized and optimized reconstructions for 
PET/CT in clinical trials," J Nucl Med, vol. 56, no. supplement 3, pp. 563-563, 2015. 
[93] E. J. Ulrich, J. J. Sunderland, B. J. Smith, I. Mohiuddin, J. Parkhurst, K. A. Plichta et al., 
"Automated model-based quantitative analysis of phantoms with spherical inserts in FDG 
PET scans," Med Phys, vol. 45, no. 1, pp. 258-276, 2018. 
[94] S. Matej, R. M. Lewitt, "3D-FRP: direct Fourier reconstruction with Fourier reprojection 
for fully 3-D PET," IEEE Trans Nuc Sci, vol. 48, no. 4, pp. 1378-1385, 2001. 
[95] J. G. Colsher, "Fully-three-dimensional positron emission tomography," Phys Med Biol, 
vol. 25, no. 1, p. 103, 1980. 
 
 
199   
[96] S. Matej, M. E. Daube-Witherspoon,  J. S. Karp, "Analytic TOF PET reconstruction 
algorithm within DIRECT data partitioning framework," Phys Med Biol, vol. 61, no. 9, p. 
3365, 2016. 
[97] W. Segars, G. Sturgeon, S. Mendonca, J. Grimes,  B. M. Tsui, "4D XCAT phantom for 
multimodality imaging research," Med Phys, vol. 37, no. 9, pp. 4902-4915, 2010. 
[98] C. D. Ramos, Y. E. Erdi, M. Gonen, E. Riedel, H. W. Yeung, H. A. Macapinlac et al., "FDG-
PET standardized uptake values in normal anatomical structures using iterative 
reconstruction segmented attenuation correction and filtered back-projection," EJNMMI, 
vol. 28, no. 2, pp. 155-164, 2001. 
[99] Y. Wang, E. Chiu, J. Rosenberg,  S. S. Gambhir, "Standardized uptake value atlas: 
characterization of physiological 2-deoxy-2-[18 F] fluoro-d-glucose uptake in normal 
tissues," Molecular Imaging and Biology, vol. 9, no. 2, pp. 83-90, 2007. 
[100] M. Dahlbom, "Estimation of image noise in PET using the bootstrap method," IEEE Trans 
Nuc Sci, vol. 49, no. 5, pp. 2062-2066, 2002. 
[101] J. K. Poon, M. L. Dahlbom, W. W. Moses, K. Balakrishnan, W. Wang, S. R. Cherry et al., 
"Optimal whole-body PET scanner configurations for different volumes of LSO scintillator: 
a simulation study," Phys Med Biol, vol. 57, no. 13, p. 4077, 2012. 
[102] A. R. Pantel, V. Viswanath, M. E. Daube-Witherspoon, J. G. Dubroff, G. Muehllehner, M. J. 
Parma et al., "PennPET Explorer: Human imaging on a whole-body imager," J Nucl Med, 
vol. 61, no. 1, pp. 144-151, 2019. 
[103] A. M. Spence, M. Muzi, D. A. Mankoff, S. F. O’Sullivan, J. M. Link, T. K. Lewellen et al., "18F-
FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal 
gray matter," J Nucl Med, vol. 45, no. 10, pp. 1653-1659, 2004. 
[104]  V. Viswanath, A. R. Pantel, M. E. Daube-Witherspoon, D. A. Mankoff,  J. S. Karp, 
"Quantifying the k4 of Fluorodeoxyglucose in Normal Organs Using the PennPET Explorer, 
a Long Axial Field of View PET Scanner," in Biomedical Engineering Society Conference, 
Philadelphia, PA, 2019.  
[105]  C. Cohade, R. L. Wahl, "Applications of positron emission tomography/computed 
tomography image fusion in clinical positron emission tomography—clinical use, 
interpretation methods, diagnostic improvements," in Seminars in nuclear medicine, 
2003, vol. 33, no. 3: Elsevier, pp. 228-237.  
[106] C. K. Abbey, H. H. Barrett, "Human-and model-observer performance in ramp-spectrum 
noise: effects of regularization and object variability," JOSA A, vol. 18, no. 3, pp. 473-488, 
2001. 
[107] J. Nuyts, C. Michel, L. Brepoels, L. De Ceuninck, C. Deroose, K. Goffin et al., "Performance 
of MAP reconstruction for hot lesion detection in whole-body PET/CT: an evaluation with 
human and numerical observers," IEEE Trans Med Img, vol. 28, no. 1, pp. 67-73, 2008. 
[108] H. Gifford, P. Kinahan, C. Lartizien,  M. King, "Evaluation of multiclass model observers in 
PET LROC studies," IEEE Trans Nuc Sci, vol. 54, no. 1, pp. 116-123, 2007. 
[109] L. M. Popescu, R. M. Lewitt, "Small nodule detectability evaluation using a generalized 
scan-statistic model," Phys Med Biol, vol. 51, no. 23, pp. 6225-6244, 2006. 
[110] S. Surti, J. S. Karp, "Application of a generalized scan statistic model to evaluate TOF PET 
images," IEEE Trans Nuc Sci, vol. 58, no. 1, pp. 99-104, 2010. 
[111] S. Surti, A. R. Shore,  J. S. Karp, "Design study of a whole-body PET scanner with improved 
spatial and timing resolution," IEEE Trans Nuc Sci, vol. 60, no. 5, pp. 3220-3226, 2013. 
 
 
200   
[112] D. L. Snyder, D. G. Politte, "Image reconstruction from list-mode data in an emission 
tomography system having time-of-flight measurements," IEEE Trans Nuc Sci, vol. 30, no. 
3, pp. 1843-1849, 1983. 
[113] R. Accorsi, J. S. Karp,  S. Surti, "Improved dose regimen in pediatric PET," J Nucl Med, vol. 
51, no. 2, pp. 293-300, 2010. 
[114] G. El Fakhri, S. Surti, C. M. Trott, J. Scheuermann,  J. S. Karp, "Improvement in lesion 
detection with whole-body oncologic time-of-flight PET," J Nucl Med, vol. 52, no. 3, pp. 
347-353, 2011. 
[115]  Y. Li, M. E. Daube-Witherspoon, S. Matej,  S. D. Metzler, "Developing an expert system to 
improve lesion quantification for personalized PET imaging," in IEEE NSS/MIC, 2017: IEEE, 
pp. 1-3.  
[116] M. E. Daube-Witherspoon, S. Surti, A. E. Perkins,  J. S. Karp, "Determination of accuracy 
and precision of lesion uptake measurements in human subjects with time-of-flight PET," 
J Nucl Med, vol. 55, no. 4, pp. 602-607, 2014. 
[117] R. G. Swensson, "Unified measurement of observer performance in detecting and 
localizing target objects on images," Med Phys, vol. 23, no. 10, pp. 1709-1725, 1996. 
[118] T. Yamaya, E. Yoshida, N. Inadama, F. Nishikido, K. Shibuya, M. Higuchi et al., "A multiplex 
“OpenPET” geometry to extend axial FOV without increasing the number of detectors," 
IEEE Trans Nuc Sci, vol. 56, no. 5, pp. 2644-2650, 2009. 
[119] M. Muzi, F. O'Sullivan, D. A. Mankoff, R. K. Doot, L. A. Pierce, B. F. Kurland et al., 
"Quantitative assessment of dynamic PET imaging data in cancer imaging," Magnetic 
resonance imaging, vol. 30, no. 9, pp. 1203-1215, 2012. 
[120] M. Muzi, H. Vesselle, J. R. Grierson, D. A. Mankoff, R. A. Schmidt, L. Peterson et al., "Kinetic 
analysis of 3ʹ-deoxy-3ʹ-fluorothymidine PET studies: validation studies in patients with 
lung cancer," J Nucl Med, vol. 46, no. 2, pp. 274-282, 2005. 
[121] R. K. Doot, "Getting the most out of 18F-FDG PET scans: The predictive value of 18F-FDG 
PET–derived blood flow estimates for breast cancer," J Nucl Med, vol. 57, no. 11, pp. 1667-
1668, 2016. 
[122] H. Vesselle, J. Grierson, M. Muzi, J. M. Pugsley, R. A. Schmidt, P. Rabinowitz et al., "In vivo 
validation of 3ʹ deoxy-3ʹ-[18F] fluorothymidine ([18F] FLT) as a proliferation imaging 
tracer in humans: correlation of [18F] FLT uptake by positron emission tomography with 
Ki-67 immunohistochemistry and flow cytometry in human lung tumors," Clinical cancer 
research, vol. 8, no. 11, pp. 3315-3323, 2002. 
[123] S. Surti, A. R. Pantel,  J. S. Karp, "Total Body PET: Why, how, what for?," TRPMS, 2020 (in 
press). 
[124]  V. Viswanath, M. E. Daube-Witherspoon, M. E. Werner, S. Surti, A. Trindade, P. Rodrigues 
et al., "GATE simulations to study extended axial FOVs for the PennPET Explorer scanner," 
in IEEE NSS/MIC, 2017: IEEE, pp. 1-5.  
[125] M. Muzi, D. A. Mankoff, J. R. Grierson, J. M. Wells, H. Vesselle,  K. A. Krohn, "Kinetic 
modeling of 3ʹ-deoxy-3ʹ-fluorothymidine in somatic tumors: mathematical studies," J Nucl 
Med, vol. 46, no. 2, pp. 371-380, 2005. 
[126] H. Minn, K. R. Zasadny, L. E. Quint,  R. L. Wahl, "Lung cancer: reproducibility of quantitative 
measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET," Radiol, 
vol. 196, no. 1, pp. 167-173, 1995. 
[127] A. Dimitrakopoulou-Strauss, L. G. Strauss, C. Burger, A. Rühl, G. Irngartinger, W. Stremmel 
et al., "Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal 
 
 
201   
carcinoma receiving FOLFOX chemotherapy," J Nucl Med, vol. 45, no. 9, pp. 1480-1487, 
2004. 
[128] A. Dimitrakopoulou-Strauss, V. Georgoulias, M. Eisenhut, F. Herth, S. Koukouraki, H. R. 
Mäcke et al., "Quantitative assessment of SSTR2 expression in patients with non-small 
cell lung cancer using 68 Ga-DOTATOC PET and comparison with 18 F-FDG PET," EJNMMI, 
vol. 33, no. 7, pp. 823-830, 2006. 
[129] M. Graham, L. Peterson,  R. Hayward, "Comparison of simplified quantitative analyses of 
FDG uptake," Nucl Med and Biol, vol. 27, no. 7, pp. 647-655, 2000. 
[130]  A. Salskov, V. S. Tammisetti, J. Grierson,  H. Vesselle, "FLT: measuring tumor cell 
proliferation in vivo with positron emission tomography and 3ʹ-deoxy-3ʹ-[18F] 
fluorothymidine," in Semin Nucl Med, 2007, vol. 37, no. 6: Elsevier, pp. 429-439.  
[131] D. A. Mankoff, A. F. Shields, M. M. Graham, J. M. Link, J. F. Eary,  K. A. Krohn, "Kinetic 
analysis of 2-[carbon-11] thymidine PET imaging studies: compartmental model and 
mathematical analysis," J Nucl Med, vol. 39, no. 6, pp. 1043-1055, 1998. 
[132] S. Matej, J. Browne, "Performance of a fast maximum likelihood algorithm for fully 3D PET 
reconstruction," in Three-Dimensional Image Reconstruction in Radiology and Nuclear 
Medicine: Springer, 1996, pp. 297-315. 
[133] C. S. Patlak, R. G. Blasberg, "Graphical evaluation of blood-to-brain transfer constants 
from multiple-time uptake data. Generalizations," J Cereb Blood Flow Metab, vol. 5, no. 
4, pp. 584-590, 1985. 
[134] L. K. Dunnwald, R. K. Doot, J. M. Specht, J. R. Gralow, G. K. Ellis, R. B. Livingston et al., "PET 
tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant 
chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake," 
Clin Cancer Res, vol. 17, no. 8, pp. 2400-2409, 2011. 
[135] V. Viswanath, M. E. Daube-Witherspoon, J. P. Schmall, S. Surti, M. E. Werner, G. 
Muehllehner et al., "Development of PET for total-body imaging," Acta Phys Polonica B, 
vol. 48, no. 10, pp. 1555-1566, 2017. 
[136] A. R. Pantel, D. Ackerman, S.-C. Lee, D. A. Mankoff,  T. P. Gade, "Imaging cancer 
metabolism: underlying biology and emerging strategies," Journal of Nuclear Medicine, 
vol. 59, no. 9, pp. 1340-1349, 2018. 
[137] R. J. DeBerardinis, T. Cheng, "Q's next: the diverse functions of glutamine in metabolism, 
cell biology and cancer," Oncogene, vol. 29, no. 3, p. 313, 2010. 
[138] R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou,  C. B. Thompson, "The biology of cancer: 
metabolic reprogramming fuels cell growth and proliferation," Cell metabolism, vol. 7, no. 
1, pp. 11-20, 2008. 
[139] B. J. Altman, Z. E. Stine,  C. V. Dang, "From Krebs to clinic: glutamine metabolism to cancer 
therapy," Nature Reviews Cancer, vol. 16, no. 10, p. 619, 2016. 
[140] D. R. Wise, C. B. Thompson, "Glutamine addiction: a new therapeutic target in cancer," 
Trends in biochemical sciences, vol. 35, no. 8, pp. 427-433, 2010. 
[141] M. M. Robinson, S. J. Mcbryant, T. Tsukamoto, C. Rojas, D. V. Ferraris, S. K. Hamilton et 
al., "Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-
phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide (BPTES)," Biochemical Journal, vol. 
406, no. 3, pp. 407-414, 2007. 
[142] J.-B. Wang, J. W. Erickson, R. Fuji, S. Ramachandran, P. Gao, R. Dinavahi et al., "Targeting 
mitochondrial glutaminase activity inhibits oncogenic transformation," Cancer cell, vol. 
18, no. 3, pp. 207-219, 2010. 
 
 
202   
[143] M. I. Gross, S. D. Demo, J. B. Dennison, L. Chen, T. Chernov-Rogan, B. Goyal et al., 
"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer," 
Molecular cancer therapeutics, vol. 13, no. 4, pp. 890-901, 2014. 
[144] W. Qu, Z. Zha, K. Ploessl, B. P. Lieberman, L. Zhu, D. R. Wise et al., "Synthesis of optically 
pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors," Journal of 
the American Chemical Society, vol. 133, no. 4, pp. 1122-1133, 2010. 
[145] B. P. Lieberman, K. Ploessl, L. Wang, W. Qu, Z. Zha, D. R. Wise et al., "PET imaging of 
glutaminolysis in tumors by 18F-(2S, 4R) 4-fluoroglutamine," Journal of nuclear medicine, 
vol. 52, no. 12, pp. 1947-1955, 2011. 
[146] S. Venneti, M. P. Dunphy, H. Zhang, K. L. Pitter, P. Zanzonico, C. Campos et al., "Glutamine-
based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo," Science 
translational medicine, vol. 7, no. 274, pp. 274ra17-274ra17, 2015. 
[147] P. Kinahan, J. Fletcher, "PET/CT standardized uptake values (SUVs) in clinical practice and 
assessing response to therapy," Semin Ultrasound CT MR, vol. 31, no. 6, pp. 496-505, 
2010. 
[148] G. Lucignani, G. Paganelli,  E. Bombardieri, "The use of standardized uptake values for 
assessing FDG uptake with PET in oncology: a clinical perspective," Nuclear medicine 
communications, vol. 25, no. 7, pp. 651-656, 2004. 
[149] S. Okazumi, K. Isono, K. Enomoto, T. Kikuchi, M. Ozaki, H. Yamamoto et al., "Evaluation of 
liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and 
assessment of effect of treatment," J Nucl Med, vol. 33, no. 3, pp. 333-339, 1992. 
[150] S. Surti, J. S. Karp, A. E. Perkins, C. A. Cardi, M. E. Daube-Witherspoon, A. Kuhn et al., 
"Imaging performance of A-PET: a small animal PET camera," IEEE transactions on medical 
imaging, vol. 24, no. 7, pp. 844-852, 2005. 
[151] S. J. Kim, J. S. Lee, K. C. Im, S.-Y. Kim, S.-A. Park, S. J. Lee et al., "Kinetic modeling of 3ʹ-
deoxy-3ʹ-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous 
tumor models in mice," Journal of Nuclear Medicine, vol. 49, no. 12, pp. 2057-2066, 2008. 
[152] J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi et al., "18F-FDG 
kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes 
in response to neoadjuvant chemotherapy," (in eng), J Nucl Med, vol. 45, no. 11, pp. 1829-
37, Nov 2004. 
[153] V. Viswanath, R. Zhou, H. Lee, S. Li, A. Cragin, R. K. Doot et al., "Kinetic modeling of [18F] 
(2S,4R)4-fluoroglutamine in mouse models of breast cancer to estimate glutamine pool 
size as an indicator of tumor glutamine metabolism," J Nucl Med, 2020 (in preparation). 
[154] M. W. Miner, H. Liljenback, J. Virta, J. Merisaari, V. Oikonen, J. Westermarck et al., "(2S, 
4R)-4-[(18)F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an 
Evaluation of Multiple Pharmacokinetic Models," (in eng), Mol Imaging Biol, Jan 28 2020, 
doi: 10.1007/s11307-020-01472-1. 
[155] M. Grkovski, R. Goel, S. Krebs, K. D. Staton, J. J. Harding, I. K. Mellinghoff et al., 
"Pharmacokinetic Assessment of (18)F-(2S,4R)-4-Fluoroglutamine in Patients with 
Cancer," (in eng), J Nucl Med, vol. 61, no. 3, pp. 357-366, Mar 2020, doi: 
10.2967/jnumed.119.229740. 
[156] R. Chitalia, V. Viswanath, A. R. Pantel, L. Peterson, E. Cohen, M. Muzi et al., "Functional 4-
D clustering for characterizing intra tumor heterogeneity: evaluation in dynamic FDG-PET 
as a prognostic biomarker for breast cancer," J Nucl Med, 2020 (in preparation). 
 
 
203   
[157] Y. Li, S. Matej,  J. S. Karp, "Practical joint reconstruction of activity and attenuation with 
autonomous scaling for time-of-flight PET," Phys Med Biol, 2020 (in review). 
[158] M. E. Daube-Witherspoon, V. Vishwanath, M. E. Werner,  J. S. Karp, "Performance 
characteristics of long axial field-of-view PET scanners with axial gaps," TRPMS, 2020 (in 
preparation). 
[159]  M. Abi Akl, S. Vandenberghe, O. Bouhali, Y. Toufique,  J. S. Karp, "Monte Carlo sensitivity 
study of a long axial FOV PET scanner with patient adaptive rings," in IEEE NSS/MIC, 
Manchester, UK, 2019.  
 
